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ABSTRACT                                                                 English 
 
Vitamin E, the main non-enzymatic lipophylic antioxidant in the human body, has a major role in 
protecting the brain from damage mediated by free radicals. The term vitamin E encompasses eight 
natural congeners (forms): four tocopherols and four tocotrienols, named α, β, γ, and δ. Most 
investigation of vitamin E in relation to dementia and Alzheimer´s disease (AD) has focused primarily 
only on α-tocopherol, with conflicting findings. However, increasing knowledge regarding the biological 
properties of vitamin E provides a strong biological rationale that other forms of vitamin E, beyond just 
α-tocopherol, may play a role in AD pathogenesis.  
The aim of the present project is to investigate the relation of all eight natural vitamin E forms with mild 
cognitive impairment (MCI) and AD in older adults, by combining both an epidemiological and a clinic-
based approach.  
 
Study I. Plasma levels of all eight natural vitamin E forms, and markers of vitamin E 
oxidative/nitrosative damage (α-tocopherylquinone, 5-nitro-γ-tocopherol), were investigated in subjects 
with AD, MCI, and normal cognition (CN) in a clinical-based, multi-centre European study 
(AddNeuroMed Project). Compared to CN subjects, AD and MCI cases had lower plasma levels of total 
tocopherols, total tocotrienols and total vitamin E. Both MCI and AD cases had 85% lower odds to be in 
the highest tertile of plasma total tocopherols and total vitamin E, and they were, respectively, 92% and 
94% less likely to be in the highest tertile of total tocotrienols than the lowest tertile. Further, both 
disorders were associated with increased plasma indices of vitamin E oxidative/nitrosative damage 
(ratios α-tocopherylquinone/α-tocopherol and 5-nitro-γ-tocopherol/γ-tocopherol). 
 
Study II. Within the AddNeuroMed Project, analysis which integrated plasma levels of vitamin E forms 
with structural magnetic resonance (MRI) parameters, derived from automated regional analysis, was 
used to differentiate AD and MCI cases from CN individuals, and to predict MCI conversion to AD. The 
analysis of MRI and vitamin E data alone provided an accuracy of 83.2% and 92.8% respectively, for 
AD versus CN, and of 58.1% and 87.8% for MCI versus CN. The integrated analysis of plasma vitamin 
E and MRI data enhanced the accuracy, which were 98.2% for AD versus CN and 90.7% for MCI 
versus CN. This combination of data also correctly identified 85% of the MCI who converted to clinical 
AD at one year follow-up and 67% of the non-converters. 
 
Study III. The association of plasma levels of eight natural vitamin E forms with the incidence of AD 
was examined in a Swedish population-based prospective study (Kungsholmen Project) of oldest-old 
individuals (age 80+), using six-year follow-up data. Subjects with higher concentrations of total 
tocopherols, total tocotrienols or total vitamin E had approximately a 50% reduced risk of developing 
AD in comparison to subjects with lower plasma levels (highest versus lowest tertile).  
 
Study IV. The association of serum levels of all eight natural vitamin E forms and markers of vitamin E 
oxidative/nitrosative damage, with the incidence of cognitive impairment (MCI or AD) was investigated 
in a Finnish population-based prospective study (CAIDE) of older adults (age 65+), using eight-year 
follow-up data. The odds of cognitive impairment was reduced for subjects in the medium tertile of γ-
tocopherol serum levels, relative to those subjects in the lowest tertile [odds ratio and 95% confidence 
interval: 0.27(0.10-0.78)]. Subjects with a higher serum value for the index of γ-tocopherol nitrosative 
damage (5-nitro-γ-tocopherol/γ-tocopherol ratio; high and middle versus lowest tertile) were about three 
times more likely to develop cognitive impairment. 
 
Conclusions. α-tocopherol is the only vitamin E form currently used to define vitamin E dietary 
requirements, and it is the only congener tested in randomized controlled trials in subjects with AD and 
MCI. The results of this project provide evidence that suggests that the other natural forms of vitamin E 
can also be important in cognitive impairment and AD in older adults. Thus, all natural vitamin E forms 
should be considered when studying the association of this micronutrient with cognitive impairment and 
AD. These findings also suggest that some aspects of vitamin E supplementation in preventing and 
treating AD should be re-examined. This should include the timing of intervention, the composition of 
supplementation, and the assessment of plasma levels of all vitamin E forms. The latter can help identify 
subjects who could benefit from vitamin E supplementation, and monitor in-vivo biological response to 
treatment. 
 
Key words: Alzheimer’s disease, clinical-based study, mild cognitive impairment, 
nitrosative stress, oxidative stress, population-based study, tocopherol, tocotrienol, 
vitamin E, α-tocopherylquinone, 5-nitro-γ-tocopherol. 
 SAMMANFATTNING                                                 Svenska 
 
Vitamin E, den främsta icke-enzymatiska lipofila antioxidanten i kroppen, har en viktig roll i att skydda 
hjärnan från skador orsakade av fria radikaler. Termen vitamin E omfattar åtta naturliga föreningar: fyra 
tokoferoler och fyra tokotrienoler, namngivna α, β, γ och δ. De flesta undersökningar av vitamin E i 
förhållande till Alzheimers sjukdom (Alzheimer’s disease, AD) har främst fokuserat på α-tokoferol, med 
motstridiga resultat. Dock ger den ökade kunskapen om de biologiska egenskaperna hos vitamin E en 
stark logisk grund för att anta att även andra former av vitamin E kan spela en roll i AD-patogenesen.  
Syftet med detta projekt är att undersöka sambandet mellan alla åtta naturliga former av vitamin E med 
lindrig kognitiv svikt (mild cognitive impairment, MCI) och AD hos äldre personer, genom att 
kombinera både epidemiologiska och kliniska metoder. 
 
Studie I. Plasmanivåer av alla åtta naturliga former av vitamin E och markörer för vitamin E-
oxidativ/nitrosativ skada (α-tokoferylquinone, 5-nitro-γ-tokoferol), undersöktes hos personer med AD, 
MCI och normal kognition (NK) i en klinikbaserad, europeisk multicenterstudie (AddNeuroMed 
Project). Jämfört med personer med NK hade personer med AD och MCI lägre plasmanivåer av totala 
mängder av tokoferoler, tokotrienoler och vitamin E. Både personer med MCI och AD hade 85% lägre 
odds att vara i den högsta tertilen av totala mängder tokoferol och vitamin E i plasma, och de hade 92% 
respektive 94% lägre sannolikhet att vara i den högsta tertilen av totala tokotrienoler än i den lägsta 
tertilen. Vidare var både MCI och AD förknippade med ökade plasmanivåer av vitamin E-
oxidativa/nitrosativa skador (förhållandet mellan α-tokoferylquinone/α-tokoferol och 5-nitro-γ-
tokoferol/γ-tokoferol). 
 
Studie II. Inom AddNeuroMed-projektet användes en analys som kombinerade plasmanivåer av olika 
former av vitamin E med parametrar från automatiserad regional analys av strukturell magnetröntgen 
(MR), för att differentiera personer med AD och MCI från individer med NK och för att predicera vilka 
personer som övergick från MCI till AD. När bara uppgifter från MR respektive om vitamin E användes 
var andelen rätt differentierade personer 83,2% respektive 92,8% för AD kontra CN och 58,1% 
respektive 87,8% för MCI kontra CN. När både uppgifter från MR och om vitamin E användes 
differentierades 98,2% rätt för AD kontra CN och 90,7% för MCI kontra CN. När kombinerade data 
användes, blev 85% av dem med MCI rätt identifierade som att övergå till AD och 67% rätt 
identifierade som att inte få AD, under ett års uppföljning. 
 
Studie III. Sambandet mellan plasmanivåer av åtta naturliga former av vitamin E och förekomst av AD 
undersöktes i en svenskt populationsbaserad prospektiv studie (Kungsholmsprojektet) med personer 80 
år och äldre, som följdes upp efter sex år. Personer med högre koncentrationer av totala mängder 
tokoferoler, tokotrienoler eller vitamin E (högsta jämfört med lägsta tertilen) hade cirka 50% minskad 
risk att utveckla AD jämfört med personer med lägre plasmanivåer. 
 
Studie IV. Sambandet mellan serumnivåer av alla åtta naturliga former vitamin E och markörer för 
vitamin E-oxidativa/nitrosativa skador, och förekomsten av kognitiv svikt (MCI eller AD) undersöktes i 
en finsk populationsbaserad prospektiv studie (CAIDE) hos äldre personer (65+ år), som följdes upp 
efter åtta år. Oddsen för kognitiv svikt var lägre för personer i den mellersta tertilen av serumnivåer av γ-
tokoferol, jämfört med den lägsta [odds ratio (95% konfidensintervall): 0,27 (0,10-0,78)]. Individer med 
ett högre serumindex av γ-tokoferol nitrosativ skada (förhållandet mellan 5-nitro-γ-tokoferol/γ-tokoferol; 
högsta och mellersta jämfört med den lägsta tertilen) hade ungefär tre gånger högre risk att försämras 
kognitivt. 
 
Konlusion. α-tokoferol är den enda vitamin E-form som för närvarande används för att definiera behov 
av vitamin E i kosten och är den enda formen som är testad i randomiserade kontrollerade studier på 
patienter med AD och MCI. Resultaten från detta projekt tyder på att även de andra naturliga formerna 
av vitamin E kan vara viktiga vid kognitiv svikt och AD hos äldre personer. Därför bör alla naturliga 
vitamin E-former beaktas när man studerar sambanden mellan detta mikronäringsämne, kognitiv 
nedsättning och AD. Dessa resultat tyder också på att vissa aspekter av vitamin E-tillskott som 
förebyggande och behandling av AD bör omprövas. Denna omprövning bör innefatta tidpunkt för 
intervention, sammansättning av tillskotten och undersökning av plasmanivåer av alla former av vitamin 
E. Detta för att identifiera patienter som kan dra nytta av vitamin E-tillskott och för att observera 
biologisk in-vivo respons på behandlingen. 
 
Nyckelord: Alzheimers sjukdom, klinisk studie, lindrig kognitiv svikt, nitrosativ stress, oxidativ stress, 
populations-baserad studie, tokoferol, tokotrienol, vitamin E, α-tokoferylquinone, 5-nitro-γ-tokoferol.  
RIASSUNTO                                                                Italiano 
 
La vitamina E è il principale antiossidante lipofilo, non-enzimatico, dell’organismo, ed ha un ruolo 
rilevante nella protezione del cervello dal danno causato dai radicali liberi. Il termine vitamina E 
descrive otto composti (congeneri) naturali: quattro tocoferoli e quattro tocotrienoli, denominati α-, β-, γ- 
e δ. La maggior parte della ricerca sul ruolo della vitamina E nella malattia di Alzheimer (Alzheimer´s 
disease, AD) ha preso in considerazione solo l’α-tocoferolo, riportando risultati contradditori. Tuttavia, 
numerosi studi in-vitro e su modelli animali hanno dimostrato le diverse proprietà biologiche degli otto 
congeneri della vitamina E, che potrebbero giocare un ruolo importante nella patogenesi dell’AD.  
Lo scopo del presente progetto è lo studio della relazione tra le otto forme naturali della vitamina E e le 
diagnosi di decadimento cognitivo lieve (mild cognitive impairment, MCI) e di AD. Il progetto integra 
sia studi di popolazione che studi clinici.   
 
Studio I. I livelli plasmatici delle otto forme naturali di vitamina E e due indici di danno ossidativo e 
nitrosativo di tale micronutriente (α-tocoferilchinone e 5-nitro-γ-tocoferolo) sono stati analizzati in casi 
di AD, MCI e soggetti cognitivamente integri (CN) nell’ambito di uno studio clinico europeo 
multicentrico (Progetto AddNeuroMed). Rispetto ai soggetti CN ridotti livelli plasmatici di tocoferoli 
totali, tocotrienoli totali e vitamina E totale sono stati riscontrati nei casi di AD e MCI. Inoltre, rispetto ai 
soggetti CN, la diagnosi di MCI e di AD è risultata associata a elevati valori di indici plasmatici di 
danno ossidativo e nitrosativo della vitamina E (rapporto α-tocoferilchinone/α-tocoferolo e 5-nitro-γ-
tocoferolo/γ-tocoferolo). 
 
Studio II. Nell’ambito del Progetto AddNeuroMed, dati sui livelli plasmatici di vitamina E e dati 
strutturali di risonanza magnetica (MRI) ottenuti da analisi automatica sono stati utilizzati in un’analisi 
integrata per valutare la loro accuratezza nel distinguere casi di AD e MCI da soggetti CN e nel predire 
la progressione dei soggetti con MCI ad AD. L’analisi separata dei dati sulla vitamina E e dei dati di 
MRI ha fornito un’accuratezza dell’83.2% e del 92.8% nella distinzione di AD versus CN, e del 58.1% e 
87.8% nella distinzione di MCI versus CN. L’analisi integrata di entrambi i tipi di dati (vitamina E + 
MRI) ha migliorato tale accuratezza: per il confronto AD versus CN si è ottenuta un’accuratezza del 
98.2%, mentre per il confronto MCI versus CN l’accuratezza è risultata del 90.7%. La combinazione di 
tali dati ha inoltre permesso di identificare correttamente l’85% dei soggetti con MCI che sono 
progrediti ad AD dopo un anno di follow-up ed il 67% degli MCI che sono rimasti clinicamente stabili. 
 
Studio III. L’incidenza di AD, in relazione ai livelli plasmatici delle otto forme naturali di vitamina E, è 
stata esaminata in uno studio longitudinale di popolazione condotto su ultraottantenni svedesi (Progetto 
Kungsholmen) durato sei anni. I soggetti con elevati livelli plasmatici di tocoferoli totali, tocotrienoli 
totali e vitamina E totale (terzile superiore versus inferiore) hanno riportato un rischio ridotto del 50% 
circa di sviluppare AD. 
 
Studio IV. L’incidenza di deterioramento cognitivo (AD o MCI), in relazione ai livelli plasmatici delle 
otto forme naturali di vitamina E e degli indici di danno ossidativo e nitrosativo di tale micronutriente, è 
stata esaminata in uno studio longitudinale di popolazione condotto su ultrasessantacinquenni finlandesi 
(Studio CAIDE) durato otto anni. Il rischio di declino cognitivo è risultato ridotto nei soggetti nel terzile 
medio del γ-tocoferolo [versus terzile inferiore; odds ratio (intervallo di confidenza 95%): 0.27 (0.10-
0.78)]. Un aumento di circa tre volte del rischio di deterioramento cognitivo è stato osservato nei 
soggetti con valori elevati del rapporto 5-nitro-γ-tocoferolo/γ-tocoferolo (terzili superiore e medio versus 
inferiore). 
 
Conclusione. L’α-tocoferolo è la sola forma di vitamina E presente nelle raccomandazioni nutrizionali 
ed è l’unica forma che è stata testata nelle sperimentazioni cliniche controllate nei soggetti con AD e 
MCI. I risultati del presente progetto indicano che non solo l’α-tocoferolo, ma anche  le diverse altre 
forme di vitamina E, possono essere importanti nello sviluppo di MCI e AD negli anziani. Alla luce di 
questi dati le strategie basate sulla supplementazione con vitamina E andrebbero riesaminate. In 
particolare, gli aspetti da rivalutare sono la “finestra-terapeutica” e la composizione dei supplementi 
contenenti vitamina E. Il dosaggio ematico di tutti i congeneri della vitamina E può rivelarsi utile 
nell’identificare i soggetti che possono beneficiare della supplementazione e nel monitoraggio in-vivo 
degli effetti biologici della supplementazione stessa. 
 
Parole chiave: decadimento cognitivo lieve, malattia di Alzheimer, stress nitrosativo, stress ossidativo, 
studio clinico, studio di popolazione, tocoferolo, tocotrienolo, vitamina E, α-tocoferilchinone e 5-nitro-γ-
tocoferolo. 
 LIST OF ABBREVIATIONS 
AD Alzheimer’s disease  
5-NO2-γ-tocopherol  5-nitro-γ-tocopherol 
ADAS-Cog Alzheimer’s Disease Assessment Scale-cognitive 
subscale  
ADCS Alzheimer’s Disease Cooperative Study  
ADL Activities of daily living 
ADNI Alzheimer Disease Neuroimaging Initiative  
AHRQ Agency for Healthcare Research and Quality  
ANOVA Analysis of variance  
APOE Apolipoprotein E  
APP Amyloid beta precursor protein  
AVED Ataxia with vitamin E deficiency  
Aβ β-amyloid  
BMI Body mass index  
CAIDE The Finnish Cardiovascular Risk Factors, Aging, and 
Dementia Study 
CDR Clinical Dementia Rating scale  
CERAD Consortium to Establish a Registry for Alzheimer’s 
Disease 
CHAP Chicago Health and Aging Project  
CI Confidence interval 
CN Cognitively normal  
CNS Central nervous system  
CSBA Conselice Study on Brain Ageing  
CSF Cerebrospinal fluid  
DSM-III-R, (DSM-IV) Diagnostic and Statistical Manual of Mental Disorders, 
revised third edition, (Fourth edition) 
FDG-PET Fluorodeoxyglucose-positron emission tomography 
FINMONICA Finnish part of Monitoring trends and determinants of 
Cardiovascular disease study 
GDS Geriatric Depression Scale  
HAAS Honolulu-Asia Aging Study 
HPLC High Performance Liquid Chromatography  
HR Hazard ratio 
IU International unit 
LDL Low-density lipoprotein  
LPL Lipoprotein lipase  
LR Likelihood ratio 
MCI Mild cognitive impairment  
MMSE Mini-Mental State Examination 
MRI Magnetic resonance imaging  
NFT Neurofibrillary tangle 
NIH National Institute of Health  
NINCDS-ADRDA National Institute of Neurological and Communicative 
Disorders and Stroke-Alzheimer’s Disease and Related 
Disorders Association  
NS Nitrosative stress 
OPLS Orthogonal partial least squares to latent structures  
OR Odds ratio 
OS Oxidative stress  
PAQUID Personnes Agées QUID  
PCR  Polymerase chain reaction 
PET Positron emission tomography  
PUFA Polyunsaturated fatty acid  
RCT Randomized controlled trial  
RDA Recommended dietary allowance  
RNS Reactive nitrogen species  
ROS Reactive oxygen species  
SD Standard deviation 
SES Socioeconomic status  
SIMCA Soft Independent Modeling of Class Analogy 
SP Senile plaque  
SPSS Statistical Package for the Social Sciences 
ULSAM Uppsala Longitudinal Study of Adult Men   
VLDL Very low density lipoproteins  
WHICAP Washington Heights-Inwood Columbia Aging Project 
α-TQ α-tocopherylquinone 
α-TTP α-tocopherol transfer protein 
 
 
 
 
 
 
 
 
 
 LIST OF ORIGINAL PUBLICATIONS 
This doctorial thesis is based on the following original papers, referred to in the text by 
their Roman numerals: 
 
I. Mangialasche F, Xu W, Kivipelto M, Costanzi E, Ercolani S, Pigliautile M, 
Cecchetti R, Baglioni M, Simmons A, Soininen H, Tsolaki M, Kloszewska I, 
Vellas B, Lovestone S, Mecocci P, on behalf of the AddNeuroMed Consortium. 
Tocopherols and tocotrienols plasma levels are associated with cognitive 
impairment. Neurobiology of Aging, 2011, Epub 20th December, 
doi:10.1016/j.neurobiolaging.2011.11.019. 
 
II. Mangialasche F, Westman E, Kivipelto M, Muehlboeck JS, Cecchetti R, 
Baglioni M, Tarducci R, Gobbi G, Floridi P, Soininen H, Kłoszewska I, Tsolaki 
M, Vellas B, Spenger C, Lovestone S, Wahlund LO, Simmons A and Mecocci 
P, for the AddNeuroMed consortium. Classification and prediction of clinical 
Alzheimer’s diagnosis based on MRI and plasma vitamin E measures. 
Submitted. 
 
III. Mangialasche F, Kivipelto M, Mecocci P, Rizzuto D, Palmer K, Winblad B, 
Fratiglioni L. High plasma levels of vitamin E forms and reduced Alzheimer’s 
disease risk in advanced age. Journal of Alzheimers Disease, 2010;20:1029-37. 
  
IV. Mangialasche F, Solomon A, Kåreholt I, Fratiglioni L, Soininen H, Laatikainen 
T, Mecocci P, Kivipelto M. Serum levels of vitamin E forms and risk of 
cognitive impairment in a Finnish cohort of older adults.  
Submitted. 
 
 
 
Paper I © 2011 Reprinted with permission from Elsevier. 
Paper III © 2010 Reprinted with permission from IOS press. 
 
 
OTHER PUBLICATIONS BY THE AUTHOR NOT INCLUDED IN 
THE THESIS 
Mangialasche F, Kivipelto M, Solomon A, Fratiglioni L. Dementia prevention: current 
epidemiological evidence and future perspective. Alzheimers Res Ther. 2012;4:6. 
Pigliautile M, Ricci M, Mioshi E, Ercolani S, Mangialasche F, Monastero R, Croce MF, 
Federici S, Mecocci P. Validation Study of the Italian Addenbrooke's Cognitive Examination 
Revised in a Young-Old and Old-Old Population. Dement Geriatr Cogn Disord. 2011;32:301-7. 
Bennett S, Grant M, Creese AJ, Mangialasche F, Cecchetti R, Cooper HJ, Mecocci P, Aldred S. 
Plasma Levels of Complement 4a Protein are Increased in Alzheimer's Disease. Alzheimer Dis 
Assoc Disord, 2011, Epub Nov 2nd. 
Andrieu S, Aboderin I, Baeyens JP, Beard J, Benetos A, Berrut G, Brainin M, Cha HB, Chen 
LK, Du P, Forette B, Forette F, Franco A, Fratiglioni L, Gillette-Guyonnet S, Gold G, Gomez F, 
Guimaraes R, Gustafson D, Khachaturian A, Luchsinger J, Mangialasche F, Mathiex-Fortunet 
H, Michel JP, Richard E, Schneider LS, Solomon A, Vellas B. IAGG workshop: health 
promotion program on prevention of late onset dementia. J Nutr Health Aging, 2011;15:562-75. 
Marengoni A, Angleman S, Melis R, Mangialasche F, Karp A, Garmen A, Meinow B, 
Fratiglioni L. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev, 
2011;10:430-9. 
Sultana R, Mecocci P, Mangialasche F, Cecchetti R, Baglioni M, Butterfield DA. Increased 
protein and lipid oxidative damage in mitochondria isolated from lymphocytes from patients 
with Alzheimer's disease: insights into the role of oxidative stress in Alzheimer's disease and 
initial investigations into a potential biomarker for this dementing disorder. J Alzheimers Dis, 
2011;24:77-84. 
Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: clinical 
trials and drug development. Lancet Neurol. 2010;9:702-16. 
Ankarcrona M, Mangialasche F, Winblad B. Rethinking Alzheimer's disease therapy: are 
mitochondria the key? J Alzheimers Dis, 2010;20 Suppl 2:S579-90. 
Fratiglioni L, Mangialasche F, Qiu C. Brain aging: lessons from community studies. Nutr Rev, 
2010;68 Suppl 2:S119-27. 
  
Feliziani FT, Polidori MC, De Rango P, Mangialasche F, Monastero R, Ercolani S, Raichi T, 
Cornacchiola V, Nelles G, Cao P, Mecocci P. Cognitive performance in elderly patients 
undergoing carotid endarterectomy or carotid artery stenting: a twelve-month follow-up study. 
Cerebrovasc Dis, 2010;30:244-51. 
Iurescia S, Fioretti D, Mangialasche F, Rinaldi M. The pathological cross talk between 
apolipoprotein E and amyloid-beta peptide in Alzheimer's disease: emerging gene-based 
therapeutic approaches. J Alzheimers Dis, 2010;21:35-48. 
Maggio D, Ercolani S, Andreani S, Ruggiero C, Mariani E, Mangialasche F, Palmari N, 
Mecocci P. Emotional and psychological distress of persons involved in the care of patients 
with Alzheimer disease predicts falls and fractures in their care recipients. Dement Geriatr 
Cogn Disord, 2010;30:33-8. 
Monastero R, Mangialasche F, Camarda C, Ercolani S, Camarda R. A systematic review of 
neuropsychiatric symptoms in mild cognitive impairment. J Alzheimers Dis, 2009;18:11-30. 
Mangialasche F, Polidori MC, Monastero R, Ercolani S, Camarda C, Cecchetti R, Mecocci P. 
Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive 
impairment. Ageing Res Rev, 2009;8:285-305. 
Polidori MC, Praticó D, Mangialasche F, Mariani E, Aust O, Anlasik T, Mang N, Pientka L, 
Stahl W, Sies H, Mecocci P, Nelles G. High fruit and vegetable intake is positively correlated 
with antioxidant status and cognitive performance in healthy subjects. J Alzheimers Dis, 
2009;17:921-7. 
Pilotto A, Franceschi M, D'Onofrio G, Bizzarro A, Mangialasche F, Cascavilla L, Paris F, 
Matera MG, Pilotto A, Daniele A, Mecocci P, Masullo C, Dallapiccola B, Seripa D. Effect of 
a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. 
Neurology, 2009;73:761-7. 
Ravaglia G, Forti P, Lucicesare A, Pisacane N, Rietti E, Mangialasche F, Cecchetti R, 
Patterson C, Mecocci P. Plasma tocopherols and risk of cognitive impairment in an elderly 
Italian cohort. Am J Clin Nutr, 2008;87:1306-13.  
Mariani E, Mangialasche F, Feliziani FT, Cecchetti R, Malavolta M, Bastiani P, Baglioni M, 
Dedoussis G, Fulop T, Herbein G, Jajte J, Monti D, Rink L, Mocchegiani E, Mecocci P. 
Effects of zinc supplementation on antioxidant enzyme activities in healthy old subjects. Exp 
Gerontol, 2008;43:445-51. 
CONTENTS 
 
1 INTRODUCTION ..................................................................................... 1 
1.1 Dementia and Alzheimer’s disease: epidemiology ........................... 1 
1.2 Alzheimer’s disease diagnosis: still a challenge ............................... 5 
1.3 Alzheimer pathophysiology: oxidative and nitrosative stress ........... 7 
1.3.1 Definition of oxidative and nitrosative stress ....................... 7 
1.3.2 Oxidative and nitrosative stress in Alzheimer’s disease 
and mild cognitive impairment......................................................... 8 
1.4 Vitamin E ......................................................................................... 9 
1.4.1 Vitamin E metabolism ........................................................ 10 
1.4.2 Vitamin E biological properties .......................................... 11 
1.4.3 Vitamin E, dementia and Alzheimer’s disease: clinic- and 
population-based observational studies .......................................... 14 
1.4.4 Vitamin E and Alzheimer’s disease: clinical trials ............. 17 
2 AIMS ....................................................................................................... 27 
2.1 General aims .................................................................................. 27 
2.2 Specific aims .................................................................................. 27 
3 METHODS ............................................................................................. 28 
3.1 Clinic-based studies ....................................................................... 28 
3.1.1 AddNeuroMed Project (Studies I and II) ............................ 28 
3.1.1.1 Study population ................................................................ 28 
3.1.1.2 Data collection ................................................................... 29 
3.1.1.3 Diagnosis of dementia and mild cognitive impairment....... 29 
3.1.1.4 Vitamin E assessment ......................................................... 29 
3.1.1.5 Other biochemical analyses ................................................ 30 
3.1.1.6 MRI .................................................................................... 31 
3.2 Population-based studies ................................................................ 34 
3.2.1 Kungsholmen Project (Study III) ....................................... 34 
3.2.1.1 Study population ................................................................ 34 
3.2.1.2 Data collection ................................................................... 34 
3.2.1.3 Diagnosis of dementia ........................................................ 35 
3.2.1.4 Vitamin E assessment ......................................................... 36 
3.2.1.5 Other biochemical analyses ................................................ 36 
3.2.2 CAIDE (Study IV) ............................................................. 36 
3.2.2.1 Study population ................................................................ 36 
3.2.2.2 Data collection ................................................................... 37 
3.2.2.3 Diagnosis of dementia and mild cognitive impairment....... 38 
3.2.2.4 Vitamin E assessment ......................................................... 39 
 3.2.2.5 Other biochemical analyses ............................................... 39 
3.3 Statistical analysis ......................................................................... 39 
3.3.1 Specific analyses for each study ........................................ 40 
3.3.2 Pooled analyses ................................................................. 43 
4 ETHICAL CONSIDERATIONS ............................................................ 45 
4.1 The AddNeuroMed Project ........................................................... 45 
4.2 The Kungsholmen Project ............................................................. 45 
4.3 The CAIDE study .......................................................................... 46 
5 RESULTS............................................................................................... 47 
5.1 Clinic-based studies....................................................................... 47 
5.1.1 Characteristics of the population ....................................... 47 
5.1.2 Relation of vitamin E to Alzheimer’s disease and mild 
cognitive impairment (Study I)...................................................... 47 
5.1.3 Vitamin E and MRI in relation to Alzheimer’s disease and 
mild cognitive impairment (Study II) ............................................ 51 
5.2 Population-based studies ............................................................... 56 
5.2.1 Characteristics of the populations ...................................... 56 
5.2.2 Vitamin E and risk of Alzheimer’s disease in subjects 
aged 80+ years (Study III) ............................................................. 58 
5.2.3 Vitamin E and risk of cognitive impairment in subjects 
aged 65+ years (Study IV) ............................................................. 61 
5.3 Pooled analysis .............................................................................. 63 
6 DISCUSSION ........................................................................................ 66 
6.1 Vitamin E, Alzheimer’s disease, and mild cognitive impairment: 
clinical context ........................................................................................ 66 
6.2 Vitamin E, Alzheimer’s disease and mild cognitive impairment: 
general population context ...................................................................... 68 
6.3 Biological plausibility ................................................................... 69 
6.4 Clinical implications ..................................................................... 70 
6.5 Methodological issues ................................................................... 72 
6.5.1 Clinic-based studies ........................................................... 73 
6.5.2 Population-based studies ................................................... 76 
7 CONCLUSIONS .................................................................................... 79 
8 FUTURE DIRECTIONS ........................................................................ 80 
9 ACKNOWLEDGEMENTS.................................................................... 82 
10 REFERENCES ....................................................................................... 85 
11 APPENDIX .......................................................................................... 101 
• Dissertations from the Aging Research Center and the 
Stockholm Gerontology Research Center, 1991-2011 
• Original publications 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                               
                                                         O frati…considerate la vostra semenza: 
 fatti non foste a viver come bruti, 
 ma per seguir virtute e conoscenza 
 
 
(Dante Alighieri, Inferno, canto XXVI, vv.112-120) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
1 
 
1 INTRODUCTION 
1.1 Dementia and Alzheimer’s disease: epidemiology 
Dementia is an acquired disabling syndrome characterized by progressive deterioration in 
multiple cognitive domains that is severe enough to interfere with daily functioning, 
including social and professional functioning.1 Alzheimer’s disease (AD) is the most 
common cause of dementia, but increasing evidence from population-based 
neuropathological and neuroimaging studies shows that mixed brain pathologies 
(neurodegenerative, vascular) account for a large number of dementia cases, especially in 
very old people.2,3 
Increasing age is a well-established risk factor for dementia and AD. Both prevalence and 
incidence of dementia rise exponentially with advancing age, and 70% of all dementia 
cases occur in people aged 75+ years.4 The worldwide increase in the number of older 
adults, which is particularly pronounced in the 80+ age group, explains the epidemic 
proportions assumed by dementia. Because dementia is a major cause of disability and 
institutionalization of elderly people, the increased prevalence of this syndrome places 
enormous pressure on health care systems and society. According to the World Alzheimer 
Report, there were 35.6 million people living with dementia worldwide in 2010, a number 
that will increase to 65.7 million by 2030 and 115.4 million by 2050 unless effective means 
of reducing disease incidence are introduced.5 The total estimated worldwide costs of 
dementia were US$604 billion in 2010, including the costs of informal care (unpaid care 
provided by family and others), direct costs of social care (provided by community care 
professionals, and in residential home settings), and the direct costs of medical care (the 
costs of treating dementia and other conditions in primary and secondary care).5 
The etiology of dementia has been extensively studied over the last decades with the aim of 
identifying efficacious prevention and treatment strategies. These efforts have indicated 
that dementia/AD are multifactorial disorders involving several interrelated mechanisms in 
which the interaction of genetic and environmental factors plays a major role. The 
pathways that lead from different risk factors to dementia are not fully understood, but 
several etiological hypotheses have been proposed: the vascular hypothesis; inflammatory 
hypothesis; oxidative-stress hypothesis; toxic hypothesis; and psychosocial hypothesis.6,7 
These theories highlight potential links of various risk factors to both AD and the vascular 
brain pathology that can cause dementia.8,9  
A recent report commissioned by the American National institute of Health (NIH) to the 
Agency for Healthcare Research and Quality (AHRQ) concluded that current research 
evidence on many risk and protective factors for cognitive decline and AD is not of 
sufficient strength, thus recommendations for preventing these conditions cannot be 
made.10,11 Another previous review yielded similar conclusions.12 These negative 
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perspectives have been criticized, since epidemiological evidence that use of 
antihypertensive medications, cessation of smoking and increasing physical activity 
produces cognitive benefits in older adults is not inadequate,13 and the analytical strategy 
used in the evidence based review did not take into account the life-course perspective.14 In 
fact, observational longitudinal studies show that the risk of late-life dementia/AD is 
determined by exposures to multiple factors experienced over the life-span, and that the 
effect of specific risk/protective factors largely depends on age (Table 1).  
 
Table 1. Proposed risk and protective factors for dementia and Alzheimer’s disease 
 
Risk factors Protective factors Combined effects 
Age 
Genetic 
APOEε4 
Familial aggregation 
 
Vascular 
Cerebrovascular lesions 
Cardiovascular diseases 
Diabetes mellitus and pre-
diabetes 
Midlife positive association but late-
life negative association 
Hypertension  
High BMI (overweight and 
obesity) 
High serum cholesterol  
 
Lifestyle 
Smoking  
High alcohol intake 
 
Diet 
Saturated fats 
Homocysteine 
 
Others 
Depression 
Psychosocial factors  
High education and SES 
High work complexity 
Rich social network and social 
engagement 
Mentally stimulating activity 
 
Lifestyle  
Physical activity 
 
Diet 
Mediterranean diet 
Polyunsaturated (PUFA) and 
fish-related fats 
Vitamin B6, B12, folate  
Antioxidant vitamins (C, E) 
Increased risk 
Genetic and environmental factors in 
midlife 
APOEε4 magnifies the effect of 
high alcohol intake, smoking, 
physical inactivity and high intake of 
saturate fat 
 
Vascular factors in midlife  
Hypertension, obesity, 
hypercholesterolemia and physical 
inactivity have an additive effect 
when they co-occur 
 
Vascular factors/diseases in late-life 
Higher risk in individuals with brain 
hypoperfusion profile: chronic heart 
failure, low pulse pressure, low 
diastolic pressure 
Higher risk in individuals with 
atherosclerosis profile: high systolic 
pressure, diabetes mellitus or 
prediabetes, stroke 
 
Decreased risk 
Genetic and environmental factors  in 
midlife 
High education reduces the 
negative effect of APOEε4  
Physical activity counteracts the risk 
due to APOEε4 
 
Environmental factors in midlife 
High work complexity modulates 
the increased dementia risk due to 
low education 
APOE: apolipoprotein E.  BMI: body mass index.  PUFA: polyunsaturated fatty acid.  SES: socioeconomic 
status. 
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Thus, a life-course perspective is relevant for chronic disorders with a long latent period 
(such as dementia/AD). It allows the identification of time windows when exposures have 
their greatest effect on outcome and enables the assessment of whether cumulative 
exposures could have multiplicative or additive effects over the life course.7 Age-
dependent associations with dementia/AD have been suggested for several aging-related 
medical conditions. For example, elevated blood pressure, body mass index (BMI) and 
total cholesterol levels at a young age and in middle age (<65 years) is associated with an 
increased risk of dementia and AD, whereas having lower values in late-life (age >75 
years) is also associated with subsequent development of dementia/AD.15-20 Diabetes 
mellitus has been associated with an increased risk of dementia and AD over adult life, but 
the risk is stronger when diabetes occurs in mid-life than in late-life.21 Current smoking is 
another major risk factor for dementia and AD, and based on the worldwide prevalence of 
smoking, about 14% of all AD cases are potentially attributable to this risk factor.22 
Although it is not entirely clear whether depression is a risk factor for or a preclinical 
symptom of dementia, studies with long-term follow-up support the risk factor 
hypothesis.23 
Protective factors for dementia and AD have also been identified, including high education 
and socioeconomic status (SES) in early life as well as a number of factors in adult life: 
high work complexity, rich social network, social engagement, mentally-stimulating 
activity, not smoking and regular physical exercise.6,24,25 Living with a partner during 
midlife has been associated with reduced risk of cognitive impairment and dementia later 
in life, suggesting that being in a relationship entails cognitive and social challenges that 
can increase cognitive reserve.26 Even at old ages active engagement in mental, physical, 
and social activities may postpone the onset of dementia, possibly by increasing cognitive 
reserve.27 In addition, several follow-up studies reported a decreased risk of dementia 
associated with healthy dietary patterns and nutritional factors, such as high adherence to a 
Mediterranean diet, vitamins (B6, B12, C, E, folate) and ω-3 polyunsaturated fatty acid 
(PUFA), which is often measured as fish consumption.28-31 
Cumulative and combined exposure to different risk factors can lead to modified effects on 
dementia/AD risk (Table 1). In the Finnish Cardiovascular Risk Factors, Aging and 
Dementia study (CAIDE), the risk of dementia has been evaluated in relation to a score 
(CAIDE Dementia Risk Score) combining midlife risk factors, including low education 
and cardiovascular factors (i.e., hypertension, obesity, hypercholesterolemia, physical 
inactivity). The risk of dementia increases as the score increases in a dose-response trend, 
making it possible to identify individuals who can greatly benefit from preventive 
interventions that target vascular risk factors.32 Similar findings have been reported for 
late-life exposures: in the Swedish Kungsholmen Project, the cumulative effect of vascular 
risk factors and vascular diseases on dementia/AD risk has been investigated in people 
aged 75+ years. These factors were aggregated according to two pathophysiological 
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hypotheses: the brain hypoperfusion profile, defined by chronic heart failure, low pulse 
pressure, and low diastolic pressure, and the atherosclerosis profile, which included high 
systolic pressure, diabetes mellitus or prediabetes, and stroke. In both profiles, 
dementia/AD risk increases with increasing scores in a dose-response manner, suggesting a 
synergy of vascular risk factors in promoting dementia/AD also in advanced age.33 The 
American Cardiovascular Health Cognition Study developed a Late-life Dementia Risk 
Index, which groups older adults into three categories of low, moderate, and high risk of 
developing dementia. This index supports the cumulative effect of different factors in 
determining the risk of dementia after the age of 65 years, and it includes information from 
different domains, including demographic factors (age), genetic (presence of the 
Apolipoprotein E (APOE)-ε4 allele), lifestyle (BMI<18.5, lack of alcohol consumption), 
comorbid vascular conditions (internal carotid artery thickening, angina, coronary artery 
by-pass surgery, stroke, peripheral artery disease), evidence of brain abnormalities showed 
by magnetic resonance imaging (MRI) (white matter diseases or enlarged ventricles), 
cognitive test scores and physical performances.34,35    
The combined effect of genetic-environmental or environmental-environmental joint 
exposures may also lead to the attenuation of the dementia risk. Population-based studies 
suggest an effect modification for the APOE ε4 allele, the most important genetic risk 
factor for sporadic AD. APOE ε4 carriers seem more vulnerable to risk factors like alcohol 
drinking, smoking, physical inactivity, and high intake of saturate fat, indicating that 
people with genetic susceptibility may reduce their initial AD risk by lifestyle interventions 
(i.e., physical activity, sufficient intake of PUFA, and avoiding excess alcohol drinking and 
smoking).36 Further, it has been shown that high education may reduce dementia risk 
among APOE ε4 allele carriers.37 Regarding the interactions among modifiable risk factors, 
results from the Kungsholmen Project suggested that complexity of work with data and 
people was related to a decreased dementia risk and that the highest level of work 
complexity may modulate the increased dementia risk due to low education.24 
In conclusion, even though evidence is sparse for some risk and protective factors and their 
role in dementia and AD needs to be clarified, evidence from observational studies points 
towards a multifactorial nature of dementia/AD, with age-dependent associations for 
several factors. Epidemiological findings indicate the possibility to prevent or delay 
dementia/AD onset, by addressing modifiable risk/protective factors. It has been estimated 
that half of AD cases worldwide are potentially attributable to modifiable risk factors, and 
a 10-25% reduction in these factors could potentially prevent three million AD cases 
worldwide, with a reduction in all risk factors having the greatest impact on dementia 
prevalence.22 However, randomized controlled trials (RCT) are needed to confirm the 
effect of risk reduction strategies targeting multiple risk factors. Multidomain 
interventional RCT, which aims to simultaneously target several risk factors for dementia 
in older adults, are now ongoing and will provide new insights into prevention of cognitive 
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impairment and dementia/AD.38 
 
1.2  Alzheimer’s disease diagnosis: still a challenge  
The pathogenetic mechanisms leading to selective neuronal loss in AD are still unclear and 
effective treatments are slow to emerge.39 AD neuropathology is characterized by 
regionalized neuronal death, synaptic loss, accumulation of intraneuronal neurofibrillary 
tangles (NFT) and extracellular senile plaques (SP), and proliferation of reactive astrocytes 
in the entorhinal cortex, hippocampus, amygdala and association areas of frontal, temporal, 
parietal, and occipital cortex. NFTs are formed by intracellular deposits of paired helical 
filaments composed of hyperphosphorylated tau. SP can be present as diffuse plaques, 
composed of amorphous extracellular deposits of β-amyloid (Aβ) that lack neuritis, and as 
neuritic plaques, which consist of extracellular deposits of insoluble Aβ surrounded by 
dystrophic neurites, reactive astrocytes, and activated microglia. Aβ is a 39-43 amino acid 
peptide derived from the larger amyloid beta precursor protein (APP) by proteolytic 
cleavage. Aβ 1-40 is the most frequent form of Aβ even if the minor species (i.e., Aβ 1-42) 
has a higher propensity to aggregate and is greatly enriched in amyloid deposits. Recent 
studies suggest that soluble Aβ oligomers are present in the AD brain and they may 
represent the main toxic form of Aβ.40-42 Aβ accumulation is considered a key early event 
in AD pathophysiology, but its role in sporadic late-onset AD has yet to be clarified. There 
may be pathophysiological events that are “upstream” of Aβ accumulation, including 
mitochondrial, metabolic, inflammatory, oxidative/nitrosative stress (OS/NS) alterations, 
which may play an even earlier, or more central, role than Aβ peptides in the pathogenesis 
of AD.43-47 
AD clinical onset is insidious and often characterized by memory impairment. The disease 
progressively evolves over a period of years, eventually leading to global cognitive 
impairment.48 AD is frequently manifested by a symptomatic pre-dementia phase, which is 
often identified as mild cognitive impairment (MCI). Although there are different 
definitions of MCI, the general concept is of a condition in which memory or other 
cognitive abilities are slightly abnormal but they coexist with predominantly normal 
functions in activities of daily living (ADL) and absence of dementia.49,50 MCI has been 
related to an increased risk of conversion to dementia and it may be considered, in many 
cases, prodromal AD. Patients in memory disorder clinics who are diagnosed with MCI 
progress to AD at the rate of 10-15% per year, while population-based studies show a 
lower rate of progression with some individuals remaining stable or even improving.51-54 
Clinical diagnosis of AD is currently based on the National Institute of Neurological and 
Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders 
Association (NINCDS-ADRDA) criteria, established in 1984.55 These criteria essentially 
involve a two-step procedure, in which i) the presence of a dementia syndrome is defined, 
and ii) typical features of the AD phenotype (i.e., presence of memory impairment, gradual 
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onset and progression) are identified, and the presence of systemic or central nervous 
system (CNS) diseases capable of producing a dementia syndrome is excluded. 
These diagnostic criteria rely on the close correspondence between clinical symptoms and 
the underlying brain pathology, but research on AD conducted in the last three decades has 
shown that AD neuropathology and the AD clinical syndrome should not be considered as 
synonymous of each other.56 Indeed, extensive AD pathology, particularly diffuse SPs, can 
be present in individuals who are cognitively normal and in those with MCI.57-60 Moreover, 
AD pathophysiology can manifest itself with clinically atypical presentations, such as 
prominent language and visuospatial disturbances.61-63 
The NINCDS-ADRDA criteria create a dichotomy between dementia and non-dementia, 
not considering the spectrum of cognitive impairment. Indeed, several studies have shown 
that the pathophysiological process of AD begins years, if not decades, before the 
diagnosis of Alzheimer’s dementia and individuals generally experience a gradual 
impairment of cognitive functions, which can progress to a dementia syndrome.64,65 Recent 
advances in neuroimaging, cerebrospinal fluid (CSF) assays, and other techniques now 
provide the ability to detect evidence of the AD pathophysiological process in vivo, but the 
diagnostic criteria currently in use do not take into account these biomarkers. 
Three international workgroups promoted by the American National Institute of Aging and 
the American Alzheimer’s Association recently proposed new diagnostic guidelines to 
identify dementia due to AD, MCI due to AD, and preclinical AD.45,66,67 These new criteria 
formalize the different clinical stages of AD and incorporate biomarkers (genetic, 
biochemical, neuroimaging) that can be detected in vivo and are believed to reflect AD 
pathology. These diagnostic criteria can be revised as long as new findings from research 
on biomarkers in AD will clarify the link between AD pathophysiology and the AD 
clinical syndrome. 
 
Role of biomarkers 
Biomarkers are defined as characteristics that can be objectively measured and evaluated as 
indicators of normal biological processes, pathogenic processes, or pharmacological 
responses to a therapeutic intervention.68 
The new diagnostic criteria for AD, MCI due to AD and preclinical AD include two main 
categories of biomarkers: i) biomarkers of Aβ accumulation, which are abnormal tracer 
retention on amyloid positron emission tomography (PET) imaging and low CSF Aβ 1-42, 
and ii) biomarkers of neuronal degeneration or injury, which are elevated CSF tau (both 
total and phosphorylated tau); decreased fluorodeoxyglucose uptake on PET (FDG-PET) in 
a specific topographic pattern involving temporoparietal cortex; and atrophy on MRI - 
again in a specific topographic pattern - involving medial, basal, and lateral temporal lobes 
and medial and lateral parietal cortices.56  
The choice of these biomarkers in the new diagnostic recommendations is based on the 
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assumption that SPs and NFTs define AD neuropathology. The diagnostic criteria also 
postulate the presence of a temporal order of biomarker abnormalities, and assign a key, 
early role to Aβ in AD pathophysiology. Validation and standardization of the proposed 
biomarkers are needed before they can be implemented in clinical practice, and the 
diagnostic recommendations emphasize that the clinical diagnosis is still paramount for 
both AD-related dementia and MCI. Further, since the diagnosis of pre-symptomatic AD is 
based almost entirely on biomarkers, it is intended only for research purposes.56 
Among other candidates for biomarkers, there are compounds reflecting biochemical 
changes related to processes occurring in AD, such as OS/NS and inflammation. Markers 
of these processes may provide information about specific pathways that are altered in AD, 
but their utility in AD diagnosis is still unclear.66  
The combination of different biomarkers may prove to be more useful than using single 
biomarkers separately. For instance, a large amount of data on different brain regions can 
be obtained with structural MRI, and the combined analysis of these data can increase the 
diagnostic accuracy for MCI and AD, compared to the examination of single brain 
regions.69-71 Combined analysis could also be done by integrating biomarkers assessed with 
different modalities. Blood/plasma markers are less invasive to acquire than CSF and could 
support diagnosis and monitoring of disease progression in AD.72,73 Combining different 
types of biomarkers, including neuroimaging, CSF, blood and neuropsychological data, 
could increase their diagnostic and prognostic value for AD and MCI, but few studies have 
tested the utility of a multimodal biomarkers approach.74-76 
 
1.3 Alzheimer pathophysiology: oxidative and nitrosative stress 
1.3.1 Definition of oxidative and nitrosative stress 
OS/NS are promoted by the dysregulation of the redox balance, caused by a deficiency of 
antioxidants and/or overproduction of free radicals, such as reactive oxygen species (ROS) 
and reactive nitrogen species (RNS).77,78 Exogenous agents (e.g., photochemical smog, 
ozone, pesticides, xenobiotics and ionizing radiation) and a variety of endogenous 
processes (mitochondrial respiration, cytochrome P-450 detoxification reactions, 
phagocytic oxidative bursts, and peroxisomal leakage) can generate significant amounts of 
ROS and RNS in the human body.79 Indeed, both species of free radicals are products of 
normal cellular metabolism, and mitochondrial oxidative phosphorylation generates the 
majority of free radicals in the cell.43 ROS/RNS take part in many physiological processes, 
including cellular signaling, reactions to stress/noxia, induction of mitogenic and apoptotic 
responses.77,78 However, ROS and RNS can be harmful as they can damage cellular 
components, thus inhibiting their normal function, which can compromise cell viability or 
induce cell death.78  
Living systems have developed mechanisms with which to control the harmful effects of 
ROS/RNS. These systems are mainly based on: i) the presence of antioxidants, both 
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enzymatic (e.g., catalase, superoxide dismutase, glutathione peroxidase) and non-
enzymatic (e.g., vitamin A, C, E, β-carotene, glutathione, uric acid); ii) the repair or 
removal of damaged molecules. The wide variety of antioxidant defence systems help to 
prevent and repair ROS and RNS-induced damage.80 If free radicals production is not 
balanced by their neutralization OS/NS can occur.  
Free radical attack against lipids, proteins, sugars and nucleic acids leads to the formation 
of respective bioproducts, which can be assessed in tissues and provide information on the 
oxidant/antioxidant balance of the organism. Measurements of antioxidants’ levels or 
activities can also be used for the same purpose.  
 
1.3.2 Oxidative and nitrosative stress in Alzheimer’s disease and mild 
cognitive impairment 
The fact that age is the main risk factor for AD has provided the basis for the involvement 
of oxidative and nitrosative imbalance in this disease, since products of oxidative and 
nitrosative damage do accumulate during aging, and senescence seems to be characterized 
by a shift from redox regulation to oxidative and nitrosative damage.78,81 Also, the brain is 
particularly vulnerable to oxidative/nitrosative damage since: i) it contains a high 
proportion of PUFAs, which are highly susceptible to lipid peroxidation, and 
catecholamines prone to autoxidation; ii) it has a high metabolic activity that requires large 
amounts of oxygen (the brain uses approximately 20% of the oxygen consumed by the 
resting body); iii) it is relatively deficient in antioxidant systems with a lower activity of 
glutathione peroxidase and catalase compared to other organs; and iv) it contains redox-
active metals (copper, iron) that can promote the production of free radicals.43,82,83 
In the mid-1950’s Harman was among the first to suggest that OS may promote age-related 
degenerative diseases causing dementia.84 Since then, several experimental, clinical, 
neuropathological and population-based observational studies have shown data supporting 
the role of OS/NS as central processes in AD pathophysiology.43,78 It is still unclear 
whether OS/NS are primary initiating events associated with neurodegeneration or a 
secondary effect related to other pathological pathways. It is likely that OS/NS are both 
early, “upstream” events which contribute to AD pathogenesis, and also secondary, 
“downstream” consequences of other pathogenetic mechanisms, which amplify 
oxidative/nitrosative damage, thus generating a vicious circle promoting 
neurodegeneration.46,78,85 
Oxidative/nitrosative modification to virtually all classes of biomacromolecules has been 
described in brain regions susceptible to degeneration in subjects with AD and MCI, and 
also in the peripheral tissues (i.e., blood, urine) of these individuals.43 In addition to their 
individual role, biomarkers of OS/NS in AD have been shown to be associated with altered 
bioenergetics and Aβ metabolism.43,44,78,86 
It is not fully clear whether the increased oxidative/nitrosative damage in MCI and AD 
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subjects constitutes an acceleration of the “normal” age-related raise in OS/NS, or whether 
alternative pathways of free radicals production are involved. Several sources/conditions 
causing ROS/RNS hyperproduction have been suggested:87 i) loss of metal homeostasis, 
with a subsequent accumulation of iron and/or copper in the brain;88,89 ii) activation of 
microglia/astrocytes, such as those surrounding most SPs;90,91 iii) mitochondrial 
dysfunction, which seems to be a major source of ROS in AD;87,92-94 iv) APP and Aβ, 
which have been directly implicated in ROS formation.95-97 Specifically, Aβ oligomers 
seem to be more efficient in promoting OS, compared to the fibrilized form of Aβ.98 
Oxidative damage may, in turn, promote amyloid deposition.78,99,100 
Not only free radical hyperproduction, but also a less efficient antioxidant system may 
predispose the accumulation of oxidative and nitrosative damage in AD. Particularly, 
reduced antioxidant defences, due to low levels of non-enzymatic antioxidants (e.g., 
vitamin E), have been hypothesized to increase the risk of dementia and AD.   
The role of antioxidants in AD, including vitamin E, is not yet understood, but it is 
becoming clear that evaluation of these compounds could help in clarifying AD 
etiopathogenesis, and provide information which might support the monitoring of disease 
progression and of treatment based on antioxidant supplements.43  
 
1.4 Vitamin E 
Vitamin E was discovered by Evans and Bishop (1922) as a dietary factor necessary for 
reproduction in rats.101 Since it supported fertility, vitamin E was scientifically named as 
tocopherol. This comes from the Greek word tokos meaning childbirth, and phero meaning 
to bring forth, and the ol ending was added to indicate the alcohol properties of this 
molecule. The term vitamin E includes eight naturally occurring, lipophilic compounds 
(congeners): four tocopherols and four tocotrienols, named as α-, β-, γ-, and δ (Figure 1).102  
 
Figure 1. Structures of tocopherols and tocotrienols. 
 
Tocopherols consist of a chromanol ring and a saturated side chain, which serves to anchor 
tocopherols in biological membranes. Tocotrienols differ structurally from tocopherols by 
the presence of an unsaturated side chain, with three trans-double bonds, at C3, C7 and 
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C11. The four members of each family (α-, β-, γ-, δ-) differ by the number and placement 
of methyl groups on the chromanol ring (Figure 1). 
Vitamin E is an essential fat soluble nutrient, which is synthesized exclusively by 
photosynthetic organisms.103 So far there is no evidence that the different vitamin E forms 
can be interconverted in the human body. 
The main dietary sources of vitamin E are vegetable oils. Tocopherols are found mainly in 
wheat germ oil, almonds, sunflower and olive oil, which are rich in α-tocopherol. γ -
tocopherol is the major form of vitamin E in corn oil and soybean oil. Major food sources 
of tocotrienols are rice bran, barley, oats, and palm oil.104 Palm oil is one of the most 
abundant natural sources of tocotrienols. It contains a mixture of tocopherols and 
tocotrienols, and is used by the food industry (e.g., bakery products, breakfast cereals). α-
tocotrienol is the predominant form of tocotrienol in oat and barley, while β-tocotrienol is 
the major form of tocotrienol found in wheats. Rice bran oil, common in Asian countries, 
is a major natural source of γ-tocotrienol.103,105  
Other dietary sources of vitamin E are animal fats, dairy products, fruit, and vegetables. α-
tocopherol is the main form of vitamin E present in the European diet, while γ-tocopherol 
intake is higher than α-tocopherol in the USA diet.106 It has been estimated that, in the 
Western diet, about 50% of α-tocopherol is supplied by vegetable oils, 25% by animal fats, 
meat, and dairy products, and 25% by vegetables and fruit. Similar data for the other 
vitamin E forms are not available. 
 
1.4.1 Vitamin E metabolism 
The intestinal absorption of vitamin E ingested with food or supplements follows that of 
lipids. Specifically, absorption of vitamin E requires the secretion of pancreatic esterases 
and bile acids. These secretions are needed for the micellarization of dietary fats, including 
vitamin E, and the hydrolysis of triglycerides that release free fatty acids. The micelles are 
taken up by intestinal enterocytes. Vitamin E is subsequently incorporated into 
chylomicrons, which are secreted into the lymphatic system, and thus enters into the 
bloodstream. The different vitamin E forms are equally absorbed and incorporated into the 
chylomicrons.102,107,108 In the peripheral circulation, part of the newly absorbed vitamin E is 
released and transferred from chylomicrons to tissues and to other lipoproteins, during the 
lipoprotein lipase (LPL) activity and by nonspecific transfers through lipoproteins. The rest 
of the vitamin E remains with the chylomicron remnants and reaches the liver, where the 
uptake is mediated by the low-density lipoprotein (LDL) receptor.102,108 The liver 
repackages the dietary fats into very low density lipoproteins (VLDL) for secretion into the 
plasma and uptake by peripheral tissues. The liver has a key role in regulating vitamin E 
distribution. In the hepatocytes the α-tocopherol transfer protein (α-TTP) enriches the 
nascent VLDL with vitamin E, and α-TTP has a high preference for α-tocopherol, which is 
the main form incorporated in the VLDL. The importance of the α-TTP for tissue delivery 
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of α-tocopherol is confirmed by the severe α-tocopherol deficiency detected in subjects 
with a genetic deficit of the α-TTP, which compromise α-tocopherol transport in the 
VLDL. This disease, defined as “ataxia with vitamin E deficiency” (AVED), is 
characterized by progressive peripheral neuropathy with ataxia, and visual and cognitive 
problems.106 
The role of α-TTP in the transport of non α-tocopherol forms is still unclear. However, 
even if less efficiently, non α-tocopherol vitamin E forms can bind α-TTP.109 The relative 
affinities of α-TTP for different vitamin E congeners have been estimated to be 100% for 
α-tocopherol, 38% for β-tocopherol, 9% for γ-tocopherol, 2% for δ-tocopherol, and 12% 
for α-tocotrienol. Furthermore, other tocopherol binding proteins have been described,110 
and tocotrienols may be carried in plasma through lipoproteins.111 As a result, all eight 
natural vitamin E forms can be delivered to tissues, including the CNS. Indeed, α-, β- and 
γ-tocopherol have been detected in the brain,112,113 and recent studies have shown that 
tocotrienols are delivered to the CNS, where they reach concentrations adequate for 
beneficial biological activity.114 
The liver has a main role also in vitamin E excretion; within the hepatic cells vitamin E 
undergoes several steps of oxidation and enzymatic conjugation, leading to final 
metabolic products, which are excreted in either the bile or the urine. Different vitamin E 
forms are metabolized at different metabolic rates, with non α-tocopherol forms being 
metabolized faster than α-tocopherol, and a fraction of vitamin E is directly excreted by 
the liver without metabolic transformation.108 Many aspects about hepatic vitamin E 
trafficking and biotransformation in humans are not yet clear. It is clear, however, that 
the liver has a critical role in determining plasma levels of vitamin E forms. This is due 
to the selective affinity of α-TTP for the different vitamin E forms, and the regulation of 
vitamin E metabolism and excretion.106  
Plasma α-tocopherol concentration in humans range from 11 to 37 µmol/L, whereas γ-
tocopherol concentration is generally 2 to 5 µmol/L, and tocotrienols levels are less than 
1 µmol/L. When plasma lipids are taken into account, the lower limit of normal is 2.5 
µmol α-tocopherol/mmol cholesterol.106 Plasma concentrations of α-tocopherol are 
generally higher in European populations, compared to USA cohorts, while there is an 
opposite trend for γ-tocopherol levels. This difference is likely to reflect the high 
consumption in Europe of sunflower and olive oil (rich in α-tocopherol), and the high 
consumption in USA of soybean and corn oils (rich in γ-tocopherol).106,115 
In tissues, different amount of specific vitamin E forms are found, suggesting the 
presence of tissue specific mechanisms for enrichment and/or storage of tocopherols and 
tocotrienols, but there is scarce information on this aspect in humans.110 
 
1.4.2 Vitamin E biological properties 
The evidence on vitamin E biological properties comes from in-vitro studies, studies in 
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animal models, and human studies (Table 2). The interest of researchers in tocotrienols is 
relatively recent, with a lower number of human studies as compared to α-tocopherol, 
which is the most investigated vitamin E congener. 
The most well-known function of vitamin E is that of a chain-breaking antioxidant, that 
prevents the cyclic propagation of lipid peroxidation of PUFAs in cell membranes and 
lipoproteins. Peroxidation of membrane lipids is known to modify and inactivate cellular 
components, which can have damaging effects on crucial cellular factors leading to 
disease. Vitamin E functions in vivo as a potent peroxyl radical scavenger; α-tocopherol 
chemical reaction with oxidized lipids (peroxyl radicals) leads to the production of 
oxidized α-tocopherol (tocopheroxyl radical), which is regenerated to α-tocopherol by 
reductants compounds, such as vitamin C, ubiquinol, and glutathione.102,106,116  
α-tocopherol is considered the major lipid-soluble, non-enzymatic antioxidant in the 
human body.117 However, all tocopherols and tocotrienols have antioxidant activity, with γ-
tocopherol being highly effective in scavenging RNS,103,113 and tocotrienols being more 
efficient than α-tocopherol in neutralizing free radicals. This could be explained by 
different mechanisms, including i) the presence of the unsaturated side chain, which allows 
tocotrienols to distribute more efficiently into cell membranes; ii) a more efficient 
interaction of the chromanol ring with lipid radicals; and iii) a higher recycling efficiency 
from chromanoxyl radicals.103,118 
α-tocopherylquinone (α-TQ) is among the main products of α-tocopherol oxidation, 
while 5-nitro-γ-tocopherol (5-NO2-γ-tocopherol) is generated by γ-tocopherol reaction 
with RNS. It has been suggested that analysis of the relative levels of these compounds 
can provide information on the body level of OS/NS.113,116,119,120 
Vitamin E biological activity is not limited to antioxidant properties. Vitamin E forms are 
involved in the regulation of membrane-bound enzymes, gene expression, inflammatory 
response, cellular trafficking, and proliferation.103 Each vitamin E congener is functionally 
unique and exhibits specific biological functions, often not shared by the other family 
members (Table 2). The specificity of these biological properties is believed to rely on 
selective interactions of each vitamin E congener with enzymes, structural proteins, lipids, 
and transcription factors.110  
Because of their biological properties, vitamin E forms can play an important role in 
different diseases, including atherosclerosis and cardiovascular disease, cancer, and 
neurodegenerative disorders (AD, Parkinson’s disease, amyotrophic lateral 
sclerosis).85,103,121   
Biological properties of vitamin E that could be relevant for neuroprotection include 
antioxidant and anti-inflammatory activity and modulation of different signaling pathways 
(Table 2).103,122 As previously mentioned, OS/NS are believed to be key processes in AD 
onset and progression. Being the main lipid-soluble antioxidant, vitamin E has a prominent 
role in protecting cellular membranes. This could be crucial in mitochondria, since they are 
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both a main source and elective target of free radicals, and their dysfunction can promote 
neurodegeneration.123  
Table 2. Tocopherols and tocotrienols biological properties.103,110,122,124-127 
Vitamin E form Biological properties 
Tocopherols All forms 
- antioxidant  
- transcriptional and/or post-translational modulation of proteins expression and 
activity (specific for each congener) 
α-tocopherol 
- anti-inflammatory activity, inhibition of platelet and monocyte adhesion, inhibition of 
adhesion molecules expression 
- modulation of cell proliferation 
- regulation of bone remodelling, by stimulating osteoclast fusion 
γ-tocopherol 
- anti-inflammatory and natriuretic functions  
- antineoplastic activity, due to modulation of signal transduction and apoptosis, and 
inhibition of cell proliferation  
δ-tocopherol 
- antineoplastic activity, due to modulation of signal transduction and apoptosis, and 
inhibition of cell proliferation 
Tocotrienols All forms 
- antioxidant 
- transcriptional and/or post-translational modulation of proteins expression and 
activity (specific for each congener) 
All forms* 
- cholesterol lowering activity (total cholesterol, LDL cholesterol), due to modulation of 
the HMG-CoA-reductase 
- anti-aging effect, in cellular models of senescence and in animal models (extended 
mean life span)  
- antineoplastic activity (several cancer models), due to modulation of cell growth, 
proliferation and apoptotic signaling, and regulation of immunological functions 
- anti-inflammatory, anti-angiogenetic and anti-atherogenic activity, inhibition of 
adhesion molecules expression and monocyte adhesion 
α-tocotrienol 
- inhibition of the glutamate-induced neurotoxicity and neuronal death by modulating 
proteins activity, including phospholipase A2 and 12-lipoxygenase 
- protection against stroke related damage 
γ-tocotrienol 
- natriuretic properties 
δ-tocopherol 
- antineoplastic activity, due to modulation of signal transduction and apoptosis, 
inhibition of cell proliferation 
*In some studies the biological activity has been tested by using tocotrienol rich fractions (TRF), which 
contain different proportions of all natural tocotrienols. 
HMG-CoA-reductase: 3-hydroxy-3-methyl-glutaryl coenzyme A reductase.  
 
Inflammatory pathways also seem to be involved in AD pathogenesis,44 and some vitamin 
E forms (α- and γ-tocopherol, tocotrienols) exhibit anti-inflammatory properties that appear 
to be more potent for the non-α-tocopherol congeners.103,122,124 Modulation of cellular 
signaling can also be relevant for neuroprotection. At nanomolar concentrations, α-
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tocotrienol prevents neurodegeneration in mice and rat neurons, by regulating specific 
mediators of cell death.103 In fact, α-tocotrienol attenuates the Arachidonic Acid cascade 
leading to oxidative brain injury and inhibits the glutamate-induced neurotoxicity by 
modulating the phospholipase A2 activity.128,129 Finally, in experimental studies in 
transgenic mice models of AD, the potential role of α-tocopherol in reducing β-amyloid 
deposition and β-amyloid induced damage has been shown.85,130  
α-tocopherol is the only vitamin E form currently used to estimate vitamin E dietary 
requirements in humans,131 since it has the highest bioavailability and α-tocopherol 
deficiency causes well-known clinical signs and symptoms, including erythrocyte 
hemolysis and peripheral neuropathy.106,132  
Despite the official definition of vitamin E dietary requirement, which considers only α-
tocopherol, the increasing knowledge of vitamin E family biological properties provides a 
strong biological rationale of a possible role of different vitamin E forms in human health 
and disease, including dementia and AD. 
 
1.4.3 Vitamin E, dementia and Alzheimer’s disease: clinic- and population-
based observational studies 
In human studies the relationship between vitamin E and dementia/AD has been 
investigated mainly by measuring vitamin E concentration in serum/plasma or by assessing 
vitamin E dietary (i.e., food sources) or supplemental intake. 
Vitamin E plasma and serum levels 
Several studies investigating the association between vitamin E plasma/serum levels and 
dementia/AD are cross-sectional analyses in small clinical samples (Table 3). In all these 
studies only α-tocopherol has been evaluated, and usually absolute plasma/serum values of 
this vitamin have been compared between subjects with dementia/AD (different disease 
severity among studies) and controls. However, vitamin E biokinetics is tightly related to 
lipoproteins, and lipid levels need to be considered when assessing the effects of vitamin E 
on any outcome; standardization to total cholesterol (absolute plasma/serum concentration 
of vitamin E divided by total cholesterol) is commonly used.115,133,134 There is indeed some 
evidence that the association of vitamin E with cognitive decline/dementia is influenced by 
concurrent cholesterol levels, but data on this aspect are scarce.115,135-137 
All cross-sectional clinical studies have reported reduced α-tocopherol plasma/serum levels 
in subjects with dementia/AD compared to controls138-149 or no association.148,150-155 The 
majority of the studies reporting reduced α-tocopherol levels in dementia/AD cases were 
done in non-malnourished subjects, while in some other studies the reduced value of α-
tocopherol could be explained by malnourishment. Some studies showed decreased plasma 
α-tocopherol also in subjects with MCI,138,147 while other studies did not confirm this 
finding.115,136 
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Cross-sectional analyses in population-based studies have also shown conflicting results, 
reporting reduced α-tocopherol plasma/serum levels in cases of dementia156 or no 
association (Table 4).115,157 Only one study, the Conselice Study on Brain Ageing (CSBA), 
analyzed all tocopherol forms, together with markers of vitamin E oxidative/nitrosative 
damage (α-TQ and 5-NO2-γ-tocopherol). In the CSBA cohort increased prevalence of 
dementia was found for higher levels of δ-tocopherol and α-TQ when analyzing vitamin E 
values standardized by cholesterol, but there was no association when considering 
absolute values of vitamin E.115 Population-based studies analyzing α-tocopherol 
plasma/serum concentration in relation to cognition consistently report the presence of 
higher α-tocopherol levels is subjects with better cognitive performance158-161 and reduced 
brain atrophy.161  
The cross-sectional design of the all above-mentioned studies does not allow the inference 
of any causal association between vitamin E and dementia/AD. Few prospective 
population-based studies have analyzed α-tocopherol plasma/serum levels in relation to the 
risk of cognitive decline and dementia/AD, with inconsistent results (Table 5). One study 
based on volunteers reported no association between α-tocopherol, measured in red blood 
cells, and cognition,162 while another study in women found that higher γ-tocopherol 
plasma levels were associated with better cognitive performance, but only among subjects 
with low α-tocopherol plasma concentration, suggesting the presence of an interactive 
effect between the two congeners.163 
Among studies with dementia/AD as the outcome, one (Personnes Agées QUID, 
PAQUID) showed an increased risk of dementia and AD in elderly, French subjects with 
low plasma concentration of α-tocopherol,164 but this finding was not confirmed in another 
French cohort (Three-City Study),165 in an Italian cohort (CSBA),115 or in a Swedish study 
on men (Uppsala Longitudinal Study of Adult Men - ULSAM)166 (Table 5). A lower 
incidence of dementia in subjects with higher plasma γ-tocopherol levels (middle but not 
highest tertile) was detected in the CSBA cohort.115 The association between γ-tocopherol 
concentration and dementia/AD risk was not found in the ULSAM study.166  
Inconsistency between results from the longitudinal studies could be explained by 
different methodological factors, including differences across investigations in the 
sample size, age of study participants, and duration of follow-up. These studies report 
different ranges of vitamin E levels, which are not always comparable, since they are 
reported either as absolute or as standardized values, and standardization has been done 
with different methods (i.e., dividing vitamin E by total cholesterol or by total cholesterol + 
triglyceride). Overall, studies assessing the association between vitamin E levels and 
incidence of dementia/AD are scarce, none of them have evaluated midlife exposure, and 
none examined all vitamin E family members.  
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Vitamin E intake 
The relationship of vitamin E dietary or supplemental intake with the risk of cognitive 
decline and dementia/AD has been investigated in different population-based prospective 
studies (Table 6). Vitamin E supplements are over-the-counter products, which usually 
contain only α-tocopherol, and are available in doses of 100 to 1000 international units 
(IU) (synthetic α-tocopherol).106 
Studies with cognitive function as the main outcome have mainly evaluated the intake of 
vitamin E supplements, alone or in combination with vitamin C supplements. Some of 
these studies reported a reduced risk of cognitive decline in supplement users,167,168 in 
some cases only for the combined use of vitamin E and C supplements,169,170 while other 
studies found no association.171 In the American Chicago Health and Aging Project 
(CHAP), vitamin E supplement use was inversely associated with cognitive decline only 
among participants who had low levels of intake from food, while vitamin E 
supplementation was not associated with further reductions in the rate of cognitive 
decline among participants who had high food-intake levels of vitamin E.172 
Population-based studies assessing vitamin E intake in relation to dementia/AD risk are 
difficult to compare, because of the different methodology used in each investigation 
(Table 6). Some studies evaluated only dietary intake, others supplements use alone, and 
other studies assessed total vitamin E intake (food + supplements). Almost all studies 
examined late-life exposure, with follow-up durations from 3 to 14 years. Only one 
investigation analyzed midlife exposure in men (Honolulu-Asia Aging Study - HAAS), 
and found no association between vitamin E dietary intake and dementia/AD risk.173 It is 
worth mentioning that the results of the HAAS study are based on a single 24-hour 
dietary recall questionnaire, which might not be representative of usual food selection. 
Overall, studies investigating vitamin E intake only from supplements found no 
association with dementia/AD risk,170,174-177 or a reduced incidence was found only for 
the combined use of vitamin E and C supplements.169,178 On the other hand, studies 
examining vitamin E dietary intake consistently report a reduced risk of dementia/AD in 
individuals with high vitamin E intake.179-183 Only one study found no association: the 
Washington Heights-Inwood Columbia Aging Project (WHICAP),174 in which the 
participants had a narrow range of low vitamin E intake compared to studies reporting a 
positive association180 (Table 6). 
Discrepancies between results from dietary and supplement intake studies, and within 
both categories of investigation, can be explained by several methodological factors, 
including differences across investigations in the sample size, age and ethnic 
characteristics, and length of follow-up. In all these studies, assessment of the exposure 
(vitamin E intake) is based on self-report, and is thus prone to recall bias, which can 
occur more often in subjects having subtle cognitive problems, who could be in a very 
early phase of dementia. 
Introduction 
17 
 
Regarding studies on supplement use, information on vitamin E concentration was in 
general not available. Thus differences in vitamin E supplement dosage have been not 
taken into account. Further, vitamin E supplements usually contain only α-tocopherol, 
while dietary intake guarantees a more balanced availability of micronutrients, including 
all vitamin E forms. This could be more relevant for a neuroprotective effect. Indeed, in the 
CHAP study a high intake of vitamin E from food (all tocopherols + all tocotrienols) was 
associated with a reduced risk of developing AD. When considering the individual 
congeners, intakes of α- and γ-tocopherol and α-tocopherol equivalents (index including α-, 
β-, and γ-tocopherol, and α-tocotrienol) were independently associated with a reduced 
incidence of AD.181 On the other side, studies evaluating dietary intake are prone to other 
types of bias, due to the fact that food sources of vitamin E also provide other beneficial 
micronutrients, which could be relevant for neuroprotection. 
Vitamin E intake from food generally reflects long-term intake, whereas supplement 
intake is commonly of shorter duration. Information on duration of supplement use is 
often unavailable, and one study reported an increased positive effect on cognitive 
function for long duration of supplement intake.168 Further, in some studies a time-trend 
in the use of vitamin E supplements was observed.178,184  
It is also possible that diets already provide sufficient levels of nutrients for optimum 
functioning in supplement users. Moreover, supplement users tend to be healthy 
behaviour-seeking individuals and their lifestyle (diet, smoking habit, physical and 
mental activity, social engagement) can be significantly different compared to subjects 
not using supplements. Indeed, supplement users often have a higher education compared 
to non-users; they are also more likely to consume other antioxidants and exercise 
regularly.171,177,184 Health status among supplement users and non-users can also vary, 
with some studies reporting better or poorer general health being associated with 
supplement consumption.178,185,186 The overall impact on dementia/AD risk, due to 
additive and interactive effects of these factors, cannot always be fully examined. Thus 
residual confounding may explain the conflicting findings of studies on vitamin E intake 
and risk of developing dementia/AD.  
 
1.4.4 Vitamin E and Alzheimer’s disease: clinical trials 
Vitamin E has been tested as a preventive/therapeutic agent in AD. α-tocopherol is the only 
form that has been evaluated in RCTs, with conflicting results. A review by Isaac et al., 
examining RCTs on α-tocopherol in patients with AD and MCI, concluded that there is no 
evidence of efficacy.187 Moreover, the analysis performed by the authors on the 
methodological quality of the RCTs examined, highlighted the lack of high quality, robust 
RCTs. In fact, only two RCTs were considered as methodologically adequate. One was a 
multicenter RCT done by the AD Cooperative Study. The RCT enrolled 341 patients with 
moderate AD, who were randomly assigned to receive either α-tocopherol (2000 IU/day), 
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selegiline (10 mg/day), both selegiline and α-tocopherol, or placebo for two years. The 
primary outcome measure was the time to reach any one of the following endpoints: 
institutionalization, loss of basic ADL, severe dementia, or death. The risk of reaching the 
primary outcome was significantly reduced by vitamin E treatment, selegiline treatment, 
and combined treatment. However, no significant benefit on performance on cognitive tests 
was shown in all treatment groups.188 The second RTC enrolled 769 subjects with amnestic 
MCI, who were randomly assigned to receive 2000 IU of α-tocopherol, 10 mg of donepezil 
daily, or placebo for three years. In this study, α-tocopherol therapy had no benefits.189  
Different aspects should be taken into account when considering RCTs on vitamin E in 
AD. There are general methodological issues, which affect all RCTs in AD prevention and 
treatment, including the difficulties in identifying the target population and in monitoring 
the treatment effect with clinically relevant tools and scales.  
In the vitamin E supplement RCTs in AD and MCI, baseline levels of plasma vitamin E 
have often not been considered, while they may support the choice of the target population 
(i.e., subjects with lowest levels are likely to benefit more from the supplements). 
Longitudinal assessment of vitamin E levels in supplemented individuals can also help in 
monitoring treatment adherence and biological effects of supplementation.  
Other general aspects in AD prevention and treatment are related to the timing of 
intervention, which emphasize the importance of the “therapeutic window” (i.e., time when 
intervention can exert a beneficial effect), and the adequate duration.38,39 Since OS/NS 
increase with age and seem to be early events in AD, which has a long preclinical phase, 
RCTs done in AD and MCI could miss the time-window when supplement intake would 
have a significant beneficial effect. So far no RCT has succeeded in reversing the disease 
either in AD subjects or people in the MCI phase.39 Further, duration of supplement use 
has usually been short compared to the length of subjects’ exposure to OS/NS, which is 
likely to occur during a large part of the life span. The protective effect reported by 
observational studies on dietary intake, which can reflect prolonged exposure, suggests that 
a long-term exposure is more likely to reduce the risk of AD. These studies also support 
the fact that a balanced combination of different vitamin E forms could be important for 
neuroprotection. RCTs on supplements have been done only with α-tocopherol, often in 
high doses, which can decrease the bioavailability of the other congeners. Indeed, α-
tocopherol supplementation can decrease plasma and tissue concentration of γ-
tocopherol,122,190 and compromise tissue delivery of α-tocotrienol.191 
 
In summary, the role of the vitamin E family in AD is unclear in spite of the strong 
biological plausibility of a possible neuroprotective activity of these micronutrients. The 
majority of studies investigating vitamin E in relation to cognitive decline, dementia and 
AD, have focused on α-tocopherol, and no study has examined all eight natural vitamin E 
congeners in relation to cognitive decline and dementia/AD. 
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Since all natural vitamin E forms are potentially relevant for neuroprotection, each of the 
vitamin E forms may represent an index of vitamin E status, and provide information on 
the association between vitamin E and AD. Further, assessment of all vitamin E forms 
could help develop therapeutic interventions based on vitamin E supplementation. 
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Table 3. Vitamin E plasma/serum levels and dementia/AD: cross-sectional clinical studies. 
Study (Country) Population Vitamin E measure Results 
Zaman et al., 1992 
(UK)149 
20 dementia (10 AD, mean age 83 y; 10 VaD, 
mean age 85 y) 
20 controls, mean age 80 y 
Plasma α-tocopherol 
 
Mean plasma level of α-tocopherol lower in dementia 
cases (both AD and VaD) compared to controls 
Ahlskog et al., 1995 
(USA)150 
12 AD, mean age 74 y, 
43 PD, mean age 58 y, 
16 diabetes mellitus, mean age 57 y 
15 controls, mean age 61y 
Plasma α-tocopherol 
 
No association 
Jimènez-Jimènez et al., 1997 
(Spain)140 
44 AD, mean age 73 y, 
37 controls, mean age 70 y 
Serum α-tocopherol Mean serum level of α-tocopherol lower in AD cases 
compared to controls 
Sinclair et al., 1998 
(UK)137 
42 dementia (25 AD, 17 VaD), mean age 74 y 
41 controls, mean age 73 y 
Plasma α-tocopherol, 
standardized by cholesterol 
and absolute values   
Absolute values of vitamin E: mean plasma level of α-
tocopherol lower in AD cases compared to controls 
Vitamin E adjusted by cholesterol and triglyceride: no 
association 
Rivière et al., 1998 
(France)153 
24 moderate AD, mean age 79 y, 
20 severe AD, mean age 78 y, 
9 AD hospitalized, mean age 80 y, 
20 controls, mean age 79 y 
Plasma α-tocopherol 
 
No association 
Foy et al., 1999 
(UK)135 
134 dementia (79 AD, and 37 VaD,  
median age 79 y; 18 PDD, median age 72 y) 
58 controls, median age74 y 
41 PD, median age 67 y 
41 controls, median age 67 y 
Plasma α-tocopherol, 
standardized by cholesterol 
and absolute values   
Absolute values of vitamin E: median plasma level of α-
tocopherol lower in dementia cases (both AD and VaD) 
compared to controls  
Vitamin E adjusted by cholesterol: no association  
Fernandes et al., 1999 
(Portugal)151 
74 mild-severe AD, mean age 68 y, 
35 controls, mean age 65 y 
Plasma α-tocopherol No association 
Schippling et al., 2000 
(Germany)154 
29 mild-moderate AD, mean age 72 y, 
29 controls, mean age 55 y 
Plasma α-tocopherol 
 
No association 
Tabet et al., 2001 
(UK)155 
31 AD (20 mild-moderate, 11 severe ) 
10 VaD, 10 DLB, 30 controls, age 65+y  
Plasma α-tocopherol 
 
No association 
AD: Alzheimer’s disease. DLB: dementia with Lewy bodies. PD: Parkinson disease. PDD: dementia in Parkinson disease. VaD: vascular dementia. y: years.    
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Table 3 (continued). Vitamin E plasma/serum levels and dementia/AD: cross-sectional clinical studies. 
Study (Country) Population Vitamin E measure Results 
McGrath et al., 2001 
(UK)152 
29 AD, mean age 74 y 
46 controls, mean age 73 y 
Plasma α-tocopherol 
standardized by cholesterol 
No association 
Bourdel-Marchasson et al., 
2001, (France)139 
20 mild-moderate AD, mean age 80 y, 
23 controls, mean age 76 y 
Plasma α-tocopherol 
 
Mean plasma level of α-tocopherol lower in AD cases 
compared to controls 
Ravaglia et al., 2001  
(Italy)146 
30 dementia, mean age 98 y 
32 controls, mean age 96 y 
Plasma α-tocopherol 
 
Mean plasma level of α-tocopherol lower in dementia 
cases compared to controls, only in men 
Mecocci et al., 2002 
(Italy)141 
40 mild-moderate AD, mean age 76 y, 
39 controls, mean age 75 y 
Plasma α-tocopherol 
 
Mean plasma level of α-tocopherol lower in AD cases 
compared to controls  
Polidori et al., 2002 
(Italy)143 
35 mild-moderate AD (female), mean age 86 y, 
40 controls (female), mean age 85 y  
Plasma α-tocopherol Mean plasma level of α-tocopherol lower in AD cases 
compared to controls 
Ryglewicz et al., 2002 
(Poland)148 
68 dementia (26 AD, mean age 67 y, 42 VaD, 
mean age 71 y) 
46 controls, mean age 68 y 
Plasma α-tocopherol Mean plasma level of α-tocopherol lower in VaD cases 
compared to AD and controls 
Praticò et al., 2000, 2004 
(USA)144,145 
25 AD, mean age 76 y 
25 controls, mean age 75 y 
Plasma α-tocopherol Mean plasma level of α-tocopherol lower in AD cases 
compared to controls 
Rinaldi et al., 2003 
(Italy)147 
63 AD, mean age 77 y 
25 MCI, mean age 76 y 
56 controls, mean age 76 y  
Plasma α-tocopherol Mean plasma level of α-tocopherol lower in AD and 
MCI cases compared to controls 
Polidori et al., 2004 
(Italy)142 
86 mild-moderate dementia (63 AD, 23 VaD)  
mean age 77 y, 
55 controls, mean age 76 y 
Plasma α-tocopherol Mean plasma level of α-tocopherol lower in dementia 
cases (both AD and VaD) compared to controls 
Baldeiras et al., 2008 
(Portugal)138 
42 mild AD, mean age  73 y 
85 MCI, mean age 71 y 
37 controls, mean age 68 y 
Plasma α-tocopherol 
Red blood cell α-tocopherol 
Mean plasma level of α-tocopherol lower in AD and 
MCI cases compared to controls 
Iuliano et al., 2010 
(Italy)136 
37 AD, mean age 76 y 
53 MCI, mean age 70 y 
24 controls, mean age 70 y 
Plasma α-tocopherol, 
standardized by cholesterol 
and absolute values   
Absolute values of vitamin E: no association 
Vitamin E adjusted by cholesterol: mean plasma level 
of α-tocopherol lower in AD cases compared to controls 
AD: Alzheimer’s disease. MCI: mild cognitive impairment. VaD: vascular dementia. y: years.    
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Table 4. Vitamin E plasma/serum levels, cognitive function and dementia/AD: cross-sectional population-based studies. 
Study (Country) Design and population Outcomes  Vitamin E 
measure 
Results 
Perkins et al., 1999 
(USA)160 
Third National Health and Nutrition Examination 
Survey (NHANES III), N=4,809, 98% white, 2% 
non-white, age 60+ y 
Cognition Serum α-tocopherol 
standardized by 
cholesterol 
Higher α-tocopherol levels were associated 
with better memory performance 
Ortega et al., 2002 
(Spain)159 
120 community dwellers (Voluntary sample),  
age 65-91 y 
Cognition Plasma α-tocopherol, 
standardized by 
cholesterol and 
absolute values   
Higher α-tocopherol levels (both absolute 
value and adjusted by cholesterol) were 
associated with better cognitive performance  
Engelhart et al., 2005 
(The Netherlands)157 
Case control within the Rotterdam Study 
65 AD, mean age 84 y 
293 cognitive impairment, mean age 76 y 
437 controls, mean age, 72 y 
 
AD 
Cognitive impairment 
Plasma α-tocopherol No association 
 
Cherubini et al., 2005 
(Italy)156 
Case-control study within the InCHIANTI cohort  
58 dementia (22 degenerative, 36 VaD or mixed) 
mean age 85 y, 
168 cognitive impairment, mean age 81 y 
807 controls, mean age 74 y 
Dementia 
Cognitive impairment 
Plasma α-tocopherol Higher α-tocopherol levels were associated 
with lower odds for dementia or cognitive 
impairment  
Dunn et al., 2007 
(USA)158 
Cognitive Change in Women (CCW) study, 
ancillary study to the Women’s Health Initiative 
N=526 (123 memory impairment, 61 mixed 
impairment), 91% white, 9% non-white, age 60+ y 
Cognition Serum α-tocopherol Higher α-tocopherol levels were associated 
with lower odds for memory impairment or 
mixed impairment  
 
Bowman et al., 2011 
(USA)161 
Subsample of the Oregon Brain Aging Study 
(OBAS), 
N=104, mean age 87 
Cognition,  
MRI measures 
Plasma α-tocopherol The plasma profile of nutrients which included 
high α-tocopherol levels was associated with 
better cognition and MRI measures 
AD: Alzheimer’s disease. MRI: magnetic resonance imaging. VaD: vascular dementia. y: years.    
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Table 5. Vitamin E plasma/serum levels, cognitive decline and dementia/AD risk: prospective population-based studies. 
Study (Country) Design and population Follow-up Outcomes  Vitamin E measure Results 
Berr et al., 1998 
(France)162 
Etude du Vieillissement Arteriel (EVA) 
Study (Voluntary sample), N=1389   
mean age 65 y 
4 y Cognition Red blood cell α-tocopherol No association 
Helmer et al., 2003 
(France)164 
Nested case-control within the PAQUID 
cohort,  
N=626 (46 dementia, 39 AD) 
age 65+ y 
9 y Dementia 
AD 
Plasma α-tocopherol Higher risk of dementia among subjects in the 
lowest α-tocopherol tertile   
Similar results when examining only AD cases 
(results statistically significant at the 10% level)  
Kang & Grodstein, 
2007 (USA)163 
Nurses’ Health Study (NHS),  
N=858  
age 43-68 y (mean 65 y) 
10 y Cognition Plasma α- and γ-tocopherol No association of tocopherols sum with cognition 
When examining individual tocopherols, higher γ-
tocopherol levels were associated with better 
cognitive performance only among subjects with α-
tocopherol levels under the median  
Samieri et al., 2008 
(France)165 
Three-City (3C) Study,  
N=1214 (65 dementia) 
age 65+ y 
4 y Dementia Plasma α-tocopherol Higher risk of dementia in subjects with higher α-
tocopherol levels (results statistically significant at 
the 10% level) 
Ravaglia et al., 2008 
(Italy)115 
Conselice Study on Brain Ageing 
(CSBA), age 65+ y 
Baseline: N=761 (666 CN, 52 MCI, 43 
dementia) 
 
73 incident cases of dementia (45 AD,  
26 VaD, 2 NOS) 
4 y Dementia 
MCI 
Plasma α-, β-, γ- and δ-
tocopherol, α-TQ, and 5-
nitro-γ-tocopherol, 
standardized by cholesterol 
and absolute values   
Cross-sectional analysis, vitamin E standardized by 
cholesterol: 
- increased prevalence of dementia in the highest 
tertile of δ-tocopherol and α-TQ levels 
Longitudinal analysis, vitamin E standardized by 
cholesterol: 
-reduced risk of dementia in the middle tertile of γ-
tocopherol 
Absolute values of vitamin E: no association  
Sundelöf et al., 2009 
(Sweden)166 
Uppsala Longitudinal Study of Adult 
Men (ULSAM), two age cohorts:  
- 70y, N=616 (86 dementia, 36 AD, 4 
AD+VaD, 27 VaD, 19 NOS) 
-77y, N= 761 (80 dementia, 45 AD, 2 
AD+VaD, 21 VaD, 12 NOS) 
age 70: 4 y 
age 77: 8 y 
Dementia, 
AD 
Plasma α- and γ-tocopherol, 
standardized by 
cholesterol+triglyceride 
No association  
AD: Alzheimer’s disease.  α-TQ: , α-tocopherylquinone. CN: normal cognition.  MCI: mild cognitive impairment. N: number of subjects. NOS: dementia not otherwise specified. 
VaD: vascular dementia. y: years.    
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Table 6. Vitamin E intake, cognitive decline and dementia/AD risk: prospective population-based studies. 
Study (Country) Design and population Follow-up Outcomes  Vitamin E source Results 
La Rue et al., 1997 
(USA)167 
New Mexico Aging Process Study, 
(voluntary sample) 
N=137 
age 60-84 y  
6 y Cognition Dietary and supplements    
(3-day dietary record) 
Better cognitive performance in subjects taking vit. 
E supplements 
No association with vit. E dietary intake  
Luchsinger et al., 2003 
(USA)174 
Washington Heights-Inwood Columbia 
Aging Project (WHICAP), 
68% white, 32% non-white 
N=980 (242 AD) 
age 65+ y (mean 75 y) 
4 y AD Dietary and supplements   
(FFQ) 
No association  
Grodstein et al., 2003 
(USA)168 
Nurses' Health Study (NHS) 
N=14968 women 
age 35-59 y 
15 y Cognition Supplements  Better cognitive performance is subjects taking vit. 
E supplements. Evidence of increasing benefit 
with longer duration of supplement use 
Masaki et al., 2000 
Laurin et al., 2002 
Laurin et al., 2004 
(USA)169,173,175 
Honolulu-Asia Aging Study (HAAS), 
Japanese-American men 
Study on prevalent cases: 
N=3385 (2999 CN, 47 AD, 35 VaD, 50 
mixed/NOS, 254 low cognition) 
age 71-93 y 
 
Study on incident cases: 
Mid-life exposure: 
N=2459 (235 dementia, 102 AD, 38 
AD+VaD, 44 VaD, 51 others) 
age 45-68 y 
 
Late-life exposure 
N=2369 (222 dementia, 94 AD, 38 
AD+VaD, 42 VaD, 48 other dementia) 
age 71-92 y 
 
 
5 y (10 y in a 
subgroup) 
 
 
 
30 y 
 
 
 
 
5 y 
Cognition 
Dementia 
AD 
VaD 
Mixed dementia 
 
 
Supplements of vit. E and  
vit. C 
 
 
 
 
 
Dietary (24h dietary recall) 
Study on prevalent cases: 
Reduced risk of VaD and mixed dementia in 
subjects taking both vit. E and vit. C supplements 
Short term use of supplements (5y): better 
cognitive performance in subjects taking vit. E 
supplements 
Long term use of supplements (10 y): better 
cognitive performance in subjects taking both vit. 
E and vit. C supplements 
 
Study on incident cases: 
Midlife exposure: no association  
Late-life exposure: no association 
AD: Alzheimer’s disease.  CN: normal cognition.  FFQ: food frequency questionnaire.  N: number of subjects.  NOS: dementia not otherwise specified.  VaD: vascular dementia.  vit: 
vitamin. y: years.    
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Table 6 (continued). Vitamin E intake, cognitive decline and dementia/AD risk: prospective population-based studies. 
Study (Country) Design and population Follow-up Outcomes  Vitamin E source Results 
Engelhart et al., 2002 
Devore et al., 2010 
(Netherlands)179,180 
Rotterdam study 
N=5395, age 55+ y (mean 68 y)  
6 y follow-up: 197 dementia, 146 AD 
9.6 y follow-up: 465 dementia, 365 AD 
 
6 y 
9.6 y 
Dementia 
AD 
Dietary and supplements   
(FFQ) 
Reduced dementia and AD risk in subjects with 
higher dietary intake of vit. E 
Zandi et al., 2004 
Wengreen et al., 2007 
(USA)171,178 
Cache County Study on Memory, Health 
and Aging, 
age 65+ y 
3 y follow up: N=4540 (185 dementia, 
104 AD) 
7 y follow-up: N=3632  
3 y 
7 y 
AD 
Cognition 
Dietary (FFQ) and 
supplements of vit. E and vit. 
C 
Reduced risk of AD in subjects taking both vit. E 
and vit. C supplements 
Reduced risk of cognitive decline in subjects with 
higher vit. E intake from food or food+supplements 
 
Morris et al., 2002, 2005, 
(USA)172,181,184 
Chicago Health and Aging Project  
(CHAP) 
 
N=2889, 45% white, 55% non-white, 
age 65+ y (mean 74 y) 
 
N=3718 
age 65+ y 
 
N= 815 (131 AD),  
49% white, 51% non-white, 
age 65+ y (mean 73 y) 
 
N=1041 (162 AD) 
age 65+ y 
 
 
 
 
3 y 
 
 
6 y 
 
 
4 y 
 
 
 
 
 
 
 
 
 
Cognition 
 
 
 
 
 
AD 
Dietary and supplements   
(FFQ) 
Reduced risk of cognitive decline in subjects with 
higher vit. E intake from food or food+supplements 
Beneficial effect of supplement on cognition only in 
subjects with low vit. E dietary intake 
Reduced risk of cognitive decline in subjects with 
higher dietary intake of vitamin E (Total vit. E, α- 
and γ-tocopherol, α-TE) 
Reduced dementia and AD risk in subjects with 
higher dietary intake of vitamin E, only in APOEε4 
non-carriers 
Reduced dementia and AD risk in subjects with 
higher dietary intake of vitamin E (Total vit. E, α- 
and γ-tocopherol, α-TE) 
AD: Alzheimer’s disease.  FFQ: food frequency questionnaire.  N: number of subjects. vit: vitamin. y: years.  α-TE: α-tocopherol equivalents, based on conversion factors of biologic 
activity of the different vitamin E forms: 1.0 for α-tocopherol, 0.5 for β-tocopherol, 0.1 for γ-tocopherol, and 0.3 for α-tocotrienol.181 
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Table 6 (continued). Vitamin E intake, cognitive decline and dementia/AD risk: prospective population-based studies. 
Study (Country) Design and population Follow-up Outcomes  Vitamin E source Results 
Corrada et al., 2005 
(USA)182 
Baltimore Longitudinal Study of Aging 
(BLSA), 
N=579 (voluntary sample within the 
BLSA cohort) (57 AD) 
mean age 70 y 
9.3 y AD Dietary and supplements   
(7-day dietary record) 
Reduced AD risk in subjects with higher intake of 
vit. E (significant at the 10% level)  
No association when intake of vit. E, folate, and vit. 
B6 were considered simultaneously 
 
Fillenbaum et al., 2005 
(USA)176 
Duke Established Populations for 
Epidemiologic Studies of the Elderly 
(EPESE), 38% white, 62% non-white, 
N=616 (141 dementia, 93 AD, 30 VaD, 
18 NOS) 
mean age 73 y 
14 y  Dementia 
AD 
Supplements of vit. E and  
vit. C 
No association 
Maxwell et al., 2005 
(Canada)170 
Canadian Study of Health and Aging 
(CSHA), 
N=894 (279 cognitive decline), (230 
dementia, 107 AD, VCI: ns) 
age 65+y (mean 78 y) 
5 y Cognition 
Dementia 
AD 
VCI 
Supplements of vit. E and  
vit. C 
Reduced risk of cognitive decline in subjects taking 
both vit. E and vit. C supplements. 
No association with dementia, AD, and VCI  
Gray et al., 2008 
(USA)177 
Adult Changes in Thought study (ACT), 
N=2969 (405 dementia, 289 AD) 
age 65+y 
5.5 y Dementia 
AD 
Supplements No association 
AD: Alzheimer’s disease.  N: number of subjects.  NOS: dementia not otherwise specified.  ns: not specified.  VaD: vascular dementia.  VCI: vascular cognitive impairment. 
 vit: vitamin. y: years.    
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2 AIMS 
2.1 GENERAL AIMS 
The general aims of this thesis are to investigate and understand the relation of the vitamin 
E family (α-, β-, γ, and δ-tocopherol; α-, β-, γ-, and δ-tocotrienol) to cognitive impairment 
and AD in older adults, by combining clinic-based and population-based studies. 
 
2.2 SPECIFIC AIMS 
The specific aims addressed in four different studies are summarized below. 
 
1. To examine the relation of plasma levels of all eight natural vitamin E forms and 
markers of vitamin E oxidative/nitrosative damage (α-tocopherylquinone, 5-nitro-γ-
tocopherol) to MCI and AD, in a multi-centre European clinical study (AddNeuroMed 
Project) (Study I). 
 
2. To investigate the potential use of combining plasma vitamin E forms - including all 
eight natural vitamin E congeners and markers of vitamin E oxidative/nitrosative 
damage - and structural MRI measures in differentiating AD and MCI cases from 
cognitively intact individuals (CN), and in predicting MCI conversion to AD 
(AddNeuroMed Project) (Study II). 
 
3. To examine the longitudinal association between plasma levels of eight natural forms of 
vitamin E and the risk of AD among oldest-old individuals (age ≥ 80 years), in a 
Swedish population-based study (Kungsholmen Project) (Study III). 
 
4. To verify the association between serum levels of all eight natural vitamin E forms, 
markers of vitamin E oxidative/nitrosative damage and the incidence of cognitive 
impairment (MCI or AD) in older adults (age ≥ 65 years), in a Finnish population-based 
prospective study (CAIDE Study) (Study IV). 
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3 METHODS 
The data used in this thesis are derived from three projects: The European AddNeuroMed 
Project, The Swedish Kungsholmen Project, and The Finnish Cardiovascular Risk Factors, 
Aging, and Dementia (CAIDE) Study. 
 
3.1 Clinic-based studies                                            
3.1.1 AddNeuroMed Project (Studies I and II)     
3.1.1.1 Study population  
The AddNeuroMed project is part of Innovative Medicines in Europe (InnoMed), an 
Integrated Project funded by the European Union Sixth Framework programme.72,192 
AddNeuroMed is a multi-centre European longitudinal study aiming to develop and 
validate novel surrogate markers in AD, which can assist diagnosis, prognosis, drug 
discovery and treatment monitoring. The project includes a neuroimaging part utilising 
MRI. At baseline, 716 community-living subjects were recruited: 259 AD cases, 225 MCI 
and 232 CN individuals. All subjects were gathered from six different sites across Europe: 
University of Kuopio, Finland; University of Perugia, Italy; Aristotle University of 
Thessaloniki, Greece; King’s College London, United Kingdom; University of Lodz, 
Poland; and University of Toulouse, France.72,193 All AD and MCI cases were recruited 
from the local memory clinics of the six participating sites, while CN individuals were 
recruited from non-blood relatives of the patients’ families, caregivers’ relatives, and social 
centers for the elderly.  
Study I included 521 subjects: 168 AD cases, 166 MCI, and 187 CN individuals. Sample 
selection was based on availability of plasma samples for vitamin E analysis. Subjects with 
plasma vitamin E available were similar to all AddNeuroMed participants at baseline in 
terms of age, gender, education, APOE status, Mini-Mental State Examination (MMSE)194 
score, and duration of cognitive decline. For this subsample of subjects, plasma levels of 
two other antioxidant micronutrients - retinol and β-carotene - were also available, and 
were evaluated in order to provide a broader picture of the antioxidant micronutrients status 
in cognitive impairment. 
Study II included 253 subjects (AD: 81, MCI: 86, and CN: 86), for whom MRI and 
vitamin E data from baseline were available. Both MCI and AD cases included in Study II 
were slightly younger in comparison to MCI and AD AddNeuroMed participants without 
MRI (MCI: 74.6±5.2 versus 76.7±5.7; AD: 75.1±5.7 versus 78.1±6.5), while the sample 
was similar to all AddNeuroMed participants in terms of gender, education, APOE status, 
MMSE194 score, and duration of cognitive decline. 
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3.1.1.2 Data collection 
At baseline, a health interview was administrated to all participants following a 
standardized protocol (the full protocol is available at http://www.innomed-
addneuromed.com)195 and data on demographics, medical history, current health status, 
medication use, and family history were collected. For AD and MCI cases, information on 
the duration and severity of cognitive decline was obtained from the subjects or informants 
through a detailed questionnaire, which evaluated the presence of memory problems, time 
of their onset, subsequent course, and investigations performed for the cognitive problems.  
For all participants, cognition, behaviour, functional status, and global severity were 
assessed and the MMSE194 and the Clinical Dementia Rating scale (CDR)196 were 
administered. Evaluation of AD included the Hachinski ischemic scale,197 the Alzheimer’s 
Disease Assessment Scale-Cognitive subscale (ADAS-Cog),198 the Neuropsychiatric 
Inventory,199 and the Alzheimer’s Disease Cooperative Study (ADCS)-activities of daily 
living scale.200 Evaluation of MCI and CN individuals comprised the Consortium to 
Establish a Registry for Alzheimer’s Disease (CERAD) Cognitive Battery201 and the 
Geriatric Depression Scale (GDS).202 The same procedure was used for follow-up at one 
year. 
 
3.1.1.3 Diagnosis of dementia and mild cognitive impairment 
Dementia was diagnosed following the Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition (DSM-IV),203 while probable AD was diagnosed according to the 
NINCDS-ADRDA criteria.55 Patients with significant neurological or psychiatric illness 
other than AD, any significant unstable systemic illness/organ failure, alcohol/substance 
misuse were excluded.  
The inclusion criteria for both MCI and CN subjects were: 1) absence of dementia 
according to the DSM-IV;203 2) age ≥ 65 years; 3) MMSE score range between 24 and 30; 
4) GDS score ≤ 5; 5) good general health and stable medication. Subjects with significant 
neurological or psychiatric illness, or any significant unstable systemic disease/organ 
failure, or alcohol/substance misuse were excluded. The CDR total score was 0.5 for MCI 
cases and 0 for CN individuals. 
MCI subjects were required to meet the following criteria, in line with consensus criteria 
for amnestic MCI:65,204 1) absence of dementia according to the DSM-IV;203 2) normal 
general cognitive function; 3) memory complaint: self- or informant-reported memory 
problem; 4) CDR196 memory score of 0.5 or 1 (Total CDR = 0.5); and 5) normal ADL.  
 
3.1.1.4 Vitamin E assessment 
At baseline blood samples were taken from subjects after a minimum of 2 hours fasting; 
serum and plasma samples were aliquoted and frozen at -80 °C until analysis. Plasma 
tocopherols, tocotrienols, αTQ, and 5-NO2-γ-tocopherol were measured with reverse-phase 
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High Performance Liquid Chromatography (HPLC) using electrochemical-coularray 
system (ESA-Chelmsford, MA, USA). Aliquots of 200µL were mixed and extracted three 
times with a 1:2 ratio of ethanol to hexane, concentrated to dryness with high-purity 
nitrogen gas, and reconstituted in 300µL mobile phase. β-tocopherol (Superchrome, Milan, 
Italy); α-, γ-, and δ-tocopherol (Sigma-Aldrich, Milan, Italy), α-, γ-, and δ-tocotrienol 
(LGC-Promochem, Milan, Italy), β-tocotrienol (Matreya-DBA, Pleasant-Gap, PA, USA), 
αTQ (Research Organics, Rome, Italy) and 5-NO2-γ-tocopherol (gift from Prof K. Hensley, 
University of Toledo Health-Sciences-Center, OH, USA) were used as standards (Figure 
2). After filtration, analyte separation was conducted at room temperature on a Discovery-
C18-column (Sigma-Aldrich, Milan, Italy). Mobile phase [30mmol lithium acetate/L, 83% 
HPLC grade acetonitrile, 12% HPLC grade methanol, and 0.2% HPLC grade acetic acid 
(pH 6.5)] was delivered at 1mL/min.  
 
 
Figure 2. HPLC chromatogram of known concentration of pure standards. 1: α-tocopherol; 2: β-tocopherol; 3: 
γ-tocopherol; 4: δ-tocopherol; 5: α-tocotrienol; 6: β-tocotrienol; 7: γ-tocotrienol; 8: δ-tocotrienol; 9: α-TQ; 10: 5-
NO2-γ-tocopherol. 
 
3.1.1.5 Other biochemical analyses  
Baseline plasma retinol and β-carotene (non-enzymatic antioxidants) were measured with 
reverse-phase HPLC using electrochemical-coularray system (ESA-Chelmsford, MA, 
USA). Pure retinol and β-carotene (Sigma-Aldrich, Milan, Italy) were used as standards, 
and the HPLC procedure was the same as the one used for vitamin E assessment. Baseline 
serum total cholesterol and albumin were measured by standardized enzymatic assay on a 
ILab-600-Plus Chemistry System analyzer (Instrumentation Laboratory, Milan, Italy). The 
APOE genotype was determined from blood leukocytes. DNA was extracted by a 
standard phenol-chloroform extraction, and APOE genotypes were analyzed by 
polymerase chain reaction (PCR), Hha I digestion and polyacrylamide gel 
electrophoresis.205 
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3.1.1.6 MRI  
Data acquisition for the AddNeuroMed study took place using six different 1.5T magnetic 
resonance systems (four General Electric, one Siemens and one Picker), and was designed 
to be compatible with the Alzheimer Disease Neuroimaging Initiative (ADNI).206 The 
imaging protocol for both studies included a high resolution sagittal 3D T1-weighted 
MPRAGE volume (voxel size 1.1x1.1x1.2 mm3) and axial proton density/T2-weighted fast 
spin echo images. The MPRAGE volume was acquired using a custom pulse sequence 
specifically designed for the ADNI study to ensure compatibility across scanners.206 Full 
brain and skull coverage was required for both of the latter datasets and detailed quality 
control was carried out on all MRI images according to the AddNeuroMed quality control 
procedure.193,207  
 
Regional volume segmentation and cortical thickness parcellation 
Imaging data were processed using the Freesurfer pipeline (version 4.5.0), which produces 
regional cortical thickness and volumetric measures (Figure 3). Cortical reconstruction and 
volumetric segmentation includes removal of non-brain tissue using a hybrid 
watershed/surface deformation procedure,208 automated Talairach transformation, 
segmentation of the subcortical white matter and deep grey matter volumetric structures 
(including hippocampus, amygdala, caudate, putamen, ventricles),208,209 intensity 
normalization,210 tessellation of the grey matter white matter boundary, automated 
topology correction,211,212 and surface deformation following intensity gradients to 
optimally place the grey/white and grey/CSF borders at the location where the greatest 
shift in intensity defines the transition to the other tissue class.213,214 Once the cortical 
models are complete, registration to a spherical atlas takes place which utilizes individual 
cortical folding patterns to match cortical geometry across subjects.215 This is followed by 
parcellation of the cerebral cortex into units based on gyral and sulcal structure.209,216  
The pipeline generated 68 cortical thickness measures (34 from each hemisphere) and 50 
regional volumes. Volumes of white matter hypointensities, optic chiasm, right and left 
vessel, and left and right choroid plexus were excluded from further analysis. Cortical 
thickness and volumetric measures from the right and left side were averaged.69 In total 57 
variables obtained from the pipeline were used as input variables for the orthogonal partial 
least squares to latent structures (OPLS) classification, 34 regional cortical thickness 
measures and 23 regional volumes (Table 7). All volumetric measures from each subject 
were normalized by the subject’s intracranial volume. Cortical thickness measures were not 
normalized.  
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Figure 3. Representations of regions of interest (ROI) included as candidate input variables in the multivariate 
orthogonal partial least squares to latent structures (OPLS) model. (A) Regional volumes. (B) Regional cortical 
thickness measures (Figure provided by Eric Westman). 
 
 
 
 
Methods 
33 
 
Table 7. Variable included in orthogonal partial least squares to latent structures (OPLS) analysis. 
Cortical thickness measures Volumetric measures Vitamin E 
Banks of superior temporal sulcus Third ventricle  α-tocopherol 
Caudal anterior cingulate Fourth ventricle β-tocopherol 
Caudal middle frontal gyrus Brainstem γ-tocopherol 
Cuneus cortex Corpus callosum anterior δ-tocopherol 
Entorhinal cortex Corpus callosum central α-tocotrienol 
Fusiform gyrus Corpus callosum midanterior β-tocotrienol 
Inferior parietal cortex Corpus callosum midposterior γ-tocotrienol 
Inferior temporal gyrus Corpus callosum posterior δ-tocotrienol 
Isthmus of cingulate cortex CSF Ratio αTQ/α-tocopherol 
Lateral occipital cortex Accumbens Ratio 5-NO2-γ-tocopherol/ 
γ- tocopherol Lateral orbitofrontal cortex Amygdala 
Lingual gyrus Caudate  
Medial orbitalfrontal cortex Cerebellum Cortex  
Middle temporal gyrus Cerebellum White Matter  
Parahippocampal gyrus Hippocampus  
Paracentral sulcus Inferior lateral ventricle  
Frontal operculum Putamen  
Orbital operculum Cerebral Cortex  
Triangular part of inferior frontal gyrus Cerebral White Matter  
Pericalcarine cortex Lateral Ventricle  
Postcentral gyrus Pallidum  
Posterior cingulate cortex Thalamus Proper  
Precentral gyrus Ventral diencephalon (DC)  
Precuneus cortex   
Rostral anterior cingulate cortex   
Rostral middle frontal gyrus   
Superior frontal gyrus   
Superior parietal gyrus   
Superior temporal gyrus   
Supramarginal gyrus   
Frontal pole   
Temporal pole   
Transverse temporal cortex   
Insular   
 
In total, 67 variables were included in OPLS analysis: 34 cortical thickness measures, 23 volumetric measures 
and 10 vitamin E related values. 
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3.2 Population-based studies 
3.2.1 Kungsholmen Project (Study III) 
3.2.1.1 Study population 
The Kungsholmen Project is a Swedish community-based prospective study on aging and 
dementia.217,218 The initial population gathered all registered inhabitants (n=2,368) who 
were living in the Kungsholmen district of Stockholm and were aged 75+ years in 1987, 
and 1,810 (76.4%) individuals participated in the Phase I survey (Figure 4).  
Study III included 232 subjects derived from the non-demented cohort (n=792 subjects) 
participating in Phase III of the Kungsholmen Project (baseline for this study) (Figure 4). 
Sample selection was based on availability of plasma samples for vitamin E analysis. 
Subjects in this sample were slightly older in comparison to the other cognitively intact 
participants (mean age±SD: 84.9±3.2 versus 83.9±4.3 years, p<0.001) and with a slightly 
lower MMSE194 score (26.8±2 versus 27.1±2, p=0.009). The sample was representative of 
the entire dementia-free cohort as regard to sex, education, BMI, and APOE status. The 
232 non-demented subjects aged 80+ years were clinically examined on two different 
occasions during the following six years to detect new dementia cases. Among study 
participants, 16 subjects refused to participate in the first follow-up examination or had 
moved before the assessment, and 14 refused to undertake the second follow-up 
examination. The other participants received a full dementia work-up, which included a 
structured interview by trained nurses (if the subject was not able to answer, an informant, 
usually a next-of-kin, was interviewed), a comprehensive clinical examination by 
physicians, and neuropsychological assessment by psychologists. For those subjects who 
had died before the first (n=53) or second (n=31) follow-up examination (Figure 4) 
information regarding their health status was obtained from the Stockholm Inpatient 
Register System, which encompasses all hospitals in the Stockholm area since 1969, and 
records up to six diagnoses at discharge.   
 
3.2.1.2 Data collection 
At baseline, data on age, sex, education, alcohol consumption, and smoking habit were 
collected from the subjects following standardized protocols.217,218 Diagnosis of chronic 
diseases was made by the examining physician, based on the clinical examination, medical 
history, laboratory data, and current drug use. Further information on health status for all 
participants was derived from the computerized Stockholm Inpatient Register System. 
Presence of multimorbidity was defined as any co-occurrence of 2+ chronic diseases in the 
same individual, according to a previous study within the Kungsholmen Project.219 Global 
cognitive functioning was assessed with the MMSE.194 The Katz index of ADL was used 
to measure basic functional status.220 Weight and height were measured with a standard 
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scale in light clothing and no shoes. BMI was calculated as weight in kilograms divided by 
the square of height in meters (kg/m2). Data on lipid lowering medications and vitamin 
supplements use were collected from the subjects and verified by inspecting drug 
prescriptions and containers. Vitamin supplements were coded following the Anatomical 
Therapeutic and Chemical classification system.221  
 
 
  Figure 4. Flowchart of the Kungsholmen Project, 1987-1998. AD= Alzheimer’s disease. 
 
3.2.1.3 Diagnosis of dementia  
At baseline and at each follow-up of the study, all participants underwent an extensive 
clinical and neuropsychological evaluation. Dementia was diagnosed on the basis of 
clinical judgment following the Diagnostic and Statistical Manual of Mental Disorders, 
revised third edition (DSM-III-R) criteria,1 in which a validated three-step diagnostic 
procedure was used.217,218 In brief, two examining physicians independently made a 
preliminary diagnosis, and in the case of disagreement, a third opinion from a specialist 
was sought to reach a concordant diagnosis. The diagnosis of AD required gradual onset, 
Study Participants 
1810 participants aged ≥75 years in October 1987 
792 dementia-free subjects  
 
560 subjects had no plasma 
available for vitamin E analysis 
180 dementia-free subjects at the first follow-up 
232 subjects had plasma 
available for vitamin E analysis  
163 examined: 33 AD 
incident cases 
53 deceased: 3 AD incident 
cases 
14 subjects refused or moved 
95 dementia-free subjects at the second follow-up 
85 examined: 18 AD incident 
cases 
31 deceased: 3 AD incident 
cases 
Phase I-II survey 
    1987-1989 
Phase III 
1991-1993 
Phase V 
1997-1998 
Phase IV 
1994-1996 
Time Period 
16 subjects refused or moved 
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progressive deterioration, and lack of any other specific causes of dementia. Diagnostic 
criteria for AD were equivalent to probable AD according to the NINCDS-ADRDA 
criteria.55 To verify the presence of dementia and AD in subjects who died during each 
follow-up period specialists reviewed medical records and death certificates, and diagnoses 
were made using the same procedure as above. The incident cases were all subjects who 
developed AD over the two follow-up periods.  
 
3.2.1.4 Vitamin E assessment 
Venous blood samples were taken at baseline (fasting was not compulsory) and plasma 
aliquots were stored at -80 °C until analysis. Tocopherols and tocotrienols were measured 
on plasma with reverse-phase HPLC with electrochemical-coularray system (ESA-
Chelmsford, MA, USA) as previously described (see paragraph 3.1.1.4). 
 
3.2.1.5 Other biochemical analyses  
Genomic DNA was prepared from peripheral blood samples that were taken at Phase I, and 
APOE allelic status was determined following a standard procedure.222 Baseline serum 
total cholesterol was measured by standardized enzymatic assay on a ILab-300-Plus 
Chemistry System analyzer. 
3.2.2 CAIDE (Study IV) 
3.2.2.1 Study population              
The CAIDE study is a prospective long-term cohort study in Finland.223 The participants 
were derived from four independent, randomly selected, population-based samples 
originally studied within the framework of the North Karelia Project and the Finnish part 
of Monitoring trends and determinants of Cardiovascular disease study (FINMONICA) 
in 1972, 1977, 1982 or 1987 (midlife visit). The average age of the participants was then 
50.6±6.0 years. These two studies were conducted to evaluate the risk factors, morbidity, 
and mortality from cardiovascular diseases.224 The methods used in midlife visit were 
standardized and complied with international recommendations.225  
A random sample of 2000 persons (still alive at the end of 1997, aged 65-79 years and 
living in the region of Kuopio and Joensuu towns, Finland) were invited for a first re-
examination carried out in 1998, and 1449 persons (72.5%) participated. A second re-
examination of the same cohort was conducted in 2005-2008.  
Study IV included a sub-sample of 140 subjects, derived from the cohort without cognitive 
impairment participating in the re-examination carried out in 1998. The 140 subjects in the 
present study were selected based on availability of serum samples from 1998 for vitamin 
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E assessment (Figure 5). All subjects with cognitive impairment in 2005-2008 (MCI or 
AD) and available 1998 serum samples were selected, and at least one age and sex-
matched control for each case. Sixty-four of the 140 subjects had cognitive impairment (24 
MCI, 40 AD) at the second re-examination in 2005-2008, and 76 represented the control 
group. The mean duration of follow-up from 1998 examination (baseline for this study) to 
2005-2008 was 8.2 years.  
 
 
 
 
Compared to the other CAIDE participants without cognitive impairment in 1998, the sub-
sample included in Study IV had a higher percentage of females (72% versus 61%, 
p<0.01), a higher education (9.5±0.3 versus 8.7±0.1, p<0.01), and a slightly higher 
MMSE194 score (26.6±2 versus 26.1±2, p<0.01). There were no differences with regard to 
age, APOE status, BMI, mean serum levels of total cholesterol and history of 
cardio/cerebrovascular conditions (myocardial infarction or stroke or diabetes). 
 
3.2.2.2 Data collection 
The examination in 1998 comprised a self-administered questionnaire on 
sociodemographic characteristics, health related behaviours, including smoking habits, 
Study Participants 
North Karelia Project & FINMONICA study 
(Participants’ mean age 50.6±6.0 years) 
1306 subjects without cognitive impairment  
1166 subjects had no 
serum available for 
vitamin E analysis 
76 cognitively 
normal subjects 
140 subjects had 
serum available for 
vitamin E analysis  
Midlife survey 
1972, 1977 
1982, 1987 
First  
re-examination 
1998 
Second 
re-examination 
2005-2008 
Time Period 
64 cases of cognitive impairment 
(24 MCI, 40 AD) 
1449 participants aged 65-79 years in 1997 
82 MCI incident cases  
61 dementia incident cases 
Figure 5. Flowchart of the CAIDE Study. AD= Alzheimer’s disease; MCI: mild cognitive impairment 
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alcohol consumption, medications and vitamin supplements use, medical history, including 
cerebrovascular and cardiovascular events, and conditions diagnosed by physicians. Nurses 
specifically trained for the survey checked the questionnaires to ensure that they were fully 
completed. Information on the use of lipid lowering medications (i.e., statins, fibrates) was 
also available from the Drug Reimbursement Registry. Height, weight, and blood pressure 
were measured. BMI was calculated as weight (in kilograms) divided by height squared (in 
meters). The same procedure was used for the re-examination in 2005-2008. 
 
3.2.2.3 Diagnosis of dementia and mild cognitive impairment 
Both in 1998 and 2005-2008 cognitive status of the participants was determined with a 
three-step protocol including a screening phase, a clinical phase and a differential 
diagnostic phase. In 1998 the screening phase included the following cognitive tests: 
MMSE, as a measure of global cognition;194 immediate word recall tests for episodic 
memory;226,227 category fluency test for semantic memory;228 Purdue Peg Board test and 
letter-digit substitution test for psychomotor speed;229,230 Stroop test for executive 
functioning;231 prospective memory task;232 subjective memory rating.233 In 2005-2008 the 
screening phase included the all tests used in 1998 and the Finnish version of the 
CERAD neuropsychological test battery.201 In the 1998 screening, subjects who scored 24 
or less in the MMSE were referred for further investigations (clinical phase). In the 2005-
2008 screening, subjects who scored 24 or less in the MMSE, had a decline of 3 points or 
more in MMSE since the 1998 examination, had a delayed recall in CERAD word list of 
<70%,201 or serious informant concern regarding participant’s cognition, were referred for 
further investigations. The clinical phase included neurologic, cardiovascular, and detailed 
neuropsychological examinations. A review board consisting of the study physician, the 
study neuropsychologist, and a senior neurologist ascertained the primary diagnosis based 
on all available information. Subjects with possible MCI or dementia were invited to the 
differential diagnosis phase which included including laboratory tests, brain neuroimaging 
(MRI), chest radiograph, electrocardiogram and CSF analysis. All data accumulated from 
the screening and clinical phases were carefully reanalyzed by the review board before the 
final diagnosis was established. Dementia was diagnosed according to the DSM-IV 
criteria,203 and probable and possible AD was diagnosed according to the NINCDS-
ADRDA criteria.55 Information on the use of AD drugs (i.e., acetylcholinesterase 
inhibitors, memantine) was also available from the Drug Reimbursement Registry. 
Participants were classified as having MCI using a modified version of the Mayo Clinic 
AD Research Center Criteria,234,235 which was also in line with the more recent consensus 
criteria.50 These included: 1) memory complaint by patient, family or physician; 2) normal 
ADL; 3) normal global cognitive function as judged by physician; 4) objective impairment 
of memory or other areas of cognitive functioning as evidenced by scores >1.5 standard 
deviation (SD) below age-appropriate mean; 5) CDR score of 0.5; 6) absence of dementia. 
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As suggested by the Mayo Clinic AD Research Center Criteria, the cut off point 1.5 SD 
below the norm in the neuropsychological tests was used as a guideline in the clinical 
assessment of cognitive performance.234  
 
3.2.2.4 Vitamin E assessment 
At baseline (1998) blood samples were taken from subjects after a minimum of two hours 
fasting; serum samples were aliquoted and stored initially at -20 °C and then at -70 °C. 
Serum tocopherols, tocotrienols, αTQ and 5-NO2-γ-tocopherol were measured with 
reverse-phase HPLC using electrochemical-coularray system (ESA, Chelmsford, MA, 
USA) as previously described (see paragraph 3.1.1.4). 
 
3.2.2.5 Other biochemical analyses  
Serum total cholesterol was assessed at baseline by standardized enzymatic essay.236 Blood 
leukocyte samples were analyzed to determine APOE genotype. To extract DNA, a 
standard phenol-chloroform technique was used; APOE genotypes were analyzed by PCR 
and restriction enzyme HhaI digestion.237 
 
3.3 Statistical analysis    
All data analyses were completed with the Statistical Package for the Social Sciences 
(SPSS, version 17.0 for Windows; SPSS Inc., Chicago, IL, USA), the Stata version 10.0 
and 12.0 for Windows (Stata-Corp, LP, Texas, USA), and the software package Soft 
Independent Modeling of Class Analogy (SIMCA, Umetrics AB, Umea, Sweden). Table 8 
summarizes the outcome variables and the determinants for each study. 
 
Statistical tests. The main associations examined in this thesis were between vitamin E 
plasma/serum levels - four tocopherols, four tocotrienols, markers of vitamin E 
oxidative/nitrosative damage -, MCI and AD. Throughout the four studies a range of 
statistical tests were employed. Chi-square test, logistic regression, Student’s t-test, one-
way analysis of variance (ANOVA) with Bonferroni post-hoc comparison, or linear 
regression were performed to assess the statistical differences of proportions and means 
between groups.  
As vitamin E is transported by plasma lipoproteins, and lipoproteins metabolism might 
affect the delivery of vitamin E to tissues, the vitamin E/cholesterol ratio (absolute 
plasma/serum concentration of vitamin E divided by total cholesterol) has been used in the 
main analyses.134 Absolute plasma/serum levels of vitamin E were considered in additional 
analyses in Study I, III and IV. The sum of all tocopherols (α+β+γ+δ tocopherol), all 
tocotrienols (α+β+γ+δ tocotrienol) and all vitamin E forms (all tocopherols+all 
tocotrienols) were considered, in order to have informative indices of vitamin E status in 
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the body; each vitamin E form was also considered separately. Further, the ratios αTQ/α-
tocopherol and 5-NO2-γ-tocopherol/γ-tocopherol were used in the analyses, as indices of α- 
and γ-tocopherol consumption due to oxidative and nitrosative damage, respectively. 
Indeed, αTQ is the primary product of α-tocopherol oxidation,119 while 5-NO2-γ-tocopherol 
is a product of reaction between γ-tocopherol and RNS.113 
In Study I, III and IV, plasma/serum levels of each vitamin E indices were tertiled, and the 
lowest tertile was used as reference in the analysis. Separate models were fitted for each 
vitamin E index. In Study II vitamin E indices were used as continuous variables, and 
partial correlation was used to explore the relationship among each vitamin E index and 
MRI data while controlling for age and gender. Logarithmic transformation of the MRI 
data was done in case of non-normal distribution. 
 
3.3.1 Specific analyses for each study 
Study I: Multivariable polytomous-logistic-regression analyses were used to estimate the 
odds ratios (OR) and 95% confidence intervals (CI) of vitamin E plasma levels for AD and 
MCI, with CN subjects as the reference group. Retinol and β-carotene plasma levels were 
also considered. As for vitamin E indices, plasma levels of these micronutrients were 
tertiled, and the lowest tertile was used as reference in the analysis. Age, sex, education, 
APOE genotype, location (six dummy variables with France as reference), and disease 
duration were considered as potential confounders in all models. Age, education and 
disease duration (in years) were used as continuous variables. APOE genotype was used 
dichotomously in the analyses: absence of ε4 allele versus presence of either 1 or 2 ε4 
alleles. Two main models were fitted: a basic adjusted (Model 1: adjusted by age, gender, 
education), and a fully adjusted model (Model 2). Albumin plasma level as a continuous 
variable was also adjusted for in the supplementary analysis. Statistical interactions were 
examined by incorporating the independent variables and cross-product terms in the same 
model. 
Additional analyses were also performed, including i) analyses of absolute values of 
plasma vitamin E, using serum total cholesterol as covariate; ii) polytomous-regression 
excluding patients with moderate (n=39) and severe (n=2) AD, thus comprising only 
subjects with very mild (CDR: 0.5, n=12) or mild (CDR: 1, n=115) AD.    
 
Study II: MRI measures and plasma vitamin E values were analyzed using OPLS, a 
supervised multivariate data analysis method included in the software package SIMCA 
(Umetrics AB, Umea, Sweden).70,238,239 Pre-processing was performed using mean 
centering and unit variance scaling. Mean centering improves the interpretability of the 
data, by subtracting the variable average from the data. By doing so the data set is 
repositioned around the origin. Large variance variables are more likely to be expressed in 
modeling than low variance variables. Consequently, unit variance scaling was selected to 
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scale the data appropriately. This scaling method calculates the standard deviation of each 
variable. The inverse standard deviation is used as a scaling weight for each MRI and 
vitamin E measure.  
Altogether 67 variables were used for OPLS analysis (57 MRI variables and 10 vitamin E 
indices, Table 7). No feature selection was performed, meaning all measured variables 
were included in the analysis. MRI and vitamin E variables were analyzed separately; a 
separate OPLS model was created for each set of variables. The two models were then 
combined using hierarchical modeling. This means that the scores obtained from each 
variable model (the MRI OPLS model and the vitamin E OPLS model) were used as new 
latent variables in a hierarchical model. Three OPLS models were created for AD versus 
CN and MCI versus CN: (1) MRI data; (2) vitamin E data; and (3) a hierarchical model 
containing models (1) and (2).  
The AD versus CN OPLS model including MRI + vitamin E baseline data was used as 
training set to prospectively predict MCI conversion to AD at one year follow-up. This 
produced a discriminant score (the OPLS MRI + vitamin E based score) for each 
individual with MCI, reflecting the degree to which the individual’s pattern (based on MRI 
and vitamin E) resembled the pattern of subjects with AD or the pattern of CN subjects.  
A seven fold cross-validation was utilized to validate the OPLS model, which means that 
1/7th of the data is omitted for each cross-validation round. The OPLS analysis generates a 
model with a predictive component, and it is characterized by a Q2(Y) value that describes 
its statistical significance for separating groups. Q2(Y) values > 0.05 are regarded as 
statistically significant.240  
Variables included in the OPLS analysis were plotted according to their importance for the 
separation of groups. The plots describe the MRI and vitamin E measures and their 
corresponding jack-knifed CIs. Jack-knifing is used to estimate the bias and standard error. 
The cross-validation results from each model can be fed directly to jack-knifing. By doing 
so, the various sub-models generated by cross-validation are used to calculate the standard 
error of the different model parameters, which are then converted into CIs via the t-
distribution.240 Measures with CIs that include zero have low reliability.238 A measure with 
high covariance is more likely to have an impact on group separation than a variable with 
low covariance.  
Sensitivity and specificity were calculated from the cross-validated prediction values of the 
OPLS models. The sensitivity was calculated as the percentage of AD (or MCI) subjects 
classified as AD (or MCI), and the specificity as the percentage of CN subjects classified 
as CN subjects. Finally, the positive and negative likelihood ratios (LR) (LR+ = 
sensitivity/(100-specificity) and LR- =(100-sensitivity)/specificity) were calculated. A 
positive LR between 5-10 or a negative LR between 0.1-0.2 increases the diagnostic value 
in a moderate way, while a value above 10 or below 0.1 significantly increases the 
diagnostic value of the test.241  
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Study III: The incidence rates of AD were calculated as the number of events occurring 
during the entire follow-up period divided by person-years of follow-up. Cox proportional 
hazard models were used to estimate the hazard ratios (HRs) and 95% CI of AD in relation 
to vitamin E plasma levels determined at baseline. For non-demented subjects the follow-
up time was calculated from the date of baseline interview to the date of the last follow-up 
examination or death. For demented subjects the follow-up time was estimated as the full 
time during which the subjects were free of dementia plus half of the follow-up time during 
which dementia developed. For each vitamin E index, two sets of Cox proportional hazard 
models were performed: i) Unadjusted analysis; ii) Multiadjusted analysis. The 
proportional hazard assumption was confirmed by the test based on Schoenfeld 
residuals.242 
Age, sex, education, baseline MMSE score, APOE status, BMI, current smoking status 
(yes/no) and alcohol use (yes/no) were considered as potential confounders. Because ADL 
status (absence of disability versus presence of any disability) and multimorbidity 
(presence versus absence of multimorbidity) did not significantly affect the vitamin E - AD 
association, models without ADL and multimorbidity are presented. Age, MMSE score, 
and BMI were used as continuous variables; education was split in three levels: 0-7 years, 
8-14 years, and ≥14 years. APOE genotype was used dichotomously in the analyses: 
absence of ε4 allele versus presence of either 1 or 2 ε4 alleles. As it is likely that dementia 
was under diagnosed in deceased individuals, and there is evidence of association between 
vitamin E plasma levels and mortality,166,243 analyses were adjusted also for survival status 
at follow-up. 
Additional analyses were performed, considering absolute values of plasma vitamin E. To 
take into account cholesterol levels, the population was grouped according to their median 
levels of vitamin E and cholesterol. This grouping was done to consider both vitamin E 
levels (absolute value) and the influence of lipoproteins on vitamin E biokinetics: increased 
lipids levels may be associated with increased plasma levels of vitamin E (absolute value) 
but it is not known if this promotes a linear increase in vitamin E delivery to tissues. 
Indeed, in impaired metabolic states, like hyperlipidaemia, vitamin E deficiency may be 
missed if lipid concentration is not considered. The following three groups were identified: 
1) subjects with vitamin E plasma level under the median and cholesterol serum level over 
the median; 2) subjects with both vitamin E and cholesterol levels either under or over the 
median; 3) subjects with vitamin E plasma level over the median and cholesterol serum 
level under the median. Group 2 and 3 included subjects with vitamin E – cholesterol 
proportions more likely to facilitate the delivery of vitamin E to tissues. Subjects in group 1 
constituted the reference category. Each vitamin E index was tested in a separate Cox 
proportional hazard model, while adjusting for the same confounders considered in the 
main analysis. 
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Study IV: Cognitive impairment was defined as development of MCI or AD. Logistic 
regression analyses were used to estimate the ORs and 95% CIs for the relation between 
vitamin E serum levels and cognitive impairment. Age, education, BMI (given linear 
representation), gender, APOE genotype (presence/absence of the ε4 allele), current 
smoking status (yes/no), alcohol use (yes/no), and history of cardio/cerebrovascular 
conditions (considered positive if the subjects had been diagnosed with myocardial 
infarction, stroke or diabetes) were considered as potential confounders. Two main models 
were fitted: a basic adjusted (Model 1: adjusted by age, gender, and education) and a multi-
adjusted model (Model 2). Because baseline MMSE score, lipid lowering medications use, 
and duration of follow-up did not significantly affect the vitamin E - cognitive impairment 
association, they were excluded from analyses. In order to ensure representativeness of the 
study sample, the data were weighted for the inverse of the probability of each person from 
the original CAIDE population to be included in the vitamin E study population. 
Absolute values of serum vitamin E were considered in additional logistic regression 
analyses, grouping the population according to the median levels of vitamin E and 
cholesterol, with the same procedure applied in Study III. 
 
3.3.2 Pooled analyses  
To further evaluate the correlation among vitamin E levels and cognition, the three 
populations used in the project were pooled together, which yielded a final sample of 893 
subjects, including 168 AD cases, 166 MCI and 559 CN individuals.  
Logistic quantile regression was used to evaluate the correlations among each vitamin E 
index and the MMSE total score, which was administered at the time of vitamin E 
assessment. This analytical method is valid for any population distribution and is 
appropriated for continuous outcomes variables that take on values within a defined range, 
such as the MMSE.244 To describe the correlation among vitamin E and the whole range of 
MMSE values in our population, four percentiles of the MMSE total score were 
considered: 5th, 25th, 50th, and 75th. Each vitamin E form, total tocopherols, total 
tocotrienols, total vitamin E, the ratios α-TQ/α-tocopherol and 5-nitro-γ-tocopherol/γ-
tocopherol were tested in separated models. The following variables, available for all 
subjects, were considered as potential confounders: age and education (given linear 
representation), gender, APOE genotype (presence/absence of the ε4 allele), and cohort of 
origin (three dummy variables with AddNeuroMed as reference). Two models were fitted: 
a basic adjusted (Model 1: adjusted by age) and a fully adjusted (Model 2). The p-values of 
the coefficients calculated for each percentile were based on 100 bootstrap samples. 
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Table 8. Statistical models used in various studies of this thesis  
 
Clinical 
Studies Model Independent variables  
Dependent 
variables Covariates Comments 
Study I Multivariable 
polytomous logistic 
regression 
Vitamin E plasma levels 
standardized by cholesterol 
and absolute values  
Retinol, β-carotene 
AD 
MCI 
CN 
Age, sex, education, APOE 
genotype, location, disease 
duration, albumin 
Model 1: age, sex, education 
Model 2: age, sex, education, APOE  genotype, 
location, disease duration 
Additional model: subjects with moderate-severe 
AD excluded 
Interactions of vitamin E with the other covariates 
were tested by adding specific terms to the model 
      
Study II Orthogonal partial 
least squares to 
latent structures 
(OPLS) 
 
Vitamin E plasma levels 
standardized by cholesterol 
MRI (automated regional 
volume and cortical thickness 
measures) 
AD 
MCI 
CN  
 
 Model 1: 57 MRI variables 
Model 2: 10 vitamin E variables 
Model 3: 67 variables (MRI+vitamin E) 
AD versus CN (Model 3) used as training set to 
prospectively predict MCI conversion to AD  
Population 
Studies Model Exposure Outcome Covariates Comments  
Study III Cox proportional 
hazards model  
Vitamin E plasma levels 
standardized by cholesterol 
and absolute values 
AD  
 
Age, sex, education, baseline 
MMSE score, BMI, APOE 
genotype, smoking status, alcohol 
use, survival status, ADL, 
multimorbidity 
Model 1: unadjusted 
Model 2: age, sex, education, MMSE score, BMI, 
APOE genotype, smoking status, alcohol use, 
survival status 
      
Study IV Logistic regression 
 
 
Vitamin E serum levels 
standardized by cholesterol 
and absolute values 
AD+MCI 
 
 
Age, sex, education, baseline 
MMSE score, BMI, APOE 
genotype, smoking status, alcohol 
use, history of 
cardio/cerebrovascular conditions*, 
lipid lowering medications use, 
duration of follow-up 
Model 1: age, sex, education 
Model 2: age, sex, education, BMI, APOE 
genotype, smoking status, alcohol use, history of 
cardio/cerebrovascular conditions. 
Weighting was used to ensure representativeness 
of the study sample  
Pooled 
analysis 
Logistic quantile 
regression 
Vitamin E levels standardized 
by cholesterol MMSE 
Age, sex, education, APOE 
genotype, cohort of origin 
Model 1: age 
Model: all covariates included 
AD: Alzheimer’s disease;  MCI: mild cognitive impairment;  CN: normal cognition;  ADL: activities of daily living;  BMI: body mass index;  MMSE: Mini-Mental State Examination;  
MRI: magnetic resonance imaging. *Cardio/cerebrovascular conditions: myocardial infarction, stroke, diabetes. 
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4 ETHICAL CONSIDERATIONS 
4.1 The AddNeuroMed Project 
For the AddNeuroMed study written informed consent was obtained directly from the 
study participants if they had capacity, and in those cases where dementia compromised 
capacity then assent from the patient and written consent from a relative, according to local 
law and process, was obtained. This study was approved by ethical review boards at each 
data acquisition site and the data coordination site (local ethical review board at University 
of Perugia, Italy; University of Toulouse, France; Aristotle University of Thessaloniki, 
Greece; Medical University of Lodz, Poland; University of Eastern Finland and University 
Hospital of Kuopio, Finland; King’s College London, United Kingdom). 
 
4.2 The Kungsholmen Project 
For the Kungsholmen Project informed consent was obtained at baseline from the study 
participants, after explaining the aims of the project and clarifying that all information 
would be kept strictly confidential. If there was any indication that the subject had severe 
cognitive impairment, consent was taken from a proxy, usually a next-of-kin or close 
relative. However, the examination or interview was to be interrupted if the participant, in 
any way, expressed anguish or discomfort, regardless of whether the informed consent had 
been given by the subjects themselves or by a proxy. All phases of the Kungsholmen 
Project received approval from the Ethics Committee at the Karolinska Institutet, 
Stockholm, Sweden. 
 
Study III included in this thesis used the data collected from Phase III to Phase V of the 
project, as well as data from medical records, death certificates, and the inpatient register 
database. For each phase data collection, approval from the Ethics Committee at the 
Karolinska Institutet was obtained: 
 Phases I & II (baseline survey): Dnr. 87:148; Dnr. 87:234 
 Phase III (the first follow-up examination): Dnr. 90:251 
 Phase IV (the second follow-up evaluation): Dnr. 94:122 
 Phase V (the third follow-up examination): Dnr. 99:308 
 Death certificate and Inpatient register data: Dnr. 99:025; Dnr. 01:020 
 
All staff working with the Kungsholmen Project database follow the guidelines of the 
Swedish Council for Research in the Humanities and Social Sciences: the principles of 
autonomy and integrity, the rule of consent, and the demand for research.245 
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4.3 The CAIDE study 
For the CAIDE study written informed consent was obtained from all participants. All 
phases of the CAIDE Project received approval from the local ethics committee 
(University of Kuopio and Kuopio University Hospital). 
 First examination: Dnr. 24/97 
 Second examination: Dnr. 124/2004 
The Ethics Committee at the Karolinska Institutet further approved the project (Dnr: 
2004/2:3). 
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5 RESULTS 
5.1 Clinic-based studies 
5.1.1 Characteristics of the population 
Five hundred and twenty one AddNeuroMed study participants had plasma available for 
vitamin E assessment at baseline: 168 cases with AD, 166 MCI, and 187 CN individuals. 
The characteristics of this group are reported in Table 9. Compared with MCI and CN 
subjects, AD patients were older and more often female. Both AD and MCI patients were 
less educated and more likely to be APOE ε4 carriers compared to CN subjects (Table 9). 
Mean duration of cognitive problems was 4.3±3.0 years for AD and 3.1±3.1 years for MCI 
(p<0.01) cases, respectively. Both total cholesterol and albumin mean serum levels were in 
the range of normality, and did not differ among the three groups. As expected, 
performance on the MMSE was poorest among patients with AD and best among CN, with 
the MCI group having scores between the AD and the CN groups (Table 9). Only 5 
subjects were taking α-tocopherol supplements (CN: n=1; MCI: n=3; AD: n=1, p=0.36). 
Table 9. Characteristics of the study participants (N = 521) by diagnosis of cognitive impairment. 
Subjects characteristics  CN  
n = 187 
MCI 
n = 166 
AD 
n = 168 
Age, y 74.7 (5.3) 75.8 (5.6) 77.4 (6.3)* §§ 
Gender, % female a 54% 58% 68% 
Education, y  10.3 (4.4) 8.8 (4.3) †† 8.0 (4.1)* 
Any APOE ε4 allele, % a,b 29% 41% 52% 
MMSE score 28.8 (1.3) 27.1 (1.8) † 20.2 (4.7)* § 
Serum albumin (g/dl) 4.3 (0.4) 4.3 (0.4) 4.3 (0.4) 
Serum total cholesterol (mmol/L) 5.2 (1.1) 5.4 (1.2) 5.4 (1.2) 
 
 
If not otherwise specified, data are given as mean (SD). Mini-Mental-State-Examination (MMSE) score ranged 
from 0 (worst) to 30 (best). 
AD: Alzheimer’s disease; MCI: mild cognitive impairment. CN: cognitively normal. 
a p<0.05. b APOE was available for 489 subjects 
AD versus CN: *p<0.0001;    AD versus MCI: §p<0.0001; §§ p<0.05;    MCI versus CN: †p<0.0001; †† p<0.01 
 
5.1.2 Relation of vitamin E to Alzheimer’s disease and mild cognitive 
impairment (Study I) 
When considering plasma levels of vitamin E standardized by cholesterol, AD subjects 
showed reduced mean plasma levels of all vitamin E congeners, total tocopherols, total 
tocotrienols, and total vitamin E, as compared to CN subjects. Similar results were found 
for MCI cases, but for β-tocotrienol the difference with CN subject was not statistically 
significant (Table 10).  
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Table 10. Vitamin E plasma levels by diagnosis of cognitive impairment. 
Vitamin E forms  CN 
n = 187 
MCI 
n = 166 
AD 
n = 168 
Vitamin E adjusted by cholesterola 
α-tocopherol  
 
6.66 (1.81) 
 
5.95 (1.83) † 
 
5.53 (1.32)* 
β-tocopherol 0.49 (0.15) 0.43 (0.13) † 0.46 (0.12)*** 
γ-tocopherol 0.46 (0.13) 0.38 (0.11) † 0.35 (0.09)* 
δ-tocopherol 0.057 (0.015) 0.051 (0.014) † 0.053 (0.013)** 
α-tocotrienol 69.85 (20.38) 54.61 (15.92) † 54.34 (13.79)* 
β-tocotrienol 28.88 (7.93) 27.60 (7.70) 25.77 (6.32)* 
γ-tocotrienol 16.81 (4.84) 12.92 (4.11) † 9.44 (2.51)* § 
δ-tocotrienol 2.48 (1.03) 2.15 (1.06) †† 1.78 (0.81)* §§ 
Total tocopherols  7.67 (2.05) 6.80 (2.08) † 6.40 (1.52)* 
Total tocotrienols  118.02 (30.61) 97.28 (27.44)† 91.33 (22.19)* 
Total vitamin E  7.80 (2.07) 6.90 (2.10) † 6.49 (1.54)* 
Ratio α-tocopherylquinone/α-
tocopherol  
1.55 (0.29) 1.70 (0.21) † 1.80 (0.19)* § 
Ratio 5-nitro-γ-tocopherol/γ-
tocopherol  
9.93 (1.63) 13.22 (1.88) † 12.49 (1.74)* § 
Vitamin E absolute valuesb 
α-tocopherol  
 
33.21 (5.15) 
 
30.24 (3.33)† 
 
28.18 (2.42)* § 
β-tocopherol 2.46 (0.44) 2.18 (0.24)† 2.33 (0.25)** § 
γ-tocopherol 2.30 (0.26) 1.92 (0.19)† 1.80 (0.16)* § 
δ-tocopherol 0.29 (0.02) 0.26 (0.02)† 0.27 (0.02)* § 
α-tocotrienol 349.0 (68.5) 278.9 (27.6)† 276.1 (26.0)* 
β-tocotrienol 143.7 (18.6) 141.0 (11.1) 131.1 (10.0)* § 
γ-tocotrienol 83.63 (12.80) 65.87 (10.17)† 48.15 (7.40)* § 
δ-tocotrienol 12.33 (4.27) 11.0 (4.34)†† 9.00 (3.23)* § 
Total tocopherols 38.26 (5.50) 34.61 (3.63)† 32.58 (2.70)* § 
Total tocotrienols 588.7 (74.7) 496.8 (37.6)† 464.3 (31.2)* § 
Total vitamin E 38.85 (5.55) 35.10 (3.64)† 33.04 (2.71)* § 
 
 
Data are given as mean (SD). a Levels of tocopherols and total vitamin E are expressed as µmol per mmol 
cholesterol. Tocotrienols are expressed as nmol per mmol cholesterol. The ratios α-tocopherylquinone/α-
tocopherol and 5-nitro-γ-tocopherol/γ-tocopherol are expressed as nmol/µmol. bAbsolute values of plasma 
tocopherols and total vitamin E are expressed as µM; tocotrienols are expressed as nM. 
AD versus CN: *p<0.0001; **p<0.01; ***p<0.05;    AD versus MCI: §p<0.0001; §§p<0.01;  
MCI versus CN: †p<0.0001; †† p<0.01 
 
The mean plasma levels of the ratios αTQ/α-tocopherol and 5-NO2-γ-tocopherol/γ-
tocopherol were significantly higher in AD and MCI cases, in comparison to CN subjects 
(Table 10). 
The evaluation of the absolute values of plasma vitamin E yielded the same pattern of 
differences among the three groups: mean plasma levels of each vitamin E form, total 
tocopherols, total tocotrienols and total vitamin E were lower in MCI and AD patients, in 
comparison to CN subjects, and the difference was statistically significant for all 
compounds, except for β-tocotrienol in MCI (Table 10). 
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Results of polytomous-regression are showed in Table 11.  
Table 11. Association of vitamin E with diagnosis of AD and MCI. 
Vitamin E  
plasma level 
MCI AD 
Model 1 
OR (95%CI) 
Model 2 
OR (95% CI) 
Model 1 
OR (95%CI) 
Model 2 
OR (95% CI) 
Total tocopherols     
Lowest tertile 
Middle tertile 
Highest tertile 
1.0 (reference) 
0.37 (0.21-0.66) 
0.21 (0.11-0.38) 
1.0 (reference) 
0.64 (0.21-1.92) 
0.15 (0.05-0.44) 
1.0 (reference) 
0.59 (0.34-1.05) 
0.21 (0.11-0.4) 
1.0 (reference) 
1.16 (0.39-3.51) 
0.16 (0.05-0.46) 
Total tocotrienols     
Lowest tertile 
Middle tertile 
Highest tertile 
1.0 (reference) 
0.30 (0.16-0.56) 
0.11 (0.06-0.21) 
1.0 (reference) 
0.32 (0.10-1.06) 
0.08 (0.02-0.26) 
1.0 (reference) 
0.32 (0.18-0.59) 
0.07 (0.04-0.14) 
1.0 (reference) 
0.38 (0.12-1.25) 
0.06 (0.02-0.21) 
Total vitamin E     
Lowest tertile 
Middle tertile 
Highest tertile 
1.0 (reference) 
0.39 (0.22-0.69) 
0.19 (0.10-0.36) 
1.0 (reference) 
0.65 (0.22-1.95) 
0.15 (0.05-0.42) 
1.0 (reference) 
0.61 (0.34-1.07) 
0.20 (0.11-0.39) 
1.0 (reference) 
1.15 (0.38-3.47) 
0.15 (0.05-0.45) 
Ratio α-tocopherylquinone/α-tocopherol 
Lowest tertile 
Middle tertile 
Highest tertile 
1.0 (reference) 
4.74 (2.71-8.3) 
6.53 (3.22-13.3) 
1.0 (reference) 
3.97 (1.52-10.4) 
4.43 (1.27-15.5) 
1.0 (reference) 
11.9 (5.8-24.2) 
32.8 (14.4-74.6) 
1.0 (reference) 
10.5 (3.6-30.6) 
25.3 (6.8-93.7) 
Ratio 5-nitro-γ-tocopherol/γ-tocopherol  
Lowest tertile 
Middle tertile 
Highest tertile 
1.0 (reference) 
14.3 (7.0-29.3) 
133.8 (53-338) 
1.0 (reference) 
12.7 (4.4-36.4) 
48.1 (12.7-182) 
1.0 (reference) 
8.2 (4.6-14.7) 
28.3 (12.3-65.5) 
1.0 (reference) 
8.9 (3.3-24) 
11.0 (3.1-39.0) 
 
OR with 95% CI of vitamin E plasma levels for AD and MCI diagnosis. Multivariable polytomous logistic model, 
CN subjects as reference; vitamin E, as tertile, is considered as indicator variable. Model 1: adjusted by age, 
gender, education. Model 2: adjusted by age, gender, education, APOE status, location, disease duration.  
 
In the fully adjusted model (Model 2), both diagnosis of MCI and AD were associated with 
reduced plasma levels of total tocopherols, total tocotrienols, and total vitamin E, and 
increased plasma levels of the ratios αTQ/α-tocopherol and 5-NO2-γ-tocopherol/γ-
tocopherol. Indeed, compared to CN subjects, both MCI and AD cases were less likely to 
be in the highest tertile of total tocopherols, total tocotrienols, and total vitamin E. Further, 
both AD and MCI were significantly more likely to be in the middle or in the highest tertile 
of the ratios αTQ/α-tocopherol and 5-NO2-γ-tocopherol/γ-tocopherol (Table 11). 
Regression analysis results for each vitamin E congener are shown in Figure 6, which 
illustrates the ORs with 95% CI of each vitamin E form (highest versus lowest tertile) for 
AD and MCI. Compared to CN subjects, both AD and MCI patients were less likely to be 
in the highest tertile of each vitamin E form than in the lowest; except for β- and δ-
tocopherol in AD, these associations were all statistically significant (Figure 6). For each 
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vitamin E congener, no significant association was found with the middle tertile, for both 
AD and MCI (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regression analyses evaluating absolute values of plasma vitamin E were adjusted by age, 
sex, education, APOE ε4 genotype, location, disease duration and cholesterol plasma 
levels. The fitted regression models produced results similar to the initial analysis: with 
respect to CN subjects, the OR and 95% CI of total tocopherols (highest versus lowest 
tertile) was 0.20 (0.05-0.74) for MCI and 0.02 (0.01-0.09) for AD; for total tocotrienols, 
the OR (95% CI) was 0.06 (0.02-0.24) for MCI and 0.01 (0.002-0.03) for AD, while for 
total vitamin E the OR (95% CI) was 0.20 (0.05-0.74) for MCI and 0.02 (0.01-0.09) for 
AD. When analyzing each vitamin E congener, both MCI and AD cases were less likely to 
be in the higher tertile than in the lowest, in comparison to CN subjects. For MCI cases this 
association was statistically significant for β-, γ-, and δ-tocopherol, α and γ-tocotrienol, 
while for AD the correlation was statistically significant for α-, γ-, and δ-tocopherol and all 
tocotrienols (there were no AD cases in the highest tertile of γ-tocotrienol, and there was a 
significant negative correlation with the middle tertile).  
In all regression models interactions between vitamin E and other covariates on the odds of 
AD and MCI were tested, and they were not statistically significant. Further, inclusion of 
albumin concentration in the models did not change the results for all plasma compounds 
evaluated (data not shown).  
Figure 6. Association of vitamin E forms with diagnosis of AD and MCI. The x-axis shows the different vitamin 
E forms, and the y-axis show the adjusted OR of each form (highest versus lowest tertile) for AD or MCI 
diagnosis. The bars represent the 95% CI of the ORs (dots). ORs are adjusted for age, gender, education, 
presence of APOE ε4, location, disease duration. (Multivariable polytomous logistic model,  CN subjects as 
reference). 
*γ-tocotrienol: 95%CI for AD: 0.0001-0.01. There were only 4 AD subjects (of 168) in the highest tertile, and 
only 11 cognitively normal subjects (of 187) in the lowest tertile.  
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Finally, to exclude subjects at higher risk of malnutrition, polytomous-regression models 
were fitted excluding patients with moderate (n=39) and severe (n=2) AD, thus comprising 
only subjects with very mild (CDR: 0.5, n=12) or mild (CDR: 1, n=115) AD. Results were 
similar to those from the total population, either considering vitamin E as standardized by 
cholesterol or as absolute plasma values (data not shown). 
 
Other antioxidant micronutrients. 
Retinol and β-carotene plasma levels were decreased both in AD and MCI cases, compared 
to CN subjects. Mean (SD) values for retinol were 1.73 (0.14) µM for AD, 1.73 (0.15) µM 
for MCI and 1.87 (0.24) µM for CN subjects (p<.0001 for both AD and MCI versus CN 
subjects). β-carotene mean (SD) concentrations were 444.2 (60.8) nM for AD, 467.3 (49.7) 
nM for MCI and 515.0 (37.5) nM for CN subjects (p<.0001 for both AD and MCI versus 
CN subjects and for AD versus MCI). The regression analysis confirmed the negative 
association between plasma levels of both antioxidant micronutrients and cognitive 
impairment: compared to the lowest tertile, for retinol, the OR and 95%CI of the highest 
tertile was 0.17 (0.07-0.42) for MCI and 0.22 (0.09-0.57) for AD, while for β-carotene the 
correlation was statistically significant for both the middle [OR (95% CI): 0.18 (0.05-
0.65)] and the highest tertile [OR (95% CI): 0.05 (0.01-0.19)] in MCI and AD [OR (95% 
CI), middle tertile: 0.09 (0.02-0.33); highest tertile: 0.03 (0.01-0.13)] (fully adjusted 
models). 
 
5.1.3 Vitamin E and MRI in relation to Alzheimer’s disease and mild 
cognitive impairment (Study II) 
Two hundred fifty and three AddNeuroMed study participants had both MRI and vitamin 
E data from baseline: 81 individuals with AD, 86 MCI cases and 86 CN subjects. Among 
AD cases, 6 were very mild AD (CDR= 0.5), 59 individuals were mild AD (CDR= 1), and 
16 were moderate AD (CDR = 2). Detailed description of the subjects is provided in the 
Appendix (Study II). 
Classification accuracy and MCI prediction 
The results from the OPLS analysis are visualized in scatter plots (Figure 7) by plotting the 
predictive component, which contains the information related to class separation. Figure 
7A-C illustrates the separation between AD versus CN for the three different models (MRI, 
vitamin E, and the combination of the two). The separation between AD and CN increases 
when MRI and vitamin E measures are combined. Table 12 shows the sensitivity, 
specificity, accuracy, and likelihood ratios for the different models. 
Similar results were found when repeating the analysis excluding the 16 individuals with 
moderate AD: the combination of MRI and vitamin E data had a higher predictive 
accuracy (97.4%) compared to the one provided by MRI (80.1%) or vitamin E (91.4%) 
measures alone.  
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Figure 7. OPLS cross-validated score plots for AD versus CN (A-C) and MCI versus CN (D-F). (A, D) MRI; (B, 
E) vitamin E; (C,F) MRI + vitamin E. The scatter plots visualize group separation and the predictability of the 
different models. Each red triangle represents an AD subject; each grey triangle represents an MCI individual, 
and each black triangle a control subject. CN subjects above zero and AD or MCI subjects below zero are 
falsely predicted. Q2(Y) > 0.05 is a statistically significant model. 
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Figure 7D-F illustrates the separation for the MCI versus CN models (MRI, vitamin E and 
the combination of both). Again the combination of the two measures yielded the best 
results. The prediction accuracy was 90.7%, compared to 58.1% for MRI and 87.8% for 
vitamin E measures separately (Table 12). 
 
Table 12. Accuracy, sensitivity, specificity, and LR for the AD versus CN models and the MCI 
versus CN models. 
 Accuracy Sensitivity Specificity LR+ LR- 
AD versus CN       
MRI 83.2 (76.8-88.1) 79.0 (69.9-86.5) 87.2 (78.5-92.7) 6.2 (3.5-10.8) 0.24 (0.16-0.37) 
Vitamin E 92.8 (87.9-95.8) 98.8 (93.3-99.8) 87.2 (78.5-92.7) 7.7 (4.4-13.4) 0.01 (0.00-0.10) 
MRI + vitamin E 98.2 (94.8-99.4) 98.8 (93.3-99.8) 97.7 (91.9-99.4) 42.5 (10.8-167) 0.01 (0.00-0.09) 
MCI versus CN  
MRI 58.1 (50.7-65.3) 53.5 (43.0-63.6) 62.8 (52.2-72.3) 1.4 (1.0-2.0) 0.74 (0.56-0.98) 
Vitamin E 87.8 (82.1-91.9) 88.3 (79.9-93.6) 87.2 (78.5-92.7) 6.9 (4.0-12.1) 0.13 (0.07-0.25) 
MRI + vitamin E 90.7 (85.4-94.2) 91.8 (84.1-96.0) 89.5 (81.3-94.4) 7.8 (4.7-16.3) 0.09 (0.05-0.19) 
95% confidence intervals within parenthesis. AD: Alzheimer's disease; MCI: Mild Cognitive Impairment; 
CN: cognitively normal; LR+: positive likelihood ratio; LR-: negative likelihood ratio; MRI: magnetic 
resonance imaging.  
 
Table 13 reports the analysis using the AD versus CN model containing MRI and vitamin 
E data to predict conversion from MCI to AD at one year follow-up, using baseline data. In 
this combined model 85% of the MCI converters were correctly classified. Even when we 
removed individuals with moderate AD, the model still identified 77% of the MCI 
converters. 
Table 13.  Predictions of stable and converting MCI subjects on the combined Vitamin E+MRI 
model for AD versus CN. 
 Number AD-like CN-like 
MCI Converters 13 11 (85%) 2 (15%) 
MCI Non-converters 73 24 (33%) 49 (67%) 
AD: Alzheimer's disease; MCI: Mild Cognitive Impairment; CN: cognitively normal 
 
Variables of importance and correlations 
The vitamin E and MRI variables used in the OPLS analysis were plotted according to 
their importance for the separation of groups (Figure 8 and Figure 9). The plots show the 
vitamin E and MRI measures and their corresponding jack-knifed CIs. Vitamin E and MRI 
measures below zero in the plots have lower values in AD and MCI cases compared to CN 
subjects, while vitamin E and MRI measures above zero are higher in AD and MCI cases 
compared to CN subjects in the model. 
The order of importance for the vitamin E variables is very similar for the AD versus CN 
model compared to the MCI versus CN model (Figure 8A-B). The vitamin E measures 
Results 
54 
 
more relevant for discriminating both AD and MCI from CN were α- and γ-tocotrienol, γ-
tocopherol, and the indices of vitamin E oxidative/nitrosative damage. The pattern of brain 
atrophy was not as similar for the two different group comparisons (Figure 9A-B). As 
expected, the most important regions for the separation were medial temporal lobe 
structures such as hippocampus, entorhinal cortex, and amygdala, among others, for the 
AD versus CN model (Figure 9A). The same pattern of atrophy had been observed in a 
larger sample of the AddNeuroMed cohort.69 Medial temporal lobe structures were also of 
importance for the separation between MCI and CN; however the order of the regions was 
different (Figure 9B). 
Age- and gender-adjusted correlations among each vitamin E index and the MRI data most 
relevant for group separation according to the OPLS analysis were assessed. Plasma levels 
of all vitamin E congeners were positively correlated with MRI regional cortical thickness 
and volumetric measures, but there was a negative correlation with ventricular volume 
(Table 14). The opposite trend was found for the indices of vitamin E oxidative/nitrosative 
damage, which were positively correlated with the inferior lateral ventricle measures, and 
negatively correlated with all other MRI measures. 
 
Figure 8.  Vitamin E measures of importance for the separation between groups. (A) AD versus CN; (B) MCI 
versus CN. Measures above zero have a larger value in the patient groups compared to controls and 
measures below zero have a lower value the patient groups compared to controls. A measure with a high 
covariance is more likely to have an impact on group separation than a measure with a low covariance. 
Measures with jack knifed confidence intervals that include zero have low reliability.   
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Figure 9. MRI measures of importance for the separation between groups. (A) AD versus CN; (B) MCI versus 
CN. Measures above zero have a larger value in the patient groups compared to controls and measures below 
zero have a lower value the patient groups compared to controls. A measure with a high covariance is more 
likely to have an impact on group separation than a measure with a low covariance. Measures with jack-knifed 
confidence intervals that include zero have low reliability. 
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Correlations were statistically significant for the vitamin E forms more relevant for 
discriminating AD and MCI from CN in the OPLS analyses: γ-tocopherol, α-, and γ-
tocotrienol (non-significant only for α-tocotrienol and temporal pole). Some of the 
correlations were also significant for α-tocopherol (Table 14). Regarding the indices of 
vitamin E oxidative/nitrosative damage, all correlations were statistically significant, 
except the ones with the supramarginal gyrus (both indices) and the fusiform gyrus (only 
for the ratio α-TQ/α-tocopherol).  
Table 14. Partial correlation among MRI data and vitamin E plasma levels. 
Neuroimaging EC  H Am  TP STG MTG ITG FG SMG ILV*  
Vitamin E 
α-tocopherol 0.13c 0.16c 0.12 0.09 0.11 0.12 0.11 0.14c 0.08 -0.12 
β-tocopherol 0.09 0.06 0.05 0.03 0.01 0.05 0.04 0.07 0.004 -0.02 
γ-tocopherol 0.24a 0.23a 0.17b 0.18b 0.16c 0.18b 0.17b 0.19b 0.13c 
-0.18b 
δ-tocopherol 0.10 0.08 0.07 0.08 0.07 0.08 0.08 0.11 0.07 
-0.06 
α-tocotrienol 0.17b 0.21b 0.18b 0.10 0.13c 0.15c 0.15c 0.15c 0.13c -0.15c 
β-tocotrienol 0.09 0.10 0.07 0.06 0.09 0.10 0.11 0.14c 0.10 
-0.08 
γ-tocotrienol 0.37a 0.40a 0.32a 0.26a 0.29a 0.27a 0.26a 0.27a 0.23a -0.33a 
δ-tocotrienol 0.13c 0.12 0.11 0.10 0.08 0.04 0.05 0.05 0.06 -0.15c 
Ratio αTQ/ α-
tocopherol 
-0.21b -0.23a -0.16c -0.13c -0.19b -0.13c -0.14c -0.12 -0.12 0.21b 
Ratio 5-NO2-γ-
tocopherol/  
γ-tocopherol 
-0.25a -0.19b -0.21b -0.23c -0.13c -0.22a -0.19b -0.13c -0.6 0.14c 
Partial correlation (R value, adjusted by age and gender), calculated including all study participants 
(N=253). Am: Amygdala EC: Entorhinal cortex; FG: Fusiform gyrus; H: Hippocampus; ILV: Inferior lateral 
ventricle; ITG: Inferior temporal gyrus; MTG: Middle temporal gyrus; SMG: Supra marginal gyrus; STG: 
Superior temporal gyrus; TP: Temporal pole. 
* Logarithmic transformation of this variable was done to normalize its distribution 
p value: a <0.001, b <0.01, c <0.05 
 
5.2 Population-based studies 
5.2.1 Characteristics of the populations 
The general characteristics of the Kungsholmen Project and CAIDE populations are 
presented in Table 15. As previously mentioned, the participants in the CAIDE cohort were 
younger than in the Kungsholmen Project, and the CAIDE project had a longer follow-up 
time (CAIDE: maximum 10 years; Kungsholmen Project: maximum 6.4 years). Sex 
distribution, mean education, mean baseline MMSE score and alcohol use were similar in 
both populations. Mean serum levels of total cholesterol were also comparable among the 
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two cohorts, but the use of lipid-lowering medication was present only among CAIDE 
participants. The presence of the APOE ε4 allele was higher in the Finnish population, 
particularly among cases of cognitive impairment. The APOE ε4 frequency in Finland is 
among the highest in the world.246 There were more current smokers in the CAIDE cohort, 
and mean BMI values were higher compared to the Swedish population (Table 15). None 
of the CAIDE participants reported use of vitamin E supplements, which was infrequent in 
the Kungsholmen cohort. 
Table 15. General characteristics of the Kungsholmen Project and CAIDE populations.  
Baseline characteristics Kungsholmen Project  CAIDE 
 Controls 
(n = 145) 
Incident AD  
(n = 57) 
 Controls    
 (n = 76) 
Incident cognitive 
impairment 
 (n = 64) 
Age, y,  
[range] 
84.6 (3.2)  
[80-94] 
86.2 (2.8)b 
[81-94] 
 71.3 (4.0) 
[65.4-79.1] 
71.5 (3.8) 
[65.2-79.2] 
Gender, % female 78% 84%  68% 76% 
Education, y 9.5 (3.1) 9.4 (3.3)  9.9 (3.5) 8.8 (3.2)d 
MMSE score 27.1 (2.1)  26.0 (1.5)a   26.9 (1.9) 26.3 (1.5) 
Any APOE ε4 allele, % 25% 26%  27% 52%c 
BMI (Kg/m2)  23.3 (3.4)  22.6 (2.5)  27.5 (4.0) 28.1 (4.1) 
Current smokers, % 10% 7%  28% 20% 
Alcohol use, % users 78% 75%  68% 79% 
Serum Total cholesterol, mmol/l  5.65 (1.52) 5.93 (1.37)  5.85 (0.92) 5.83 (0.97) 
Lipid lowering medication use, % (n=1) 0  18% 11% 
History of myocardial 
infarction/stroke/diabetes mellitus, %) 
--- ---  16% 28% 
Multimorbidity (% with 2+ chronic 
diseases), % 
57% 63%  --- --- 
Vitamin E supplements use (α-
tocopherol or multivitamins), % 
9% 7%  0 0 
If not otherwise specified, data are given as mean (SD). AD: Alzheimer’s disease; BMI: Body Mass Index; 
MMSE: Mini-Mental State Examination. Presence of chronic diseases is not directly comparable since 
assessment was different in the two cohorts. 
AD or cognitive impairment versus correspondent group of controls a p<0.001 b p<0.01 c p<0.05  
d difference significant at the 10% level 
 
Within the Kungsholmen Project, during the six year follow-up (which covered a total of 
771.98 person-years of follow-up) 57 incident cases of probable AD were detected. Among 
survivors, 51 subjects developed AD, while among subjects who died, 6 were diagnosed 
with AD. Subjects who developed AD were older than subjects who did not become 
demented (control group), and had a lower MMSE score at baseline. There were no 
significant differences among incident cases of AD and controls regarding sex, education, 
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presence of APOE ε4 allele, BMI, serum total cholesterol, presence of multimorbidity and 
disability at the ADL, smoking status, alcohol use, and vitamin supplements consumption 
(Table 15 and Appendix, Study III). 
The CAIDE cohort had a mean follow-up of 8.2 years. Sixty-four of the 140 subjects had 
cognitive impairment (24 MCI, 40 AD) at the second re-examination in 2005-2008, while 
the remaining 76 were cognitively intact. Subjects who developed cognitive impairment 
were more likely to be APOE ε4 carriers and to have a lower education compared to the 
control group. There were no significant differences between groups on age, gender, 
baseline MMSE total score, BMI, smoking status, alcohol use, history of 
cardiovascular/cerebrovascular conditions, lipid lowering medication use, and follow-up 
duration (Table 15 and Appendix, Study IV). 
Baseline plasma/serum concentrations of vitamin E forms for the Kungsholmen Project 
and CAIDE populations are presented in Table 16. Values standardized by total cholesterol 
and absolute plasma/serum levels are reported. Except α- and β-tocotrienol, mean levels of 
each tocopherol and tocotrienol form were higher in the Swedish cohort, compared to the 
Finnish population. This trend was present when considering both standardized and 
absolute values. 
 
5.2.2 Vitamin E and risk of Alzheimer’s disease in subjects aged 80+ years 
(Study III) 
In the Kungsholmen Project, when considering vitamin E values standardized by 
cholesterol, mean plasma levels of each tocopherol and tocotrienol congener, total 
tocopherols, total tocotrienols, and total vitamin E were lower in subjects who developed 
AD, in comparison to subjects who remained cognitively normal, but the difference was 
significant (at the 10% level) only for β-tocopherol (Table 16). 
The multi-adjusted Cox regression analysis showed that subjects with total tocopherols, 
total tocotrienols, or total vitamin E plasma levels in the highest tertile had a reduced risk 
of developing AD, in comparison to subjects in the lowest tertile: the risk was reduced, 
respectively, by 45% for total tocopherols, 54% for total tocotrienols, and 45% for total 
vitamin E (Table 17).  
When considering each individual vitamin E form, the risk of developing AD was reduced 
in subjects with plasma levels of β-tocopherol in the highest tertile, with respect to the 
lowest tertile [HR (95% CI): 0.62 (0.39-0.99)] (Figure 10). There was also a trend for a 
protective effect of α-tocopherol, α- and β-tocotrienol (highest versus lowest tertile) but it 
was not statistically significant in the multi-adjusted model [HR (95% CI): α-tocopherol: 
0.72 (0.48-1.09); α-tocotrienol: 0.70 (0.44-1.11); β-tocotrienol: 0.69 (0.45-1.06)] (Figure 
10). For each vitamin E index considered, no significant association was found for the 
middle tertile (data not shown). 
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Table 16. Vitamin E levels in the Kungsholmen Project and CAIDE populations by final diagnosis.  
Vitamin E levels Kungsholmen Project  CAIDE 
 Controls 
(n  = 145) 
Incident AD 
(n = 57) 
 Controls 
(n = 76) 
Incident cognitive 
impairment 
 (n = 64) 
Vitamin E forms adjusted by 
cholesterol# 
α-tocopherol, mean (SD) 
 
 
7.34 (2.28) 
 
 
6.86 (1.74) 
  
 
5.13 (1.02) 
 
 
5.12 (1.08) 
β-tocopherol, mean (SD) 0.47 (0.17) 0.42 (0.14)d  0.40 (0.08) 0.41 (0.09) 
γ-tocopherol, mean (SD) 0.45 (0.15) 0.41 (0.11)  0.33 (0.06) 0.32 (0.07) 
δ-tocopherol, mean (SD) 0.056 (0.020) 0.054 (0.016)  0.047 (0.01) 0.047 (0.01) 
α-tocotrienol, mean (SD) 29.78 (13.09) 27.81 (10.65)  48.29 (11.6) 47.81 (10.1) 
β-tocotrienol, mean (SD) 16.69 (7.03) 14.99 (5.41)  23.22 (4.2) 22.72 (4.4) 
γ-tocotrienol, mean (SD) 17.13 (7.34) 16.24 (7.18)  9.09 (2.28) 8.28 (2.0)c 
δ-tocotrienol, mean (SD) 2.22 (1.24) 2.15 (1.12)  1.55 (0.51) 1.54 (0.48) 
Total tocopherols, mean (SD) 8.23 (2.49) 7.62 (1.89)  5.91 (1.15) 5.90 (1.23) 
Total tocotrienols, mean (SD) 65.58 (23.55) 61.04 (17.85)  82.16 (16.61) 80.36 (14.86) 
Total vitamin E, mean (SD) 8.29 (2.51) 7.68 (1.90)  6.00 (1.16) 5.98 (1.24) 
Ratio α-tocopherylquinone/α-
tocopherol, mean (SD) 
--- ---  1.76 (0.16) 1.76 (0.14) 
Ratio 5-nitro-γ-tocopherol/γ-
tocopherol, mean (SD) 
--- ---  11.74 (2.11) 12.50 (1.40)c 
      
Vitamin E forms absolute value ‡ 
α-tocopherol, mean (SD) 
 
38.53 (3.97) 
 
38.67 (2.87) 
  
29.26 (2.99) 
 
28.91 (2.44) 
β-tocopherol, mean (SD) 2.46 (0.44) 2.36 (0.43)  2.30 (0.24) 2.33 (0.20) 
γ-tocopherol, mean (SD) 2.38 (0.29) 2.39 (0.32)  1.88 (0.17) 1.83 (0.15)d 
δ-tocopherol, mean (SD) 0.29 (0.05) 0.29 (0.04)  0.27 (0.01) 0.27 (0.02) 
α-tocotrienol, mean (SD) 157.02 (60.6) 155.8 (41.0)  275.7 (47.9) 272.9 (49.8) 
β-tocotrienol, mean (SD) 86.51 (22.14) 84.54 (22.0)  132.5 (10.3) 128.7 (9.6)c 
γ-tocotrienol, mean (SD) 90.04 (26.6) 94.8 (36.5)  51.75 (9.56) 46.82 (7.79)b 
δ-tocotrienol, mean (SD) 11.57 (4.8) 11.87 (5.3)  8.86 (2.76) 8.75 (2.27) 
Total tocopherols, mean (SD) 43.44 (2.8) 43.78 (2.93)  33.71 (3.16) 33.34 (2.58) 
Total tocotrienols, mean (SD) 346.2 (80.2) 349.6 (47.5)  468.7 (55.5) 457.1 (53.4) 
Total vitamin E, mean (SD) 43.79 (2.78) 44.14 (2.94)  34.18 (3.18) 33.79 (2.59) 
# Plama/Serum levels of tocopherols and total vitamin E are expressed as µmol per mmol cholesterol. 
Tocotrienols are expressed as nmol per mmol cholesterol. The ratios α-tocopherylquinone/α-tocopherol and 
5-nitro-γ-tocopherol/γ-tocopherol are expressed as nmol/µmol. 
‡ Plasma/Serum levels of tocopherols and total vitamin E are expressed as µM. Tocotrienols are expressed 
as nM.  
AD or cognitive impairment versus correspondent group of controls a p<0.001 b p<0.01 c p<0.05 d difference 
significant at the 10% level. 
 
Absolute values of plasma vitamin E were also examined in relation to AD risk by 
grouping the population according to their median levels of vitamin E and cholesterol. As 
specified in the Methods section (paragraph 3.3.1), this grouping was done to take into 
account the effect of cholesterol levels on vitamin E biokinetics. 
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Table 17. Vitamin E plasma levels and AD risk in the Kungsholmen Project.  
 
Vitamin E  
plasma level  
Incident AD 
Cases 
Incidence rate  
(per 1,000 person-years) 
Adjusted HR* 
(95% CI) 
Total tocopherols 
   lowest tertile (≤ 6.81) 
   highest tertile (≥ 8.73) 
 
18 
11 
 
108.9 
65.8 
 
1      (Ref.) 
0.55 (0.32-0.94) 
Total tocotrienols 
   lowest tertile (≤ 52.77) 
   highest tertile (≥ 70.45) 
 
15 
9 
 
87.4 
52.5 
 
1      (Ref.) 
0.46 (0.23-0.92) 
Total vitamin E 
   lowest tertile (≤ 6.87) 
   highest tertile (≥8.81) 
 
18 
11 
 
108.9 
66.2 
 
1      (Ref.) 
0.55 (0.32-0.94) 
 
*Crude incidence rates and HRs adjusted for age, gender, education, MMSE score, presence of APOE ε4, 
BMI, alcohol use, smoking status, and follow-up survival status.  
Plasma levels of tocopherols and total vitamin E are expressed as µmol per mmol cholesterol. Tocotrienols are 
expressed as nmol per mmol cholesterol. 
 
In all fully-adjusted models we found a trend for a protective effect in subjects with 
vitamin E-cholesterol proportions which may facilitate vitamin E delivery to tissues 
(groups 2 and 3), compared to subjects with vitamin E-cholesterol proportion less 
favourable for vitamin E delivery to cell membranes (group 1). The positive association 
was significant in group 2 for α-tocopherol [HR (95% CI): 0.41 (0.20-0.85)] and α-
tocotrienol [HR (95% CI): 0.40 (0.19-0.84)], and in group 3 for β-tocopherol [HR (95% 
CI): 0.30 (0.09-0.94)], α-tocotrienol [HR (95% CI): 0.35 (0.14-0.86)], β-tocotrienol [HR 
(95% CI): 0.35 (0.12-0.98)]  and γ-tocotrienol [HR (95% CI): 0.26 (0.71-0.96)], and total 
tocotrienols [HR (95% CI): 0.12 (0.03-0.51)]. 
 
Figure 10. Vitamin E plasma levels and AD risk in the Kungsholmen Project. The x-axis shows the different 
vitamin E forms, and the y-axis show the adjusted hazard ratio (HR) of AD by plasma level of each form 
(highest versus lowest tertile). The bars represent the 95% CI of the HRs (dots). 
HRs are adjusted for age, gender, education, MMSE score, presence of APOE ε4, BMI, alcohol use, smoking 
status, and follow-up survival status.  
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5.2.3 Vitamin E and risk of cognitive impairment in subjects aged 65+ 
years (Study IV) 
In the CAIDE study, when considering vitamin E values standardized by cholesterol, there 
was a trend comparable to the Kungsholmen cohort, with lower baseline vitamin E values 
in subjects who developed cognitive impairment. Indeed, mean serum levels of α- and γ-
tocopherol, each tocotrienol form, total tocopherols, total tocotrienols, and total vitamin E 
were lower in subjects who developed cognitive impairment, in comparison to controls, but 
the difference was statistically significant only for γ-tocotrienol (Table 16). Regarding the 
indices of vitamin E oxidative/nitrosative damage, development of cognitive impairment 
was associated with significantly higher values of 5-NO2-γ-tocopherol/γ-tocopherol ratio, 
while there was no difference for αTQ/α-tocopherol ratio (Table 16). 
Regression analyses results are shown in Table 18 as ORs with 95% CI for each vitamin E 
index (in tertiles) in relation to cognitive impairment. In the multi-adjusted model, subjects 
with higher γ-tocopherol/cholesterol ratio (middle compared to lowest tertile) were less 
likely to develop cognitive impairment [OR (95% CI): 0.27 (0.10-0.78)]. A similar 
association was found for the highest tertile, but it was not statistically significant [OR 
(95% CI): 0.85 (0.34-2.13)]. Further, subjects with a higher index of γ-tocopherol 
nitrosative damage (5-NO2-γ-tocopherol/γ-tocopherol ratio, high and middle versus lowest 
tertile) were about three times more likely to develop cognitive impairment (Table 18). No 
significant associations were found for all the other vitamin E indices. 
Absolute values of serum vitamin E were also analysed, by grouping the population 
according to the median levels of vitamin E and cholesterol, as in Study III. Similarly to 
the Kungsholmen Project, the analyses showed a trend for a protective effect in subjects 
with vitamin E-cholesterol proportions which may facilitate vitamin E delivery to tissues 
(groups 2 and 3), in comparison with subjects with vitamin E-cholesterol proportion less 
favourable for vitamin E delivery to cell membranes (group 1). In the fully adjusted model, 
the positive association was significant in group 2 for γ-tocopherol [OR (95% CI): 0.21 
(0.08-0.56)], and in group 3 for γ-tocopherol [OR (95% CI): 0.33 (0.11-0.97)], β-
tocotrienol [OR (95% CI): 0.21 (0.06-0.71)], and total tocotrienols [OR (95% CI): 0.27 
(0.08-0.90)]. For γ-tocotrienol the reduced risk of cognitive impairment in group 3 was 
only marginally significant in the multi-adjusted model [OR (95% CI): 0.33 (0.10-1.06)]. 
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Table 18. Vitamin E serum levels and risk of cognitive impairment in the CAIDE Study. 
 
Vitamin E serum levels Cases: n (%) Model 1, OR (95% CI) Model 2, OR (95% CI) 
Total tocopherols 
L (≤5.34) 
M (>5.34 & <6.17) 
H (≥6.17) 
 
23 (36) 
19 (30) 
22 (34) 
 
1.00 
0.83 (0.35-1.98) 
1.10 (0.44-2.70) 
 
1.00 
0.92 (0.35-2.43) 
1.39 (0.51-3.81) 
Total tocotrienols 
L (≤73.81) 
M (>73.81 & <86.26) 
H (≥86.26) 
 
24 (38) 
19 (30) 
21 (32) 
 
1.00 
0.69 (0.29-1.64) 
0.84 (0.35-2.04) 
 
1.00 
0.71 (0.27-1.87) 
0.90 (0.34-2.37) 
Total vitamin E 
L (≤5.42) 
M (>5.42 & <6.27) 
H (≥6.27) 
 
24 (38) 
18 (28) 
22 (34)  
 
1.00 
0.69 (0.29-1.65) 
1.01 (0.41-2.49) 
 
1.00 
0.82 (0.31-2.19) 
1.32 (0.48-3.67) 
Ratio α-TQ/ α-tocopherol 
L (≤1.667 ) 
M (>1.667 & <1.840) 
H (≥1.840) 
 
20 (31.5) 
20 (31.5) 
23 (37) 
 
1.00 
0.81 (0.31-2.10) 
1.34 (0.51-3.52) 
 
1.00 
0.58 (0.20-1.73) 
1.23 (0.44-3.58) 
Ratio 5-NO-γ-tocopherol/γ-tocopherol 
L (≤ 11.408) 
M (>11.408 & <12.85) 
H (≥ 12.85) 
 
13 (20) 
27 (42) 
24 (38) 
 
1.00 
3.50 (1.41-8.67) 
2.94 (1.17-7.38) 
 
1.00 
3.41 (1.29-9.06) 
2.89 (1.05-7.97) 
α-tocopherol  
L (≤4.6) 
M (>4.6 & <5.32) 
H (≥5.32) 
 
23 (36) 
20 (31) 
21 (33) 
 
1.00 
0.93 (0.39-2.18) 
0.96 (0.40-2.33) 
 
1.00 
1.06 (0.40-2.76) 
1.14 (0.42-3.09) 
β-tocopherol  
L (≤0.368) 
M (>0.368 & <0.435) 
H (≥ 0.435) 
 
21 (33) 
20 (31) 
23 (36) 
 
1.00 
1.17 (0.48-2.81) 
1.54 (0.61-3.88) 
 
1.00 
1.21 (0.46-3.20) 
1.79 (0.66-4.83) 
γ-tocopherol   
L (≤ 0.295) 
M (>0.295 & <0.342) 
H (≥0.342) 
 
28 (44) 
14 (22) 
22 (34) 
 
1.00 
0.29 (0.12-0.72) 
0.74 (0.31-1.80) 
 
1.00 
0.27 (0.10-0.78) 
0.85 (0.34-2.13) 
δ-tocopherol  
L (≤0.043) 
M (>0.043 & <0.05) 
H (≥0.05) 
 
24 (38) 
19 (30) 
21 (32) 
 
1.00 
0.82 (0.34-1.96) 
0.91 (0.37-2.22) 
 
1.00 
0.84 (0.31-2.24) 
0.89 (0.34-2.34) 
α-tocotrienol  
L (≤43.0) 
M (>43.0 & <51.5) 
H (≥51.5) 
 
24 (37.5) 
16 (25) 
24 (37.5) 
 
1.00 
0.52 (0.21-1.25) 
1.18 (0.49-2.86) 
 
1.00 
0.49 (0.18-1.33) 
1.03 (0.40-2.69) 
β-tocotrienol  
L (≤ 21.04) 
M (>21.04 & <24.14) 
H (≥24.14) 
 
23 (36) 
20 (31) 
21 (33) 
 
1.00 
1.03 (0.44-2.41) 
0.90 (0.37-2.20) 
 
1.00 
1.54 (0.58-4.07) 
1.17 (0.41-3.34) 
γ-tocotrienol  
L (≤7.71) 
M (>7.71 & <9.5) 
H (≥9.5) 
 
26 (41) 
21 (33) 
17 (26) 
 
1.00 
0.77 (0.33-1.80) 
0.50 (0.20-1.26) 
 
1.00 
1.04 (0.40-2.68) 
0.57 (0.21-1.57) 
δ-tocotrienol    
L (≤1.30) 
M (>1.30 & <1.66) 
H (≥1.66) 
 
21 (33) 
22 (34) 
21 (33) 
 
1.00 
1.10 (0.45-2.67) 
0.99 (0.42-2.30) 
 
1.00 
0.91 (0.33-2.50) 
0.95 (0.38-2.42) 
Odds ratios (OR) with 95% confidence interval (CI) of vitamin E serum levels (tertiles) for cognitive 
impairment. L: lowest tertile (reference); M: middle tertile; H: highest tertile. 
Model 1: adjusted for age, gender and education. Model 2: adjusted for age, gender, education, 
APOE status, BMI, smoking status, alcohol use, and history of cardio/cerebrovascular conditions. 
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5.3 Pooled analysis  
The association between vitamin E and cognition has been further investigated by pooling 
together the three populations that were included in this project, and by examining the 
correlation among each vitamin E index and MMSE total score. 
The characteristics of the pooled population are shown in Table 19. The MMSE total score 
ranged from 10 to 30, with a value of 17 for the 5th percentile, 25 for the 25th, 27 for the 
50th, and 29 for the 75th percentile.  
Table 19. Characteristics of the population included in the pooled analysis.  
 
Subjects characteristics (N=893) Value  
Age, y,  
[range] 
77.6 (6.8)  
[65-95] 
MMSE score 26.0 (3.9)  
Education 9.3 (4.0)  
Gender, % female (N=595) 67% 
Any APOE ε4 allele*, % (N= 309) 35% 
Cholesterol, mmol/l 5.50 (1.23)  
Vitamin E forms a  
 α-tocopherol 
 
6.20 (1.88)  
 β-tocopherol 0.45 (0.14)  
 γ-tocopherol 0.40 (0.12)  
 δ-tocopherol 0.053 (0.015)  
 α-tocotrienol 50.65 (20.59)  
 β-tocotrienol 24.03 (8.29)  
 γ-tocotrienol 13.15 (5.80)  
 δ-tocotrienol   2.07 (1.02)  
Total tocopherols a  7.00 (2.05)  
Total tocotrienols a 92.40 (30.35)  
Total vitamin E a 7.10 (2.07)  
Ratio α-tocopherylquinone/α-tocopherol b 1.69 (0.24)  
Ratio 5-nitro-γ-tocopherol/γ-tocopherol b 11.86 (2.18)  
 
If not otherwise specified, data are given as mean (SD). *APOE was available for 861 subjects. a Levels of 
tocopherols and total vitamin E are expressed as µmol per mmol cholesterol. Tocotrienols are expressed as 
nmol per mmol cholesterol. b The ratios α-tocopherylquinone/α-tocopherol and 5-nitro-γ-tocopherol/γ-
tocopherol are expressed as nmol/µmol. The ratios were available for the AddNeuroMed and CAIDE cohorts.  
 
For each vitamin E index, the estimated regression coefficients (Beta) for the four 
percentiles of the MMSE are reported in Table 20, together with the 95% CI. In the fully 
adjusted models, a positive correlation among each vitamin E forms, total vitamin E, total  
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Table 20. Correlation among vitamin E and MMSE 
Vitamin E forms MMSE 
Percentile 
Model 1 
Beta (95% CI) 
Model 2 
Beta (95% CI) 
Total vitamin E 5° 
25°  
50°  
75°  
0.16a 
0.10b  
0.13a  
0.10b  
0.03 
0.09b 
0.09b 
0.07b 
Total tocopherols 5° 
25°  
50°  
75° 
0.16a 
0.10b  
0.13a  
0.10b  
0.04 
0.09 b 
0.09a 
0.07c 
Total tocotrienols 5° 
25°  
50°  
75° 
0.01 
0.004  
0.01a  
0.01b  
0.01c 
0.01a 
0.01a 
0.01a 
α-tocopherol 5° 
25°  
50°  
75° 
0.20a 
0.10b  
0.11a  
0.08b  
0.04 
0.07c 
0.04 
0.05c 
β-tocopherol 5° 
25°  
50°  
75° 
1.16 
0.40  
0.92c  
0.76c  
0.55 
0.01 
0.51 
0.56 
γ-tocopherol 5° 
25°  
50°  
75° 
3.64a 
2.18a  
2.35a  
2.39a  
1.20 
1.92a 
1.82a 
1.71a 
δ-tocopherol 5° 
25°  
50°  
75° 
8.92 
3.96  
7.74c  
6.70c  
3.79 
0.09 
2.04 
2.89 
α-tocotrienol 5° 
25°  
50°  
75° 
-0.02 
0.003  
0.008a  
0.007b  
0.01b 
0.01a 
0.01a 
0.01c 
β-tocotrienol 5° 
25°  
50°  
75° 
-0.01 
 -0.01 
0.01 
0.01c 
0.01c 
0.02c 
0.02b 
0.02b 
γ-tocotrienol 5° 
25°  
50°  
75° 
0.11a 
0.07a  
0.07a  
0.08a  
0.05c 
0.07a 
0.07a 
0.07a 
δ-tocotrienol 5° 
25°  
50°  
75° 
0.41b 
0.14a  
0.20a  
0.12c  
0.07 
0.12c 
0.11c 
0.11b 
Ratio α-TQ/α-tocopherol 5° 
25°  
50°  
75° 
-0.51 
-1.81a 
-1.40a 
-1.40b 
-0.94 
-1.66a 
-1.28a 
-1.21b 
Ratio 5-nitro-γ-tocopherol/γ-
tocopherol 
5° 
25°  
50°  
75° 
-0.06 
 -0.13a  
-0.14a  
-0.19a 
-0.11 
-0.10b 
-0.11a 
-0.12a  
 
Estimated logistic quantile regression for MMSE. Model 1: adjusted by age; Model 2: adjusted by age, gender 
education, APOE genotype and cohort.    
 
a p<0.001 b p<0.01 c p<0.05 
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tocopherols, total tocotrienols, and the MMSE score was shown, while there was a 
negative correlation between the indices of vitamin E oxidative/nitrosative damage and the 
MMSE score. For each vitamin E index, the strength of the correlation was similar across 
all MMSE percentiles. For total tocotrienols, α-, β-, and γ-tocotrienol the correlation was 
statistically significant for all percentiles. Figure 11 exemplifies the estimated MMSE 
percentiles in relation to total tocotrienols, showing that increased values of tocotrienols 
levels are associated with higher predicted MMSE total score within each MMSE 
percentile. For total vitamin E, total tocopherols, γ-tocopherol, δ-tocotrienol, and the ratios 
αTQ/α-tocopherol and 5-nitro-γ-tocopherol/γ-tocopherol the correlation was not significant 
in the fully adjusted model, only for the 5th percentile. For the other vitamin E forms the 
association was not statistically significant for two or all four percentiles (Table 20).  
 
 
Figure 11. Age, gender, education and APOE status- adjusted estimated percentiles of MMSE in relation to 
total tocotrienols. All three cohorts included. 
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6 DISCUSSION 
This research project has analyzed all eight natural forms of vitamin E in relation to AD 
and MCI, in clinic- and population-based studies. Overall, individuals from seven 
European countries have been included in this investigation, from North to South Europe. 
The results suggest the existence of a relation between different natural vitamin E forms 
and AD and MCI in older adults. 
 
6.1 Vitamin E, Alzheimer’s disease, and mild cognitive impairment: clinical 
context 
Study I of this project shows that the plasma concentrations of different vitamin E forms 
are related to the diagnosis of AD and MCI in older adults. All previous cross-sectional 
clinical studies examined only α-tocopherol in subjects with dementia/AD, reporting either 
reduced plasma/serum levels in diseased individuals compared to controls138-149 or no 
association.148,150-155 Some studies showed decreased plasma α-tocopherol also in subjects 
with MCI,138,147 while other studies did not confirm this finding.115,136 Cross-sectional 
analyses in population-based studies have also shown conflicting results, and only one 
study (CSBA) analyzed all tocopherol forms.115,156,157 In the CSBA cohort plasma 
tocopherols were assessed in a population of older adults (age 65+ years) with normal 
cognition, MCI, or dementia, and higher δ-tocopherol levels were found in subjects with 
dementia (compared to MCI and CN) when analyzing vitamin E/cholesterol ratio. No 
differences were found among the three groups when tocopherols levels were analyzed as 
absolute values.115  
In the AddNeuroMed cohort, both cases of AD and MCI had lower plasma levels of 
different vitamin E forms, and reduced values for indices representing total vitamin E 
amounts, compared to CN subjects. This pattern was evident both when considering 
vitamin E values standardized by cholesterol and when evaluating absolute values of 
vitamin E. Further, both clinical diagnosis of AD and MCI were characterized by increased 
plasma indices of vitamin E oxidative/nitrosative damage.  
Within the AddNeuroMed cohort, it has also been shown that the combined analysis of 
vitamin E plasma levels and automated MRI measures can accurately distinguish AD and 
MCI cases from CN individuals. Additionally, it can prospectively identify MCI cases that 
will progress to a clinical diagnosis of AD after one year (Study II). 
The development of biomarkers for AD is an active area of research. To date, 
neuroimaging- and CSF-based markers have been the most widely studied. Structural MRI, 
PET, and CSF parameters have been included in the new diagnostic criteria for AD, MCI 
due to AD and preclinical AD. However, many clinical settings do not have the ability to 
implement some of these techniques, and further validation and standardization of the 
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proposed biomarkers would be advantageous.66,67 Brain atrophy evidenced by MRI is an 
indicator of neuronal injury, and combined assessment of different brain regions can 
highlight regional patterns of abnormalities more specific for AD compared to the 
evaluation of single structures.69 For example hippocampal atrophy is not specific to AD; it 
can also be present in hippocampal sclerosis and frontal lobe dementia. 
Blood based markers can represent inexpensive and minimally-invasive tools for early 
identification and monitoring of AD progression. Obtaining blood samples can easily be 
implemented in large scale screening and prevention studies, and for repeated measures. 
Several studies suggest that plasma levels of different proteins and metabolites might be 
related to AD pathology, including indices of OS/NS and inflammation.43,44,73,74,76,86,147,247 
Such plasma markers could be a systemic metabolic hallmark of AD or reflect a change in 
plasma secondary to a disease-specific process in the brain. A recent study of healthy older 
adults concluded that pattern of nutrient biomarkers detected in plasma correlated with 
cognitive functioning and MRI brain volumes. The plasma profile high in α-tocopherol 
was associated with better global cognition and reduced total brain atrophy.161 Plasma 
indices of vitamin E status could be indicators reflecting biochemical changes associated 
with AD pathophysiology. However, the challenge for blood-based biomarkers is still 
considerable. The main difficulty when studying blood is due to the variability of plasma 
components in response to non-AD influences (i.e., drugs, time of sampling, environmental 
factors). The combination of different methods, such as MRI, CSF parameters, blood 
measures, and neuropsychological data allow for the evaluation of different aspects of AD, 
increasing their diagnostic and prognostic value through a multimodality markers 
approach. A recent study within the ADNI project reported that combinations of 
neuropsychological data, CSF, and MRI measures attained an accuracy of 67.1% in 
predicting MCI conversion to AD after two years, outperforming the evaluation of the 
single modality markers.75 In another survey, the combination of MRI, CSF, and FDG-PET 
separated MCI converters from non-converters with a sensitivity of 91.5% and a specificity 
of 73.4%.71 However, CSF and FDG-PET are not easy to implement in large scale studies 
or for repeated measures. In Study II, the joint evaluation of plasma vitamin E and MRI 
measures increased the accuracy in separating AD and MCI from CN subjects to 98% and 
91%, respectively. This combination of parameters was also able to classify 85% of the 
MCI converters as AD-like and 67% of the stable MCI as CN-like subjects. In a previous 
study using data from AddNeuroMed and ADNI cohorts, MRI data were able to identify 
71% of the MCI converters and 60% of the stable MCI subjects. Thus the joint evaluation 
of MRI and plasma vitamin E indices seems to provide a more robust predictive tool.69 
 
Other antioxidant micronutrients 
Vitamin E is the main lipid-soluble, non-enzymatic antioxidant in the human body, in 
which other non-enzymatic antioxidants are also available. Those are a combination of 
hydrophilic and lipophilic compounds, which interact with each other and with enzymatic 
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antioxidants for a fine tuning of the redox status. In the AddNeuroMed population (Study 
I) β-carotene and retinol (non-enzymatic, lipophilic antioxidants) were also analysed, to 
provide a broader picture of the antioxidant micronutrients status in cognitive impairment. 
Both β-carotene and retinol (vitamin A) plasma levels were reduced in AD and MCI cases 
compared to CN individuals, supporting the presence of an altered antioxidant 
micronutrient status in these disorders.  
High plasma levels or high dietary intake of carotenoids/β-carotene have been associated 
with better cognitive performance160,248 and reduced risk of cognitive decline and AD in 
some,249 but not all, studies.180 Two RCTs reported protective benefits for cognition in 
subjects supplemented with β-carotene.250,251 In some population-based studies plasma 
vitamin A was not related to dementia diagnosis.157,164 while other studies reported reduced 
levels in subjects with dementia or MCI.139,147 Carotenoids and retinol are present in the 
brain,112 and evidence of their antioxidant and anti-amyloidogenic properties warrant 
further investigation of their role in neurodegeneration.252 
 
6.2 Vitamin E, Alzheimer’s disease and mild cognitive impairment: general 
population context 
In the prospective study in Swedish octogenarians (Study III) a reduced incidence of AD 
was found in subjects with higher plasma levels of total tocopherols, total tocotrienols, and 
total vitamin E. The analyses of absolute plasma values of vitamin E, in which cholesterol 
levels were also accounted for, revealed a reduced AD incidence for higher plasma levels 
of α- and β-tocopherol, α-, β-, and γ- tocotrienol, and total tocotrienols.    
In the Finnish cohort of adults aged 65+ years (Study IV) high levels of γ-tocopherol, β-
tocotrienol, and total tocotrienols seemed to be protective against cognitive impairment, 
after different adjustments for cholesterol. 
The differences in findings of the two studies could be due to different factors, including 
age of participants and follow-up duration. Also, the Swedish cohort had higher plasma 
levels of tocopherols compared to the Finnish population (the highest tertile of total 
tocopherols and total vitamin E in the CAIDE study fell within the lowest tertile of the 
Swedish cohort). The reasons for lower levels of some vitamin E forms in Finland during 
the 1990s are unclear, and other studies assessing tocopherols in Finnish cohorts reported 
values comparable to the CAIDE cohort.253-255 Interestingly, the Italian CSBA study 
reported tocopherols levels similar to CAIDE participants, and found a lower incidence of 
dementia in subjects with plasma γ-tocopherol levels in the middle (but not highest) 
tertile.115 Similar results were found in Study IV. Higher γ-tocopherol has been found to be 
associated with a high intake of saturated fats, another risk factor for dementia/AD,181 
which may partly explain this association. 
Previous population-based studies on vitamin E levels and risk of cognitive decline or 
dementia/AD have evaluated mainly α-tocopherol, reporting a reduced risk in individuals 
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with higher α-tocopherol plasma levels164 or no association.162,166 Other than the CSBA, 
two other studies analysed γ-tocopherol; the Nurses’ Health Study and the ULSAM study. 
The Nurses’ Health Study reported better cognitive outcomes in subjects with high γ-
tocopherol plasma levels and α-tocopherol concentration under the median, suggesting a 
possible interactive effect of different vitamin E forms in modulating the risk of cognitive 
decline in older adults.163 In the ULSAM study α- and γ-tocopherol levels were evaluated 
in relation to the risk of dementia/AD, and no association was found.166 
In the CAIDE population (Study IV), an elevated index of vitamin E nitrosative damage 
(5-NO2-γ-tocopherol/γ-tocopherol ratio, indicating consumption of γ-tocopherol in free 
radical reactions), was associated with increased risk of cognitive impairment. Products of 
vitamin E oxidative/nitrosative damage, such as 5-NO2-γ-tocopherol and α-TQ, were 
measured also in the CSBA,115 but the ratio with the correspondent vitamer E (i.e., γ- and 
α-tocopherol) was not considered, and these indices have so far not been studied in relation 
to cognitive decline/AD in other longitudinal studies. Elevated plasma values of the ratios 
5-NO2-γ-tocopherol/γ-tocopherol and α-TQ/α-tocopherol were found in subjects with AD 
and MCI in the AddNeuroMed cohort (Study I), and an increased 5-NO2-γ-tocopherol/γ-
tocopherol ratio was also detected in cortical brain regions in an autopsy study of patients 
with AD compared to controls.113 RNS substantially contribute to free radical-mediated 
damage in AD, and can be efficiently neutralized by γ-tocopherol with the generation of 5-
NO2-γ-tocopherol.113 Thus, the increased ratio 5-NO2-γ-tocopherol/γ-tocopherol might 
reflect elevated γ-tocopherol use due to increased NS. 
 
6.3 Biological plausibility 
Much evidence supports the role of OS/NS in the propagation of cellular injury leading to 
different types of damage observed both in brain aging and neurodegeneration.43,78 α-
tocopherol is considered the main lipophilic non-enzymatic antioxidant; it is the most 
abundant vitamin E form in the human body, and the most extensively investigated. 
However, increasing evidence is accumulating about the biological properties of the other 
vitamin E congeners. All vitamin E forms act as antioxidants, with γ-tocopherol being 
highly efficient against RNS and tocotrienols showing stronger antioxidant properties than 
α-tocopherol.103,110,113 Vitamin E has a prominent role in protecting cellular membranes, as 
it is the main lipid-soluble antioxidant. This could be crucial in mitochondria, since they 
are both the main source and elective target of free radicals. Mitochondria are crucial both 
for cell survival and death as they produce cellular energy and are central in apoptotic 
signaling. Many lines of evidence suggest that mitochondria have an important role in 
neurodegeneration, and mitochondrial dysfunction has been shown in AD.256,257 Different 
vitamin E forms may protect mitochondria through their antioxidant activity, thus 
supporting cell survival and synaptic functioning.256-260 
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Additionally, each vitamin E form is functionally unique, and has other biological 
properties that can be relevant for neuroprotection, including anti-inflammatory activity 
and modulation of the cellular signaling that regulates neuronal survival. Indeed, α- and γ-
tocopherol, and all tocotrienols have anti-inflammatory properties.105,113,122,124 Further, 
studies on mouse hippocampal and cortical neurons have shown that nanomolar 
concentrations of α-tocotrienol can prevent neuronal death by modulating specific cellular 
signaling, including phospholipase A2 and 12-lipoxygenase mediated signaling.128 
In a neuropathological study (the Religious Order Study) CSF α-tocopherol was positively 
associated with perceptual speed, while no association was found for γ-tocopherol.261 
Furthermore, α-, β-, and γ-tocopherol have been detected in the brain of cognitively normal 
subjects, and an age-related decline of these compounds was found in the frontal lobes, 
which are vulnerable to AD.112 Another neuropathological study found reduced γ-
tocopherol levels in the brain of AD subjects, with concomitant increase of its reaction 
product with RNS (5-NO2-γ-tocopherol).113 A recent study has shown that tocotrienols are 
delivered to the CNS, where they reach concentrations adequate for beneficial biological 
activity.114 Finally, population-based studies assessing vitamin E dietary intake reported a 
protective effect of the combination of different vitamin E forms against cognitive decline 
and dementia/AD.179,181,183  
All this evidence supports the hypothesis that all vitamin E forms can have a role in the 
aging brain and AD. Reduced levels of vitamin E forms and increased products of their 
oxidative/nitrosative damage could affect neurodegeneration, both through the reductions 
of the antioxidant shield and the unbalance in specific cellular signaling pathways.  
Results of the present project provide further evidence regarding the importance of 
different vitamin E forms in the development or clinical expression of AD in older adults, 
which warrants further investigation.  
 
6.4 Clinical implications  
α-tocopherol is the only vitamin E congener which has been tested in RCTs in subjects 
with AD and MCI, and the results have been inconsistent.187 α-tocopherol is also the most 
commonly used vitamin E supplement, which is a widely consumed supplement in 
Western countries, due to the belief that vitamin E may attenuate morbidity and mortality. 
It has been estimated that about 35 million Americans take vitamin E supplements, which 
are prescription-free products.262 Although the vitamin E recommended dietary 
allowance (RDA) is 15 mg [22 international units (IU)] of RRR-α-tocopherol (the 
naturally occurring form of α-tocopherol), vitamin E supplements are available in doses 
of 100 to 1000 IU (synthetic α-tocopherol, which includes eight different 
steroisomers).131 The American Institute of Medicine’s Food and Nutrition Board set the 
upper tolerance level for α-tocopherol at 1000 mg [1100 IU synthetic α-tocopherol; 1500 
IU natural α-tocopherol] per day using data from studies in rats.106  
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Similarly to RCTs investigating α-tocopherol supplement in AD, RCTs of α-tocopherol 
supplementation in other disorders, including cardiovascular disorders, heart attack, and 
cancer risk, have resulted in conflicting outcomes: beneficial effects, limited effects, no 
benefit, and possible harm.263-271 Furthermore, current data on mortality and α-tocopherol 
supplementation at high doses emphasize that such a micronutrient, if unbalanced, may not 
be as harmless as previously thought. A recent meta-analysis of RCTs testing α-tocopherol 
supplementation reported an increased risk of haemorrhagic stroke in users of this 
supplement.272 Another recent review examining primary and secondary prevention RCTs 
with α-tocopherol in different disorders reported an increased mortality risk associated with 
α-tocopherol supplementation, confirming a previous report from the same research 
group.273 The authors concluded that there is no evidence to support antioxidant 
supplements for primary or secondary prevention, and antioxidant supplements should be 
considered as medicinal products that should undergo sufficient evaluation before 
marketing. On the other side, in the last few years many new supplements containing 
vitamin E have appeared on the market. They promise to protect against different age-
related disorders, including cognitive impairment and AD, and contain different 
combinations of tocopherols and tocotrienol, despite the fact that the scientific community 
has not yet defined the RDA for non-α-tocopherol forms of vitamin E. Indeed, α-
tocopherol is the only vitamin E form currently used to define vitamin E dietary 
requirements.131 Further, the RDA for α-tocopherol is based on studies of erythrocyte 
haemolysis conducted more than 60 years ago and there is general agreement that the 
haemolysis assays might not be the optimal test for defining α-tocopherol RDA.121,131 The 
American Institute of Medicine’s Food and Nutrition Board specifies that the non α-
tocopherol forms of vitamin E were not used to estimate vitamin E requirement because of 
their failure to bind with the α-TTP. However, recent studies have shown the actual 
bioavailability of non α-tocopherol forms in several tissues, where tocopherols and 
tocotrienols can reach concentrations adequate for beneficial biological activity.114 This, 
together with the results from experimental and epidemiological studies on non α-
tocopherol forms, reinforces the hypothesis that the different vitamin E congeners play 
unique roles in human health.  
A balanced intake of different vitamin E forms can be important for neuroprotection. Even 
if there is preferential body retention of α-tocopherol, the other congeners exhibit 
biological activity at very low concentrations. Additionally, high doses of α-tocopherol, 
such as those present in supplements, can decrease the bioavailability of the other 
congeners, which could be essential for normal cell functioning. In fact, α-tocopherol 
supplementation can decrease plasma and tissue concentration of γ-tocopherol,122,190 and 
compromise tissue delivery of α-tocotrienol.191 
Evaluating only α-tocopherol might not provide the most accurate measure of vitamin E 
status in humans, and assessment of all vitamin E natural congeners might be appropriate 
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when investigating the association of vitamin E with diseases, including age-related 
cognitive decline and AD. Study of the all vitamin E forms can also help refine preventive 
therapeutic strategies based on vitamin E supplementation.   
The American Institute of Medicine’s Food and Nutrition Board guidelines for dietary 
intake specifies that the potential role of vitamin E in the reduction of disease risk was 
considered in developing the Estimated Average Requirement for this micronutrient, and 
the acquisition of additional data relating intake to chronic disease or disability would be 
considered for a revision of the Estimated Average Requirement.131  
 
6.5 Methodological issues 
The main strength of this project is its integrative approach. Vitamin E has been evaluated 
both in clinic-based and population-based cohorts, and its association with AD has been 
investigated by taking into account all eight natural vitamin E forms, together with markers 
of vitamin E oxidative/nitrosative damage. Both standardized and absolute values of 
plasma/serum vitamin E were considered, performing different adjustments for cholesterol, 
and multiple potential confounders were taken into account. Although each study design, 
method, and population has its own inherent problems and limitations, combining them can 
only reinforce the results.  
Results from pooled analyses confirmed the association of vitamin E levels with global 
cognition measured with MMSE. The main limitation of the pooled analysis is due to the 
combination of two population-based cohorts and a clinic-based study. However, the 
correlations among several vitamin E indices and MMSE were statistically significant even 
when adjusting for cohort of origin, and these results are consistent with the findings of 
independent analysis within each population. 
 
In all studies, vitamin E congeners were measured in plasma or serum. Unlike dietary 
intake assessment, micronutrient plasma/serum measurement is an objective measure and 
is independent of the capacity to estimate/remember intake over a period of time. 
Moreover, plasma level assessment considers individual variations in metabolism, giving a 
reliable evaluation of micronutrient bioavailability. 
For the longitudinal studies included in this project vitamin E measurements were available 
at only one time point. Due to possible intra-individual variation in vitamin E serum levels, 
a single measurement does not necessarily reflect the typical vitamin E bioavailability of an 
individual. However, some studies reported a good intra-individual stability for α- and γ-
tocopherol levels, for periods up to 15 years.243,274-276 Analogous data are not available for 
tocotrienols. 
 
Both standardized and absolute values of plasma/serum vitamin E have been considered. 
Vitamin E biokinetics is tightly related to lipoproteins. Tissues can acquire vitamin E by 
several major routes: (1) during LPL mediated triglyceride-rich lipoprotein catabolism; (2) 
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during LDL uptake via the LDL receptor; (3) via high-density lipoprotein-mediated 
delivery systems; and (4) by nonspecific transfers through lipoproteins. Vitamin E rapidly 
transfers between various lipoproteins and also between lipoproteins and membranes, 
which may enrich membranes with vitamin E.102,108 For these reasons, lipid levels need to 
be considered when assessing the effects of vitamin E on any outcome; standardization to 
total cholesterol is commonly used.115,133,134 However, longitudinal studies have shown that 
the relation between serum total cholesterol and risk of cognitive decline/dementia is age-
dependent. Elevated midlife total cholesterol has been associated with increased risk of 
dementia/AD, but cholesterol levels tend to decline after midlife in people who later 
develop dementia/AD.236,277 This pattern was previously reported in the CAIDE cohort.236 
Whether the pattern of change over time in vitamin E levels is similar to that of total 
cholesterol remains to be determined. Data on age-related variation on vitamin E forms are 
scarce and inconsistent.166,278 In a US population, an age-related increase of α-tocopherol 
and decrease for γ-tocopherol were described, but the increasing use of α-tocopherol 
supplements among older adults was suggested as a possible explanation.278 It is unclear if 
adjustments for cholesterol may lead to and underestimation of the association of vitamin E 
with cognitive decline, and how lipid levels should be best accounted for in longitudinal 
vitamin E studies. 
 
In the AddNeuroMed and CAIDE cohorts blood samples were collected after a minimum 
of two hours fasting, while in the Kungsholmen Project fasting was not compulsory. In the 
CAIDE sample fasting status was similar among cases and controls [hours, mean (SD): 
9.5(4.8) for cases and 9.4(4.7) for controls, p=0.91)], and additional analyses considering 
fasting time as covariate provided results comparable to the main analysis. Similar data 
were not available for the AddNeuroMed and the Kungsholmen Project. However, transfer 
of vitamin E from blood to tissues occurs both during fasting and non-fasting conditions, 
and it is reasonable to assume that these conditions of measurements were equally 
distributed among all subjects, which would not affect the results. Additionally, in the 
Nurses’ Health Study plasma levels of α- and γ-tocopherol from fasting and non-fasting 
samples were evaluated, and similar results were found when analyzing all samples and 
only fasting samples.163 
 
6.5.1 Clinic-based studies 
The main strengths of the clinical studies in this project are the multinational composition 
of the population and the sample size: the AddNeuroMed population is one of the largest 
cohorts of AD and MCI subjects, gathered from six European countries. The 
AddNeuroMed population includes subjects from the North, Center, and South of Europe, 
which to some extent takes into account differences in dietary habits that could influence 
micronutrient status. In Study I, even when considering the subject’s country of origin, the 
differences among AD, MCI and CN subjects on vitamin E indices were still significant.  
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In Study II, the combined analysis of vitamin E and MRI data integrated 67 parameters, 
obtained by non-invasive (MRI) and minimally-invasive (venipuncture) methods. The MRI 
measures included a set of automated regional cortical thickness and volumetric measures. 
The AddNeuroMed study implemented a harmonized MRI acquisition protocol across 
centers, rigorous quality control, a central data analysis hub and an automated image 
analysis pipeline.207,279 Automated image analysis techniques, such as the Freesurfer 
technique used in Study II, may have particular advantages compared to manual measures 
when it comes to widespread implementation in clinical or research practice. A further 
strength of Study II is the use of a multivariate data analysis approach, OPLS, which 
provides the opportunity to analyze many variables simultaneously and observe inherent 
patterns in the data. OPLS allows groups to be separated, highlights which measures cause 
the separation, and facilitates making predictive models of disease.238 
 
Regarding potential study limitations, information on some potential confounders was not 
available for the AddNeuroMed population. This includes information on smoking status, a 
source of OS/NS. Nevertheless, investigations on vitamin E concentrations in smokers 
have yielded inconsistent evidence: smokers’ plasma α- and γ-tocopherol levels were either 
lower or similar to non-smokers, while smoking increased 5-NO2-γ-tocopherol levels.280 
BMI was also not available. Some studies suggest an association between BMI and γ-
tocopherol levels.281 However, data on plasma α-tocopherol and BMI are 
inconsistent,243,281,282 and analogous data on tocotrienols are not available. The normal 
levels of serum total cholesterol and albumin in the AddNeuroMed cohort suggest that 
none of the study participants were malnourished. Further, after adjustment for disease 
duration (Study I) and even exclusion of subjects with moderate-severe AD (Study I and 
II), who could be at risk of malnutrition, the association between cognitive impairment and 
vitamin E levels was still significant.  
Vitamin E status can be affected by different conditions other than lifestyle, including 
disorders characterized by increased OS/NS (e.g. cancer, diabetes mellitus).78 However, in 
the AddNeuroMed study, individuals with unstable systemic illness/organ failure were not 
included. Additionally, a significant positive correlation among vitamin E plasma levels 
and brain volumes was found, while indices of vitamin E oxidative/nitrosative damage 
were positively correlated with levels of brain atrophy. The significant correlation among 
MRI measures and vitamin E plasma levels reduces the possibility that vitamin E 
differences were due only to non-specific illnesses in subjects with AD and MCI.  
When considering vitamin E levels as possible indicators associated with AD pathology, it 
is also important to consider that different CNS disorders in which OS/NS phenomena are 
described (e.g., AD, vascular dementia, Parkinson’s disease, amyotrophic lateral sclerosis) 
could influence vitamin E levels.78,85 A similar issue also exists for β-amyloid and tau 
protein, which can be assessed in CSF, and directly reflect AD neuropathology. Decreased 
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CSF levels of β-amyloid and increased levels of tau/phospho-tau are considered AD 
hallmarks, but CSF changes for both proteins also occur in other neurological disorders 
(e.g., amyloid angiopathy, dementia with Lewy body, prion disease).66 As in Study II, 
many studies on AD biomarkers are based on the comparison of diseased and disease-free 
subjects, and usually only AD and MCI cases are included, while cases with other diseases 
which can require differential diagnosis with AD are not considered.66 There is also some 
evidence that β-amyloid and tau related markers are less predictive of AD development in 
individuals with high cognitive reserve283 or very advanced age.284 Other limitations related 
to the current state of knowledge on biomarkers for AD are due to the paucity of validation 
studies implementing post-mortem data, and scarcity of combined analysis of multiple 
biomarkers. Neither AD nor MCI can be diagnosed only by laboratory or neuroimaging 
tests, and clinical judgement is still paramount for the diagnosis of both disorders.66 
Vitamin E is a nutritional indicator that could reflect biochemical changes associated with 
AD pathophysiology, such as inflammation and OS/NS. The correct interpretation of any 
potential marker, including vitamin E, requires information from validation studies. The 
concurrent evaluation of the clinical information defining the diagnostic criteria for AD 
and MCI is also essential.66  
 
Cognitively normal subjects gathered in the AddNeuroMed cohort were recruited from 
non-blood relatives of the patient's families’, caregivers’ relatives, and social centers for 
the elderly. Even though the recruitment of these CN subjects was not based on a rigorous 
random selection in the general population, the comprehensive examination protocols used 
in AddNeuroMed study excluded the presence of cognitive impairment or dementia in 
subjects included in the CN group. 
 
As Study I is cross-sectional, reverse causality cannot be excluded: reduced vitamin E 
plasma levels in AD and MCI could mirror changes in metabolism or dietary habits 
promoted by these disorders. However, in the AddNeuroMed population reduced levels of 
α- and γ-tocopherol in AD and MCI cases were associated with increased indices of α- and 
γ-tocopherol consumption due to reaction with free radicals, suggesting that vitamin E 
depletion is due, at least in part, to increased utilization in OS/NS events.  
 
In Study II there was a small number of MCI converters (n=13) and only one-year follow-
up data to evaluate the prognostic value of the combined model based on MRI and vitamin 
E measures. Although a previous study in the AddNeuroMed cohort showed the validity of 
the OPLS approach in predicting MCI conversion on a similar sample size,285 large studies 
with longer follow-up are warranted to verify this finding. Follow-up of the AddNeuroMed 
population is ongoing, offering the opportunity to further evaluate the relationship between 
vitamin E plasma levels and cognitive impairment. 
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6.5.2 Population-based studies 
The two population-based prospective studies presented here investigated late-life vitamin 
E exposure in relation to cognitive decline and AD. AD has a long preclinical phase, and it 
is difficult to identify the time of onset of the neuropathology. This explains the age-
dependent and bi-directional association with some risk factors, which can be true risk 
factors (i.e., increase the probability of developing the disease) or markers of risk, 
reflecting a preclinical phase of the disease and the risk of its clinical expression. As for 
some risk factors of dementia/AD, such as blood cholesterol levels, BMI and blood 
pressure, low vitamin E levels and increased indices on vitamin E oxidative/nitrosative 
damage in late-life could mirror a preclinical phase of AD, and they can be related to the 
risk of clinical expression of the disease. Only one study (HAAS) examined midlife 
vitamin E (dietary intake) in relation to dementia/AD risk, reporting no association. The 
HAAS cohort included only Japanese-American men, and the evaluation of vitamin E 
intake was based on a single 24-hour dietary recall, which might not be representative of 
the usual vitamin E intake.173 Longitudinal studies considering both midlife and late-life 
vitamin E plasma levels are necessary to detect a possible age-dependent association of 
vitamin E with AD. 
 
Kungsholmen Project 
The Kungsholmen Project is a prospective survey of a community-based cohort of very old 
individuals, which gathered all inhabitants who lived in the Kungsholmen area, central 
Stockholm, Sweden (response rate 76%). Data on vitamin E were available for a 
subsample of the Kungsholmen Project, which was representative of the entire dementia-
free cohort participating in the study phase when vitamin E was assessed. Overall, the 
incidence rate of AD in the Kungsholmen study participants included in Study III was 78.8 
per 1,000 person-years. Similar values were reported in other studies within the whole 
Kungsholmen cohort.286,287 Although the statistical power in Study III was limited due to 
the relatively small sample size, a significant association was found between different 
indices of vitamin E status and AD.  
The follow-up time in Study III was up to six years but, given the long preclinical phase in 
AD, it is not possible to completely exclude that potential changes in dietary habits or in 
metabolism due to early-stage subclinical AD could have promoted a reduction in vitamin 
E plasma levels. However, the extensive diagnostic procedure for dementia that was 
implemented at baseline and at follow-ups allowed for the detection of the presence of any 
cognitive problem. The diagnosis of dementia was given after consensus among three 
independent physicians. The diagnostic procedure has been validated, with a relatively 
high overall agreement on diagnosis (κ=0.70).288 Further, the analyses in Study III were 
adjusted for MMSE score. 
The population in Study III consisted of individuals aged ≥80 years who were living in a 
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geographically defined central area of Stockholm. This study population was comparable 
to the entire population of Stockholm, in terms of age and sex composition, as well as in 
terms of health care system. However, the Kungsholmen population did differ from the rest 
of the urban area of Sweden in terms of the proportion of pensioners, women, highly 
educated persons, and marital status. Cautions are thus needed when generalizing the 
findings from the Kungsholmen population to a younger population or to rural areas. The 
major findings from this population may be generalized to the urban population aged over 
80 in Western society. Results from the CAIDE cohort, where follow-up duration was 
longer and individuals from urban and suburban areas were included, further support the 
findings from the Kungsholmen Project.  
 
CAIDE 
The CAIDE study has been specifically designed to investigate risk factors for dementia 
and AD, and it is based on population-based random samples of individuals who have been 
investigated three times within the study. Blood samples from the second examination 
(1998) were used for vitamin E assessment in 140 subjects. 
The long follow-up period, and comprehensive evaluation and diagnostic protocol at each 
examination, make the findings of Study IV less prone to the influence of reverse causality 
(i.e. effects of preclinical dementia on vitamin E levels). 
 
In 1998, only participants with MMSE ≤ 24 at the screening phase entered the clinical 
phase. It would have been ideal if all persons had participated in both screening and 
clinical phases, but the three-phase protocol was probably high enough in sensitivity and 
specificity to detect cognitive impairment and dementia/AD. Nearly half of all participants 
with MMSE below the cut off point in the screening phase were considered as cognitively 
normal in the clinical phase in 1998, suggesting that the cut off score was sufficiently 
sensitive for detecting cognitive impairment and dementia/AD in this population. Using a 
higher cut off would have resulted in the inclusion of a very large proportion of the 
population in the clinical phase, as the median MMSE was 26.  
 
In 2005-2008 examination, the sensitivity for detecting MCI and very mild dementia has 
been further improved by including in the clinical phase subjects with MMSE ≤ 24, 
decline on MMSE of 3 or more points since 1998, or delayed recall word list test < 70% 
in the CERAD neuropsychological test battery. Further, the Finnish Drug Reimbursement 
Register was also used to verify diagnosis of AD. In Finland all dementia drugs 
(donepezil, rivastigmine, galantamine and memantine) are available and included in the 
reimbursement system. To receive reimbursement, patients must be diagnosed by a 
specialist physician (neurologist, geriatrician) after undergoing a thorough examination 
(including neuropsychological and laboratory tests, and neuroimaging). The specialist’s 
statement is submitted to the Social Insurance Institution. Compared to other countries, 
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reimbursement is not restricted according to dementia severity (i.e. upper or lower 
MMSE score limits). People living alone or in nursing homes are also entitled to 
reimbursed treatment. The Drug Reimbursement Register is maintained by the Social 
Insurance Institution and includes information on dates when patients became entitled for 
reimbursement, and dates of reimbursed drug purchases. Reimbursement for dementia 
drugs started in February 1999, and persons who are entitled for reimbursement are 
identified with a special code in the register.289 
Finally, within the CAIDE study individuals diagnosed with dementia in the clinical phase 
underwent brain imaging in the differential diagnostic phase. Autopsy data were not 
available to confirm the clinical diagnoses, but a previous neuropathological study 
conducted in the clinic in Kuopio has shown that the accuracy of clinical AD diagnosis is 
good (96% for probable AD and 86% for possible AD).290 
 
The main limitation of Study IV is the relatively small sample size, which may affect the 
statistical power. Since the CAIDE subsample included in Study IV was not randomly 
selected within the CAIDE cohort, data were weighted to minimize selection bias. 
 
Vitamin E serum analyses in the CAIDE study were done using aliquots stored for twelve 
years, initially at -20°C and then at -70°C. Previous studies reported some loss of α-
tocopherol during samples storage at -20°C,275,291 but the reduction during ten years was 
uniformly distributed over the whole range of α-tocopherol values.275 This may partly 
explain the lower levels of some vitamin E forms in the CAIDE cohort compared to other 
studies, and may also underestimate the association between vitamin E and risk of 
cognitive impairment.291  
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7 CONCLUSIONS 
α-tocopherol is the only vitamin E form currently used to define vitamin E dietary 
requirements and the only congener tested in RCTs in subjects with AD and MCI. The 
results of this project highlight that different natural forms of vitamin E can be important in 
cognitive impairment and AD. In older adults, diagnoses of AD and MCI are associated 
with reduced plasma levels of tocopherols and tocotrienols. Further, both MCI and AD are 
characterized by increased values of plasma indices of vitamin E oxidative/nitrosative 
damage. 
Biomarkers can have a relevant role in primary, secondary, and tertiary prevention of AD. 
The development of biomarkers for AD is an active research area, and potential candidates 
include indicators of biochemical events associated with AD, such as OS/NS and 
inflammation. In this project it is shown that combined analysis of vitamin E plasma values 
- tocopherols, tocotrienols, indices of vitamin E oxidative/nitrosative damage -, and 
structural MRI measures can support the distinction of AD and MCI cases from cognitively 
normal individuals, and can help identify subjects with MCI who are more at risk to 
progress to clinical AD. 
Higher plasma or serum levels of different vitamin E forms appear to be associated with 
reduced risk of cognitive impairment and AD in older adults, even in very advanced age. 
Vitamin E biokinetics is related to lipoproteins, and it is still unclear how lipid levels 
should be best accounted for in longitudinal vitamin E studies. In this project, the positive 
association between different vitamin E forms and reduced risk of cognitive impairment 
and AD is evident after different adjustments for cholesterol levels. 
The relationships between vitamin E and cognitive impairment as well as vitamin E and 
AD are controversial. The findings of this project emphasize the importance of taking into 
account all natural vitamin E forms when studying the association between this 
micronutrient and cognitive impairment and AD in older adults. Different aspects of 
vitamin E supplementation in preventing and treating AD should also be re-examined. This 
should include timing of interventions, supplements composition, plasma assessment of all 
vitamin E forms to identify subjects who could benefit from vitamin E supplementation, 
and to monitor in-vivo biological response to treatment. 
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8 FUTURE DIRECTIONS 
Vitamin E was discovered about 90 years ago, but it has only been in the last few years that 
researchers have started to focus on non-α-tocopherol forms in relation to human health. 
Many questions related to this issue still do not have a definite answer.  
Current developments in vitamin E research clearly indicate that members of the vitamin E 
family are functionally unique and not redundant with respect to their biological function. 
The functional implications of these properties are not yet fully understood, and the 
regulatory mechanisms that control vitamin E concentrations in plasma and tissues are 
largely unknown. Additional research is needed in order to clarify biokinetics and 
biotransformation of vitamin E family members in humans, as well as their role in 
physiological and pathological processes, including neurodegeneration. 
 
In different research areas, including dementia and AD, the term vitamin E is often used as 
synonymous for α-tocopherol, and studies investigating all natural forms in relation to 
cognitive impairment and dementia/AD are lacking. This project provides the evidence of a 
relation between different vitamin E forms and AD, but more studies are needed to verify 
this association. A life-course perspective is essential in epidemiological studies of chronic 
disorders such as dementia. Thus, longitudinal studies considering both midlife and late-
life exposures can clarify the role and the possible age-dependent association between 
vitamin E and AD. Repeated measures of vitamin E in the same subject over time can 
allow for the detection of patterns of vitamin E change, which might be more relevant than 
a single measure at only one point in time.  
A balanced presence in the body of different vitamin E forms can be important for 
neuroprotection. Hence, a key point is the evaluation of all vitamin E forms, taking into 
account their potential cumulative effect on cognition and risk of AD. The possible 
influence of plasma levels of lipids (i.e., cholesterol) on the association between vitamin E 
forms and dementia/AD needs also to be clarified. It is also important to keep in mind that 
people eat foods, not nutrients, and that they eat them in combination, not in isolation. 
Evaluation of nutrients patterns can provide additional information on the relation among 
micro- and macro-nutrients and AD. Integrating the assessment of dietary intake, plasma 
values of vitamin E, and data on other micro- and macro-nutrients intake/levels, could help 
unravel the synergistic and antagonistic effects of different nutrients on cognition. 
 
Plasma levels of vitamin E forms could be associated with biochemical changes related to 
AD pathophysiology. The new diagnostic criteria for AD consider cognitive impairment as 
a continuum and support the use of different biomarkers modalities for an accurate 
identification of different stages of the disease. Validation studies on the proposed 
biomarkers are ongoing, and the possible role of different types of plasma markers (e.g., 
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inflammation, OS/NS) as direct/indirect indicators of AD pathology still requires 
clarification. Improvement of diagnostic accuracy might be achieved with the integration 
of multiple biomarker modalities (i.e., neuroimaging, blood testing) and evaluation of 
different conditions associated with cognitive impairment which, especially in the very 
early stages, can require differential diagnosis with AD (e.g., vascular cognitive 
impairment, Lewy body disease). 
 
Many individuals, particularly older adults, consume dietary supplements in Western 
societies. α-tocopherol is among the most used supplement, and it is also the only vitamin 
E form tested in the currently ongoing RCTs in AD prevention and treatment. On the other 
side, nutriceuticals containing different proportions of all natural vitamin E congeners have 
become available on the market in the last few years. Since dietary supplements do not 
require prescriptions it can be challenging to monitor their effects on human health, 
including cognition. To be able to provide the public with optimal health nutritional 
recommendations, further studies into the effects of the different vitamin E forms are 
needed. This will also help better define the composition of vitamin E supplements that can 
be tested in the prevention/treatment of AD. Finally, since effects of supplementation are 
likely to depend on subjects’ micronutrient levels, evaluation of plasma concentrations of 
all vitamin E forms may help identify people who are most likely to benefit from vitamin E 
supplementation. It can also help monitor treatment adherence and in-vivo biological 
effects of vitamin E supplementation. 
In conclusion, the examination of all eight natural vitamin E forms could provide new 
insights into the potential role of these micronutrients in human health, including AD.  
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